
<html lang="en"     class="pb-page"  data-request-id="4742458a-4125-47e7-9474-a38f5f04dd97"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01078;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2015.58.issue-17;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity" /></meta><meta name="dc.Creator" content="Edward J.  Hennessy" /></meta><meta name="dc.Creator" content="Vibha  Oza" /></meta><meta name="dc.Creator" content="Ammar  Adam" /></meta><meta name="dc.Creator" content="Kate  Byth" /></meta><meta name="dc.Creator" content="Lillian  Castriotta" /></meta><meta name="dc.Creator" content="Gurmit  Grewal" /></meta><meta name="dc.Creator" content="Geraldine A.  Hamilton" /></meta><meta name="dc.Creator" content="Victor M.  Kamhi" /></meta><meta name="dc.Creator" content="Paula  Lewis" /></meta><meta name="dc.Creator" content="Danyang  Li" /></meta><meta name="dc.Creator" content="Paul  Lyne" /></meta><meta name="dc.Creator" content="Linda  Öster" /></meta><meta name="dc.Creator" content="Michael T.  Rooney" /></meta><meta name="dc.Creator" content="Jamal C.  Saeh" /></meta><meta name="dc.Creator" content="Li  Sha" /></meta><meta name="dc.Creator" content="Qibin  Su" /></meta><meta name="dc.Creator" content="Shengua  Wen" /></meta><meta name="dc.Creator" content="Yafeng  Xue" /></meta><meta name="dc.Creator" content="Bin  Yang" /></meta><meta name="dc.Description" content="We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screeni..." /></meta><meta name="Description" content="We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screeni..." /></meta><meta name="dc.Publisher" content="American Chemical Society2" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 26, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01078" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01078" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01078" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01078" /></link>
        
    
    

<title>Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01078" /></meta><meta property="og:title" content="Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0027.jpeg" /></meta><meta property="og:description" content="We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compounds described previously. Lead compound 2 potently inhibits S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 μM), but has poor physical properties and metabolic stability. Evolution of this compound through structure–activity relationship development and property optimization led to in vivo probes such as 4. However, this compound was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chemistry efforts were directed at addressing this liability. By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compounds for further testing in human hepatocytes, we identified lipophilicity as a key molecular property influencing the likelihood of P450 induction. Ultimately, we have identified compounds such as 46 and 47, which demonstrate the desired S1P1 antagonist activity while having greatly reduced risk of CYP3A induction in humans. These compounds have excellent oral bioavailability in preclinical species and exhibit pharmacodynamic effects of S1P1 antagonism in several in vivo models following oral dosing. Relatively modest antitumor activity was observed in multiple xenograft models, however, suggesting that selective S1P1 antagonists would have limited utility as anticancer therapeutics as single agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01078"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01078">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01078&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01078&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01078&amp;href=/doi/10.1021/acs.jmedchem.5b01078" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7057-7075</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b00992" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01105" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edward+J.++Hennessy">Edward J. Hennessy</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vibha++Oza">Vibha Oza</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ammar++Adam">Ammar Adam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kate++Byth">Kate Byth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lillian++Castriotta">Lillian Castriotta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gurmit++Grewal">Gurmit Grewal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Geraldine+A.++Hamilton">Geraldine A. Hamilton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor+M.++Kamhi">Victor M. Kamhi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paula++Lewis">Paula Lewis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danyang++Li">Danyang Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Lyne">Paul Lyne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Linda++%C3%96ster">Linda Öster</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+T.++Rooney">Michael T. Rooney</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jamal+C.++Saeh">Jamal C. Saeh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Sha">Li Sha</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qibin++Su">Qibin Su</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shengua++Wen">Shengua Wen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yafeng++Xue">Yafeng Xue</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Yang">Bin Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Oncology iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca R&D Mölndal, S-43183, Mölndal, Sweden</span></div><div class="corresp-info"><strong>*</strong>Phone: (781) 839-4153. E-mail: <a href="/cdn-cgi/l/email-protection#debbbaa9bfacbaf0b6bbb0b0bbadada79ebfadaaacbfa4bbb0bbbdbff0bdb1b3"><span class="__cf_email__" data-cfemail="dcb9b8abbdaeb8f2b4b9b2b2b9afafa59cbdafa8aebda6b9b2b9bfbdf2bfb3b1">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01078&amp;href=/doi/10.1021%2Facs.jmedchem.5b01078" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7057–7075</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 20, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 July 2015</li><li><span class="item_label"><b>Published</b> online</span>26 August 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01078" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01078</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7057%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEdward%2BJ.%2BHennessy%252C%2BVibha%2BOza%252C%2BAmmar%2BAdam%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D17%26contentID%3Dacs.jmedchem.5b01078%26title%3DIdentification%2Band%2BOptimization%2Bof%2BBenzimidazole%2BSulfonamides%2Bas%2BOrally%2BBioavailable%2BSphingosine%2B1-Phosphate%2BReceptor%2B1%2BAntagonists%2Bwith%2Bin%2BVivo%2BActivity%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7075%26publicationDate%3DSeptember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01078"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2682</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01078" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;J. Hennessy&quot;},{&quot;first_name&quot;:&quot;Vibha&quot;,&quot;last_name&quot;:&quot;Oza&quot;},{&quot;first_name&quot;:&quot;Ammar&quot;,&quot;last_name&quot;:&quot;Adam&quot;},{&quot;first_name&quot;:&quot;Kate&quot;,&quot;last_name&quot;:&quot;Byth&quot;},{&quot;first_name&quot;:&quot;Lillian&quot;,&quot;last_name&quot;:&quot;Castriotta&quot;},{&quot;first_name&quot;:&quot;Gurmit&quot;,&quot;last_name&quot;:&quot;Grewal&quot;},{&quot;first_name&quot;:&quot;Geraldine&quot;,&quot;last_name&quot;:&quot;A. Hamilton&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;M. Kamhi&quot;},{&quot;first_name&quot;:&quot;Paula&quot;,&quot;last_name&quot;:&quot;Lewis&quot;},{&quot;first_name&quot;:&quot;Danyang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Lyne&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Öster&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;T. Rooney&quot;},{&quot;first_name&quot;:&quot;Jamal&quot;,&quot;last_name&quot;:&quot;C. Saeh&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Sha&quot;},{&quot;first_name&quot;:&quot;Qibin&quot;,&quot;last_name&quot;:&quot;Su&quot;},{&quot;first_name&quot;:&quot;Shengua&quot;,&quot;last_name&quot;:&quot;Wen&quot;},{&quot;first_name&quot;:&quot;Yafeng&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;7057-7075&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01078&quot;},&quot;abstract&quot;:&quot;We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compounds described previously. Lead compound 2 potently inhibits S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 μM), but has poor physical properties and metabolic stability. Evolution of this compound through structure–activity relationship development and property optimization led to in vivo probes such as 4. However, this compound was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chemistry efforts were directed at addressing this liability. By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compounds for further testing in human hepatocytes, we identified lipophilicity as a key molecular property influencing the likelihood of P450 induction. Ultimately, we have identified compounds such as 46 and &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01078&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01078" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01078&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01078" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01078&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01078" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01078&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01078&amp;href=/doi/10.1021/acs.jmedchem.5b01078" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01078" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01078" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01078%26sid%3Dliteratum%253Aachs%26pmid%3D26291341%26genre%3Darticle%26aulast%3DHennessy%26date%3D2015%26atitle%3DIdentification%2Band%2BOptimization%2Bof%2BBenzimidazole%2BSulfonamides%2Bas%2BOrally%2BBioavailable%2BSphingosine%2B1-Phosphate%2BReceptor%2B1%2BAntagonists%2Bwith%2Bin%2BVivo%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D17%26spage%3D7057%26epage%3D7075%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290716" title="Sulfones">Sulfones</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/jmcmar.2015.58.issue-17/20150910/jmcmar.2015.58.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P<sub>1</sub> receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compounds described previously. Lead compound <b>2</b> potently inhibits S1P-induced receptor internalization in a cell-based assay (EC<sub>50</sub> = 0.05 μM), but has poor physical properties and metabolic stability. Evolution of this compound through structure–activity relationship development and property optimization led to <i>in vivo</i> probes such as <b>4</b>. However, this compound was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chemistry efforts were directed at addressing this liability. By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compounds for further testing in human hepatocytes, we identified lipophilicity as a key molecular property influencing the likelihood of P450 induction. Ultimately, we have identified compounds such as <b>46</b> and <b>47</b>, which demonstrate the desired S1P<sub>1</sub> antagonist activity while having greatly reduced risk of CYP3A induction in humans. These compounds have excellent oral bioavailability in preclinical species and exhibit pharmacodynamic effects of S1P<sub>1</sub> antagonism in several <i>in vivo</i> models following oral dosing. Relatively modest antitumor activity was observed in multiple xenograft models, however, suggesting that selective S1P<sub>1</sub> antagonists would have limited utility as anticancer therapeutics as single agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01851" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01851" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sphingosine 1-phosphate (S1P), a signaling phospholipid found throughout blood and bodily tissues, plays a role in a diverse variety of biological processes. Through its interactions with a class of five G protein-coupled receptors (GPCRs) known as the S1P receptors (S1P<sub>1</sub>–S1P<sub>5</sub>), S1P plays a role in cell proliferation and migration, cellular architecture, and immune cell trafficking.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Accordingly, agents that are capable of modulating the interactions of S1P with its receptors may have utility as therapeutics in a variety of diseases such as diabetes, inflammatory disorders, and cancer.</div><div class="NLM_p">FTY720 (fingolimod), a sphingolipid mimetic first described in 1995,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> is phosphorylated in cells to yield a potent agonist for four of the five isoforms of S1P receptor (S1P<sub>1</sub>, S1P<sub>3</sub>, S1P<sub>4</sub>, and S1P<sub>5</sub>).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Through its interactions with S1P<sub>1</sub>, this compound inhibits lymphocyte egress from secondary lymphoid organs, resulting in an immunosuppressive effect <i>in vivo</i>. As a result, it was approved for use in treatment of multiple sclerosis in 2010.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Upon binding to and activating S1P<sub>1</sub>, fingolimod causes prolonged downregulation of the receptor by inducing receptor internalization<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> followed by ubiquitinylation and proteasomal degradation.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Therefore, despite being an S1P<sub>1</sub> agonist, it is this “functional antagonism” that is responsible for the compound’s beneficial therapeutic activity.</div><div class="NLM_p">In addition to the effects on lymphocyte trafficking attributed to S1P<sub>1</sub> function, this receptor has been shown to play a key role in angiogenesis and the maintenance of vascular integrity. For example, S1P<sub>1</sub>-knockout mice demonstrate impaired vascular maturation during embryonic development, leading to lethal hemorrhaging <i>in utero</i>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Additionally, siRNA silencing of the S1P<sub>1</sub> gene within subcutaneous implants of Matrigel results in the suppression of vessel formation <i>in vivo</i>.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Furthermore, small-molecule abrogation of S1P<sub>1</sub> signaling (with fingolimod) inhibits angiogenesis in multiple <i>in vivo</i> models.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">In clinical trials of fingolimod, transient bradycardia was frequently observed upon initial dosing.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> This effect has also been observed preclinically in rodents and has been attributed to the compound’s effects on the S1P<sub>3</sub> receptor.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Alternative findings suggest that S1P<sub>1</sub> agonism, resulting in activation of G protein-coupled inwardly rectifying potassium (GIRK) channels in mouse<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and human cardiomyocytes,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> results in the heart rate decreases observed in human patients.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Taken together, these observations suggest that a compound that selectively and effectively antagonizes the S1P<sub>1</sub> receptor, without any agonism of S1P<sub>1</sub> or interaction with S1P<sub>3</sub>, should retain the desired pharmacological profile of fingolimod without any adverse cardiovascular effects.</div><div class="NLM_p last">Given the documented role of S1P<sub>1</sub> function on vessel formation, and the therapeutic potential of compounds that inhibit angiogenesis in the treatment of various cancers, we aimed to develop an orally bioavailable, selective S1P<sub>1</sub> antagonist to assess the feasibility of such a compound as an antitumor agent. While numerous examples of S1P<sub>1</sub> agonists that act as functional antagonists have been described,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> at the time we initiated our program only a few reports of pure antagonists (devoid of agonist activity) were available.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18-20)</a> As mimetics of the phospholipid S1P, these compounds are useful tools but likely have limited utility as orally available agents. More recently, however, disclosures of orally available, small-molecule S1P<sub>1</sub> antagonists have emerged in the literature.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21-23)</a> We have recently disclosed our initial efforts toward this goal, having identified a series of heterocyclic sulfonamides with sub-micromolar potency in a S1P<sub>1</sub> receptor internalization assay.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In this article, we will detail our further evolution of this series of compounds, culminating in the identification of compounds (such as <b>46</b> and <b>47</b>) with promising biopharmaceutical properties that elicit <i>in vivo</i> pharmacodynamic effects associated with antagonism of the S1P<sub>1</sub> receptor.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38870" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38870" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our previous communication,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> we highlighted the preliminary development of structure–activity relationships in a series of triazole-containing sulfonamides, with the goal of improving potency alongside physical properties and metabolic stability. These efforts established that substitution at the 4- and 5-positions of the triazole ring with small alkyl groups gave the most effective S1P<sub>1</sub> antagonists (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, R<sup>1</sup> and R<sup>2</sup>). As part of this work, we generated data which suggested that the hydrogen bond acceptor at the 1-position of the triazole ring is not required for interaction with the S1P<sub>1</sub> receptor, since the corresponding imidazole in which the 1-position nitrogen atom has been deleted retains the antagonist activity seen in the triazole. However, the acceptor at the 2-position appears to be critical for binding, since the matched-pair imidazole was inactive in an assay measuring inhibition of S1P-induced S1P<sub>1</sub> receptor internalization.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> These observations were further supported by data for other heterocycles in which the 2-position hydrogen bond acceptor was maintained, while the 1-position nitrogen atom was replaced with other heteroatoms. Unfortunately, the above modifications resulted in poorer physical properties than for the corresponding triazoles.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffold hopping from triazole to benzimidazole core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To capitalize on these findings, we proposed additional structural modifications to the triazole scaffold in order to assess the potential for improvements in potency and properties. In particular, we hypothesized that a bicyclic system (such as benzimidazole) encompassing the 5-position substituent as well as the 2-position hydrogen bond acceptor would maintain the critical elements of the pharmacophore, while offering additional opportunities for further substitution that could influence receptor binding as well as physical properties (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><div class="NLM_p">To test this hypothesis, we first prepared benzimidazole <b>2</b> containing the structural elements found to be optimal from our studies on the triazole series (ethyl substituent off five-membered ring, (<i>R</i>)-stereochemistry at chiral center).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We were pleased to find that this compound was a very effective antagonist of human S1P<sub>1</sub> in our receptor internalization assay, with improved measured potency relative to the most optimized triazoles previously prepared (exemplified by <b>1</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). No antagonism of the S1P<sub>3</sub> receptor was observed with this compound, consistent with our desired selectivity profile. Despite this promising result, however, this increased potency came at the cost of a significant increase in lipophilicity. Indeed, utilization of the lipophilic ligand efficiency (LLE) metric<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> indicates that triazole <b>1</b> is a far more “efficient” antagonist than benzimidazole <b>2</b>. Nevertheless, we were encouraged by the level of potency not yet observed in the project to that point and viewed lipophilicity as a design parameter that could be readily addressed in future rounds of chemistry. We therefore embarked on efforts to establish the likelihood of delivery of a candidate drug from the benzimidazole scaffold.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Comparison of Lead Triazole <b>1</b> with Initial Benzimidazole <b>2</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0017.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported as the mean of at least three separate determinations ± standard deviation.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">LLE = pEC<sub>50</sub> – cLogP.</p></div></div><div></div></div><div class="NLM_p">An early goal of our work on this scaffold was to study the nature of the interaction between the compound and the receptor. The cellular S1P<sub>1</sub> translocation assay that we used for primary screening measures the effects of compound treatment on S1P-induced S1P<sub>1</sub> receptor internalization; compounds that behave as receptor agonists would be expected to increase the amount of receptor internalization relative to a fixed concentration of S1P alone, while antagonists should suppress receptor internalization. On the basis of our observations with <b>2</b>, we were confident that this compound was acting as an S1P<sub>1</sub> antagonist in the same manner as we had observed with the triazoles. In order to further characterize the mode of inhibition, we conducted this assay by varying the concentrations of S1P present at a series of fixed concentrations of <b>2</b>. Increasing the concentration of <b>2</b> results in a shift of the S1P agonism dose–response curve to the right and also results in a decrease in the maximal amount of receptor internalization (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S1). This observation, that antagonism by <b>2</b> cannot be overcome by increasing the concentration of S1P, suggests that <b>2</b> and S1P bind at different sites on the S1P<sub>1</sub> receptor and that <b>2</b> is therefore a noncompetitive antagonist. We have observed a similar mode of inhibition with structurally related compounds prepared previously (unpublished data).</div><div class="NLM_p">Our initial investigations to follow up compound <b>2</b> focused on determining whether the structure–activity relationships previously established for the triazole series could be translated to this new scaffold. We therefore first systematically varied the group appended to the benzimidazole nitrogen, including larger alkyl groups (linear and branched) as well as substituents containing more polar moieties. However, none of these compounds had improved potency relative to <b>2</b> (data not shown), confirming the preference for ethyl substitution at this position (in accord with our observations from the triazole series).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Similarly, exploration of substituents at the position adjacent to the sulfonamide nitrogen reiterated our previous findings that an α-methyl group provided the most potency per unit lipophilicity and that (<i>R</i>)-stereochemistry at this position is critical to antagonist activity (data not shown).</div><div class="NLM_p">In spite of the observation that <b>2</b> represented a partially optimized early lead in this series, this compound had apparent shortcomings that needed to be rectified. For example, <b>2</b> is rapidly cleared <i>in vivo</i> when dosed intravenously to Wistar rats and has very limited oral exposure (<i>F</i>% = 5). These observations are consistent with this compound’s poor <i>in vitro</i> stability in the presence of human liver microsomes (CL<sub>int</sub> > 100 μL/min/mg). An analysis of the metabolites formed in microsomal incubations pointed to <i>N</i>-deethylation of the benzimidazole as the predominant product formed, along with compounds derived from subsequent oxidation reactions.</div><div class="NLM_p">Since our earlier data suggested that an <i>N</i>-ethyl group on the benzimidazole ring seemed to be a critical component of the pharmacophore, modification of this group was not considered to be a viable approach to address metabolic dealkylation. Instead, we next focused our attention on the variation of substituents elsewhere on the scaffold. In addition to the goal of furthering our understanding of structure–activity relationships within this series, we hoped that microsomal stability data for successive compounds would point us toward drivers for reducing the overall extent of oxidative metabolism.</div><div class="NLM_p">A survey of various substitutions on the carbocyclic ring of the benzimidazole was conducted, from which representative compounds are exemplified in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. These data highlight the effect of lipophilic groups on receptor antagonist activity. In particular, the inclusion of small nonpolar groups at the 5- or 6-positions of this ring results in significant increases in potency in the S1P<sub>1</sub> translocation assay relative to <b>2</b> (e.g., <b>3</b>–<b>5</b>), although in general these improvements in potency do not offset the increased lipophilicity. As is the case for <b>2</b>, these compounds have very limited stability in the presence of human microsomes. Reducing lipophilicity by substitution of this ring with more polar groups does appear to reduce the rate of metabolism <i>in vitro</i>; however, more polar groups also tend to result in a reduction in potency (<b>6</b>–<b>12</b>). A notable exception to this trend is the 6-hydroxymethyl-substituted analogue <b>8</b>, which has both a 10-fold improvement in potency relative to <b>2</b> as well as ∼1 log unit reduction in cLogP. Unfortunately, the microsomal stability for this compound is still low, possibly due to the oxidation-prone benzylic alcohol moiety. Substitution of the 7-position of this ring (as in compound <b>13</b>) results in a notable drop in potency relative to <b>2</b>, which may be due to steric interactions adversely affecting the orientation of the critical <i>N</i>-ethyl group.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Representative Substitutions on the Benzimidazole Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0018.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">example</th><th class="colsep0 rowsep0" align="center">substitution</th><th class="colsep0 rowsep0" align="center" char="±">S1P<sub>1</sub> translocation EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center" char=".">LLE<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Hu microsomes CL<sub>int</sub> (μL/min/mg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">6-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.009 ± 0.009</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="left"> >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">6-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.005 ± 0.004</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="left"> >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">5-F, 6-Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.001 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="left"> >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">5-CN</td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.037</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="left">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">5-CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.14</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="left">88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">6-CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="char" char="±">0.005 ± 0.0005</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">5-C(O)NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.037</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="left"> <5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">6-CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">23.5 ± 2.9</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">5-morpholino</td><td class="colsep0 rowsep0" align="char" char="±">2.42 ± 0.81</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="left">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">6-SO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">1.84 ± 0.34</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="left"> <5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">7-Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.80 ± 0.37</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="left"> >100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">EC<sub>50</sub> values are reported as the mean of at least three separate determinations ± standard deviation.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">LLE = pEC<sub>50</sub> – cLogP.</p></div></div></div><div class="NLM_p">Since we observed a trend toward improved microsomal stability with decreasing lipophilicity of the benzimidazole substituent, we next surveyed the effects of incorporating a nitrogen atom into the benzimidazole six-membered ring (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Because of the more forcing reaction conditions required to effect ring formation in these examples (as discussed in the <a class="ref internalNav" href="#sec3" aria-label="Chemistry">Chemistry</a> section), we decided to conduct this initial exploration with racemic compounds since our previous studies had shown that this tactic could be effectively applied to SAR development.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Gratifyingly, aza-substitution into this ring does not completely abrogate S1P<sub>1</sub> antagonism, with a clear preference for inclusion of nitrogen at the 5- and 4-positions of the benzimidazole (<b>16</b> and <b>17</b>, respectively). Moreover, a notable increase in microsomal stability was observed for these two compounds relative to <b>2</b>, reiterating our observations regarding the improved stability of compounds containing polar groups appended to this ring (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Not surprisingly, however, these compounds were found to have varying levels of cytochrome P450 inhibitory activity, likely owing to the iron-coordinating ability of the unhindered pyridine moiety.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> For example, compound <b>16</b> inhibits both CYP2D6 (IC<sub>50</sub> = 0.23 μM) and CYP2C19 (IC<sub>50</sub> = 0.91 μM). Nevertheless, we were encouraged by the data for this initial set of azabenzimidazoles and felt that these could be revisited at a later time as a means to potentially decrease lipophilicity and improve properties.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure–Activity Relationships for Racemic Azabenzimidazoles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0020.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported as the mean of at least three separate determinations ± standard deviation.</p></div></div><div></div></div><div class="NLM_p">Earlier in the project, we had established that small, hydrophobic groups in the 3- and 4-positions of the aryl sulfonamide ring were critical to maintaining measurable antagonist activity, and the majority of our initial studies kept the 4-chlorophenylsulfonamide moiety as a constant to allow for direct comparisons between compounds with modifications elsewhere on the scaffold. Given the increased potency with benzimidazole <b>2</b>, however, we felt it was timely to challenge these prior assertions in the hopes that a less lipophilic sulfonamide group could be identified without resulting in a drastic loss of receptor antagonism. This work was well-suited to a parallel synthesis campaign, given the facile and high-yielding formation of the sulfonamide moiety (see <a class="ref internalNav" href="#sec3" aria-label="Chemistry">Chemistry</a> section). Therefore, employing the potent 6-trifluoromethyl-substituted compound <b>4</b> as a benchmark, we prepared a large number of compounds from readily available sulfonyl chlorides, representative examples of which are presented in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effects of Variation of the Sulfonamide Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0021.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0022.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported as the mean of at least three separate determinations ± standard deviation.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">LLE = pEC<sub>50</sub> – cLogP.</p></div></div><div></div></div><div class="NLM_p">Analysis of the data for compounds in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> reveals that while a range of arylsulfonamides are tolerated, replacement of the aryl moiety with a cycloalkyl group (<b>18</b>, <b>19</b>) results in a substantial loss of antagonist activity. With respect to substitution on the aryl ring, the aforementioned preference for smaller, hydrophobic groups was reinforced here. For example, the 4-fluoro, 4-methyl, and 4-cyano substituted compounds (<b>21</b>, <b>22</b>, and <b>23</b>, respectively) have potency in the receptor internalization assay comparable to the 4-chloro analogue (<b>4</b>). Incorporation of these moieties at the 3-position (<b>24</b>, <b>25</b>) similarly results in potent antagonists. Interestingly, even the unsubstituted phenyl sulfonamide <b>20</b> maintains this level of potency. There do appear to be limitations with respect to the range of tolerated substituents, however. For example, incorporation of a more polar amide group at the 4-position (<b>26</b>) causes a >3000-fold drop in measured potency. In addition, while the 4-isobutyl-substituted analogue (<b>27</b>) is clearly outside the realm of acceptable lipophilicity, this compound serves to illustrate that placement of larger groups on the aromatic ring results in a loss of antagonist activity. Furthermore, comparison of the matched pair <b>21</b> and <b>28</b> highlights that arenes without <i>ortho</i>-substituents are preferred.</div><div class="NLM_p">The data in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> also suggest that the substitution pattern on the sulfonamide ring can address the issues of metabolic instability observed within this series. For example, changing the 4-chlorophenyl ring of <b>4</b> to a 4-fluoro or 4-cyano-substituted aryl (<b>21</b> or <b>23</b>) results in reduced human microsomal CL<sub>int</sub>, as does removal of the 4-substituent altogether (<b>20</b>). These improvements cannot be simply attributed solely to lipophilicity reduction, however, as comparably polar compounds with moieties prone to benzylic oxidation (<b>22</b>, <b>26</b>) have poorer stability.</div><div class="NLM_p">While some of the compounds prepared in this effort had improved LLE relative the 4-chlorophenyl-substituted matched pair, we recognized that these compounds still were relatively lipophilic in comparison to the triazole-based compounds. In order to introduce more favorable physical properties, therefore, we prepared additional matched pairs of <b>4</b> containing heteroaryl sulfonamides (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Unfortunately, the majority these compounds were less effective antagonists than the corresponding arylsulfonamides. However, we were pleased to observe that the 3-pyridyl and 4-pyridyl analogues (<b>30</b> and <b>31</b>) did maintain the level of potency seen previously, suggesting that properties could be effectively attenuated with selected heterocyclic sulfonamides without a substantial loss in antagonist activity. Similar to our observations with the azabenzimidazoles (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), however, these two compounds were found to be cytochrome P450 inhibitors (CYP3A4/5 IC<sub>50</sub> for <b>30</b> = 0.83 μM; CYP2C19 IC<sub>50</sub> for <b>31</b> = 0.04 μM).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Exploration of Heteroaryl Sulfonamides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0023.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0024.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported as the mean of at least three separate determinations ± standard deviation.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">LLE = pEC<sub>50</sub> – cLogP.</p></div></div><div></div></div><div class="NLM_p">At the culmination of our investigation of various sulfonamide groups, the higher LLE compounds (such as <b>20</b>, <b>21</b>, and <b>23</b>) represented attractive candidates for exploratory <i>in vivo</i> studies. These examples were among the most effective antagonists in the receptor internalization assay prepared in the project at the time and had improved microsomal stability relative to most other compounds of comparable potency. In addition, we were pleased to find that the instability of 4-chloro-substituted analogue <b>4</b> in the presence of human microsomes (as well as human hepatocytes) did not translate to equally high turnover in mouse or rat hepatocytes. Indeed, <b>4</b> has moderate <i>in vivo</i> clearance (33 mL/min/kg) and acceptable oral bioavailability (43%) in rat. While metabolic instability in human would clearly preclude further progression of this compound, these data suggested that <b>4</b> might be a useful preclinical tool compound for rodent <i>in vivo</i> studies. Moreover, we profiled a number of the more potent compounds from this series (including <b>4</b> and <b>21</b>) in a cellular receptor internalization assay using mouse S1P<sub>1</sub> and observed a correlation with potency in the human S1P<sub>1</sub> assay (data not shown). Thus, we were confident that these compounds would effectively act as S1P<sub>1</sub> antagonists in mice if sufficient plasma concentrations could be achieved.</div><div class="NLM_p">In preparation for <i>in vivo</i> experiments, we first wanted to accurately assess plasma exposures at varying doses as well as tolerance of the animals to repeated dosing. Therefore, compounds <b>4</b> and <b>21</b> were administered orally to mice at either 50 or 100 mg/kg, twice daily, for a period of 5 days (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). We did not observe a significant increase in the plasma exposure between the low and high dose for either compound, suggestive of poor solubility and/or permeability limiting intestinal absorption for both compounds. More troubling, however, we observed that plasma concentrations at 1 h postdose on day 5 were markedly lower for both compounds than they were 1 h postdose on day 1.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Reduction in plasma exposures following repeat dosing. Female CB17 SCID mice (3 animals per cohort) were dosed orally with either compound <b>4</b> or <b>21</b>, at either 50 mg/kg or 100 mg/kg twice daily, for 5 days. Plasma concentrations were measured at 1 h after the first dose on day 1 and day 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to address the observation of decreased exposures upon repeat dosing, we first ruled out pharmaceutical properties of the compounds and formulations used. No degradation or change in concentration of the oral formulations was observed over time for either compound, nor was there any observable change in solid form or particle size by microscopic assessment. As a result, we considered whether the decreased exposure of these compounds was occurring through increased expression of the cytochrome P450 enzymes responsible for their metabolism. While the detailed nature of the oxidative metabolism in mouse was not evaluated for these compounds, we recognized that a possible P450 induction liability with this series was something that needed to be identified and addressed immediately. Otherwise, the risk of not being able to achieve sufficient, durable plasma concentrations would hamper testing in relevant preclinical disease models and toxicological studies. In addition, while it is known that there are substantial interspecies differences in the regulation of cytochrome P450 enzymes,<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> the possibility of a P450 induction risk in humans (and the associated potential for adverse drug–drug interactions) would likely preclude advancement of these compounds toward clinical development.</div><div class="NLM_p">To determine if this series carried a risk for P450 induction in humans, cultured primary human hepatocytes were treated with varying concentrations of <b>4</b> for a period of 48 h and were then treated with probe substrates known to be metabolized by specific isoforms of cytochrome P450 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). No significant increase in CYP1A2 or CYP2B6 activity was observed when compared to hepatocytes treated with compounds known to be inducers of these enzymes. However, <b>4</b> was found to result in a dose-dependent increase in CYP3A activity, with a concentration of 2 μM resulting in an increase in metabolic activity comparable to the reference compound rifampicin, a known potent inducer of CYP3A4 and CYP3A5.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>4</b> induces an increase in CYP3A activity in cultured human hepatocytes. Human hepatocytes were seeded onto collagen-coated plates and were cultured in a collagen-Matrigel sandwich configuration. On day 3 of culture, the cells were treated with either DMSO (control), compound <b>4</b>, or a reference compound known to cause induction of various CYP isoforms (3-methylcholanthrene for CYP1A2, phenobarbital for CYP2B6, and rifampicin for CYP3A4/5). After 48 h of treatment, the cultures were then incubated with probe substrates (phenacetin for CYP1A2, bupropion for CYP2B6, and testosterone for CYP3A4/5), and the amount of marker metabolite formed (acetaminophen for CYP1A2, hydroxybupropion for CYP2B6, and 6-β-hydroxytestosterone for CYP3A4/5) was quantified. The amount of CYP activity for <b>4</b> is expressed as a percentage of the activity observed for the individual reference compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine whether these observations were specific to compound <b>4</b>, other compounds from this series were subsequently profiled in human hepatocytes and similarly revealed varying degrees of increased CYP3A activity (data not shown). In light of these results, remediation of the human CYP3A induction liability within this series became the priority for ongoing chemistry activities. While the human hepatocyte activity protocol described in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> clearly indicated the magnitude of the issue, this assay was not considered to be suitable for routine screening purposes due to the labor intensive nature of the assay, as well as issues surrounding the availability and variable quality of human liver tissue. Therefore, we needed a higher throughput assay in order to identify design parameters that would impact P450 induction, as well as to assess whether progress toward reducing this liability was being made.</div><div class="NLM_p">It has been established that compounds affecting expression of the genes encoding P450 enzymes can do so through interactions with certain nuclear hormone receptors, such as the pregnane X receptor (PXR)<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31-33)</a> and the constitutive androstane receptor (CAR).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> These receptors recognize xenobiotics through direct or indirect binding interactions and in turn affect expression of the metabolic enzymes that result in the clearance of such compounds from the body. Cell-based reporter gene assays that measure the increase in P450 gene expression associated with PXR activation by small molecules have been described,<a onclick="showRef(event, 'ref32 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref32 ref35 ref36">(32, 35, 36)</a> and our strategy therefore was to utilize such an assay as a filter to allow for prioritization of compounds to be screened for P450 activity in human hepatocytes. While the generation of EC<sub>50</sub> values for PXR activation, derived from multiple concentrations of each compound, would allow for rigorous rank-ordering of the compounds with respect to CYP3A induction risk, we instead opted to evaluate the extent of PXR activation at a single concentration (10 μM) of each compound in order to generate a larger data set. The resulting data were anticipated to help guide further compound design as well as to prioritize compounds for further evaluation in human hepatocyte studies.</div><div class="NLM_p">Upon screening a set of compounds from this series in a PXR gene reporter assay, we observed a loose correlation between the extent of PXR activation (at 10 μM) and the experimentally determined LogD (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A), with more lipophilic compounds resulting in greater PXR activation. This is in accord with previous literature observations and is consistent with more polar compounds having less favorable interactions with the relatively hydrophobic binding site of PXR.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> While there were compounds with lower LogD that did result in significant PXR activation, it was clear from this data that the more lipophilic compounds tested had an increased likelihood of this unwanted activity (and to a greater extent). Indeed, roughly 70% of the compounds with LogD > 2 had >30% PXR activation at a concentration of 10 μM (relative to rifampicin), a threshold considered to be indicative of a high risk of CYP3A induction in humans (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Correlation between experimentally determined LogD and extent of PXR activation. Compounds with greater than 30% PXR activation at 10 μM were considered to be at risk for CYP3A induction. (B) Compounds with LogD > 2 are more likely to have >30% PXR activation at 10 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the LogD range that these data suggested would afford the best chance of induction-free compounds, we stringently employed calculated lipophilicity as a primary filter for all newly proposed compounds prior to initiating synthesis. In order to drive down lipophilicity without sacrificing the potent S1P<sub>1</sub> antagonism within this series, we assessed which previous structural permutations resulted in increased LLE and utilized this information to design compounds that combined such modifications. Therefore, on the basis of the promising data presented in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, the focus of our efforts centered on revisiting azabenzimidazoles. In particular, we felt that compounds in which the 5-position was a nitrogen (as in <b>16</b>) would largely retain potency while effectively lowering lipophilicity. In addition, the exploration around the aryl sulfonamide ring (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) suggested the 4-cyano group (as in <b>23</b>) contributed the least lipophilicity among the higher LLE compounds. Combining these groups gave <b>41</b> (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>), a compound that validated our design strategy to address P450 induction, combining potent antagonist activity with decreased activation of PXR. Given the low LogD for this compound, we hypothesized that addition of a moderately hydrophobic substituent at the 6-position would further enhance potency while staying within the desired property space. Moreover, we anticipated that the inclusion of a substituent at this position, adjacent to the pyridyl nitrogen, might attenuate the P450 inhibitory activity observed previously with azabenzimidazole-based compounds. Thus, we prepared <b>42</b>–<b>44</b> and were pleased to find that these compounds had measured potency comparable to previous leads (<b>4</b> and <b>21</b>), but with reduced LogD and PXR activation.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Compounds with Reduced Lipophilicity and PXR Activation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0025.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported as the mean of at least three separate determinations ± standard deviation.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">Experimentally determined at pH 7.4.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">Expressed as a percentage of the activation response seen with rifampicin when both compounds are used at a concentration of 10 μM.</p></div></div><div></div></div><div class="NLM_p">In addition to the compounds resulting from these combinations, we were able to further exploit our previous finding that 3- or 4-pyridyl groups were tolerated as replacements for the substituted phenylsulfonamide (as shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). In particular, the 3-pyridyl moiety still allowed for the incorporation of a potency-boosting 4-substituent on this ring, and thus combination of all these features (3-pyridyl, 4-cyano arylsulfonamide; 6-substituted 5-azabenzimidazole) led to compounds such as <b>45</b>–<b>47</b>. These examples represent a substantial improvement in compound quality compared to our earlier lead <b>4</b>, demonstrating comparable potent S1P<sub>1</sub> antagonist activity while having a reduction in LogD of over 2 orders of magnitude.</div><div class="NLM_p">Compounds <b>41</b>–<b>47</b> clearly demonstrate that the structure–activity relationships for interactions with S1P<sub>1</sub> and PXR can diverge and that potent S1P<sub>1</sub> antagonists that do not substantially activate PXR are accessible from this series. To rationalize this observation and to potentially further inform our efforts at removing the CYP3A induction liability, we obtained a crystal structure of the potent inducer <b>4</b> bound to human PXR (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The binding site occupied by this compound is indeed relatively nonpolar, and less lipophilic compounds would be expected to have fewer favorable hydrophobic interactions in general. In retrospect, however, our successful design approach to address PXR activation by lowering overall lipophilicity could have serendipitously impacted specific binding interactions with the receptor. For example, addition of a nitrogen atom at the 5-position of the benzimidazole (as in <b>41</b>–<b>47</b>) may disrupt contacts with the side chain of Met246. Alternatively, our decision to switch to 4-cyano-substituted sulfonamides in order to reduce LogD may have resulted in unfavorable steric interactions with Tyr306 in PXR, manifesting in reduced activation in the gene reporter assay. Interestingly, compound <b>4</b> binds to PXR in a “bent-back” conformation, with the 4-chlorophenylsulfonamide group engaged in π-stacking interactions with both the benzimidazole ring as well as the indole side chain of Trp299. It is likely that the introduction of nitrogen atoms into the arylsulfonamide and benzimidazole moieties would impact the electron density in these rings, possibly reducing the ability of these groups to participate in such π-stacking<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and resulting in decreased binding to the receptor. Without detailed structural information regarding the nature of the interaction of compounds from this series to S1P<sub>1</sub>, however, the structural basis for these improvements in PXR activation profile remains unclear.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of compound <b>4</b> bound to human PXR obtained at 2.3 Å resolution (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a>). Coloration is as follows: compound <b>4</b> (yellow), Trp299 (green), Tyr306 (cyan), Met246 (brown).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having identified a number of compounds with reduced PXR activation, we proceeded to test whether these compounds in fact addressed the CYP3A induction liability in human hepatocytes. At the time of our investigations, industry guidance on <i>in vitro</i> induction testing had suggested that compounds that cause increased CYP3A activity (at concentrations approximating an <i>in vivo</i><i>C</i><sub>max</sub>) greater than 40% than that of rifampicin (at 10 μM) were considered to be at risk for induction <i>in vivo</i>.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> A number of compounds meeting our PXR activation criteria indeed resulted in <40% of the CYP3A activity caused by rifampicin in human hepatocytes (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, blue circles). For compounds that did demonstrate increased CYP3A activity (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, red circles), however, the single-point PXR activation assay was largely unpredictive, as a number of compounds perceived to be low risk for induction did carry this liability. This may be attributed, at least in part, to the variability inherent in using single point PXR activation data or hepatocyte studies using liver tissue from different donors.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Alternatively, CYP3A induction resulting from activation of other xenobiotic receptors (such as CAR) has not been considered in our approach. Nevertheless, we were pleased to see that there were no “false negatives,” or compounds that were predicted to be inducers in the PXR assay that did not show increased CYP3A activity. Thus, we felt comfortable that by utilization of the PXR reporter gene assay at a single compound concentration (instead of generating EC<sub>50</sub> values) to prioritize compounds for further testing, we had not unknowingly filtered induction-free compounds from further consideration.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Correlation of PXR activation assay with CYP3A activity in human hepatocytes. Compounds with <40% CYP3A activity observed with rifampicin (both compounds at 10 μM) are colored blue, while those with >40% activity are colored red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the culmination of our chemistry efforts, compounds <b>46</b> and <b>47</b> represented the top candidates for continued evaluation due to their potency, physical properties, and pharmacokinetic profiles in rat and dog (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). These compounds did not show any measurable inhibition of the hERG channel or of any of the major P450 isoforms, and the human CYP3A induction risk was largely mitigated with compound <b>47</b>, which did not show any increase in CYP3A activity upon incubation with human hepatocytes. Compound <b>46</b> did show a borderline increase (43%) in CYP3A activity compared to rifampicin in hepatocytes from one donor, although on retest with a different batch of hepatocytes only a slight increase (5%) in CYP3A activity was observed. In repeat dosing experiments in mouse (at 20 mg/kg) and rat (at 25 mg/kg), neither compound showed appreciable decreases in plasma exposure (1 h postdose) between day 1 and day 5; higher doses (50 mg/kg) of these compounds in mice did result in observable exposure decreases over time, with the effect more pronounced for <b>46</b> than for <b>47</b> (data not shown). Thus, despite known interspecies differences in xenobiotic-induced P450 upregulation, by addressing the human P450 induction liability in this series we had identified compounds and doses suitable for preclinical <i>in vivo</i> pharmacological and toxicological evaluation.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Physical Properties and Pharmacokinetic Parameters for Compounds <b>46</b> and <b>47</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">compound <b>46</b></th><th class="colsep0 rowsep0" align="center">compound <b>47</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (μM, pH 7.4)</td><td class="colsep0 rowsep0" align="left">765</td><td class="colsep0 rowsep0" align="left"> >1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (% free)</td><td class="colsep0 rowsep0" align="left">53 (mouse)</td><td class="colsep0 rowsep0" align="left">41 (mouse)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">32 (rat)</td><td class="colsep0 rowsep0" align="left">18 (rat)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">36 (dog)</td><td class="colsep0 rowsep0" align="left">50 (dog)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">24 (human)</td><td class="colsep0 rowsep0" align="left">19 (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</td><td class="colsep0 rowsep0" align="left">0.3 (mouse)</td><td class="colsep0 rowsep0" align="left">2.5 (mouse)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.1 (rat)</td><td class="colsep0 rowsep0" align="left">3.9 (rat)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.4 (dog)</td><td class="colsep0 rowsep0" align="left">1.7 (dog)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.2 (human)</td><td class="colsep0 rowsep0" align="left">0.2 (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP Inhibition (1A2, 2C9, 2C19, 2D6, 3A4/5) IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">all >20 μM</td><td class="colsep0 rowsep0" align="left">all >20 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG Inhibition (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left"> >200 μM</td><td class="colsep0 rowsep0" align="left"> >200 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hu hepatocyte CYP3A induction (% activity compared to rifampicin)</td><td class="colsep0 rowsep0" align="left">5, 43 (results from two different donors)</td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" colspan="2" align="center">rat pharmacokinetics</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IV dosing, 3 mg/kg</td><td class="colsep0 rowsep0" align="left">IV dosing, 4 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>dss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO dosing (10 mg/kg)</td><td class="colsep0 rowsep0" align="left">PO dosing (10 mg/kg)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="left">13.3</td><td class="colsep0 rowsep0" align="left">21.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (<i>F</i>%)</td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="left">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" colspan="2" align="center">dog pharmacokinetics</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IV dosing, 2.5 mg/kg</td><td class="colsep0 rowsep0" align="left">IV dosing, 2 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>dss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">4.9</td><td class="colsep0 rowsep0" align="left">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO dosing (10 mg/kg)</td><td class="colsep0 rowsep0" align="left">PO dosing (5 mg/kg)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="left">31.1</td><td class="colsep0 rowsep0" align="left">10.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (F%)</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">71</td></tr></tbody></table></div></div><div class="NLM_p">To assess whether treatment with these compounds resulted in pharmacodynamic effects expected from S1P<sub>1</sub> antagonism <i>in vivo</i>, we utilized a previously described Matrigel plug-based model that measured the ability of compounds to inhibit angiogenesis induced by FGF and enhanced by S1P (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In the absence of these growth factors, very little angiogenesis (quantified by the amount of hemoglobin present in the Matrigel plug) occurs in this model, whereas the combination of these results in the formation of well-developed vessels.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In control mice treated with vehicle only, this manifests as a significant increase in hemoglobin content in the plug (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S3). When mice are treated once daily with 10 mg/kg of either <b>46</b> or <b>47</b> for 4 days, a statistically significant reduction in hemoglobin content within the plugs was observed compared to the control group, consistent with these compounds acting as S1P<sub>1</sub> antagonists and suppressing S1P-promoted angiogenesis. Similar observations have been made with S1P<sub>1</sub> siRNA in this model.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0008.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of FGF/S1P-stimulated angiogenesis by compounds <b>46</b> and <b>47</b>. Matrigel (0.5 mL) containing 2 μg/mL β-FGF and 1 μM S1P was injected subcutaneously into the ventral region of female 129s1/SvImJ mice. Compounds <b>46</b> and <b>47</b> were dosed orally at 10 mg/kg, once daily, on days 5–8 postimplant (five animals per cohort). Plasma pharmacokinetics for both compounds was assessed 1 h postdose on day 4 (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S2). The plugs were then harvested, and the amount of hemoglobin per gram of gel was quantified. Treated mice were compared with mice given vehicle used in the dosed groups (0.5% HPMC, 0.1% Tween 80) as a control, as well as mice injected with Matrigel not containing proangiogenic factors. The double asterisk (**) indicates <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further establish that our compounds were exerting pharmacological effects <i>in vivo</i>, we determined whether they induced changes in capillary integrity using an Evans blue dye lung leakage model. Evans blue dye (EBD) binds tightly to the albumin present in plasma, and when vessel function is compromised an increase in EBD in tissue would be observed as a result of leakage of plasma proteins from the vasculature. Several previous studies have demonstrated an increase in EBD content in rodent lungs upon treatment with S1P<sub>1</sub> antagonists, suggesting these compounds cause an increase in pulmonary vascular permeability.<a onclick="showRef(event, 'ref20 ref23 ref42'); return false;" href="javascript:void(0);" class="ref ref20 ref23 ref42">(20, 23, 42)</a> In our hands, when female NCr nude mice were treated orally with either compound <b>46</b> (20 mg/kg) or <b>47</b> (50 mg/kg), plasma concentrations of both compounds at 1 h postdose are more than sufficient to expect target engagement based on <i>in vitro</i> potency and relatively low plasma protein binding (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S4). In this strain of mice, these doses result in a substantial increase in EBD content in the lungs relative to vehicle-treated controls (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S5), consistent with these compounds acting as S1P<sub>1</sub> antagonists <i>in vivo</i>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0009.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Induction of capillary leakage in mouse lungs by compounds <b>46</b> and <b>47</b>. Female NCr nude mice (four animals per cohort) were dosed orally with either compound <b>46</b> (20 mg/kg), compound <b>47</b> (50 mg/kg), or vehicle alone (0.5% HPMC, 0.1% Tween 80). After 1 h, the mice were injected with a solution of Evans blue dye (20 mg/kg). After an additional 30 min, the mice were anesthetized and perfused with 0.9% normal saline. The lungs were harvested, and the amount of Evans blue dye present was determined by spectrophotometry. The amount of dye present was normalized to the amount found in vehicle-treated animals. The double asterisk (**) indicates <i>p</i> < 0.005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having demonstrated that oral doses of compounds <b>46</b> and <b>47</b> achieve plasma concentrations that result in functional effects related to S1P<sub>1</sub> antagonism, we next assessed whether these compounds were efficacious in tumor xenograft studies. A number of xenograft models were explored, with a focus on those in which previous antiangiogenic agents have demonstrated effects on tumor vasculature.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> Despite the observations of <i>in vivo</i> activity described above, only modest antitumor activity was observed with our compounds across the models evaluated. For example, compound <b>47</b> demonstrated 32% tumor growth inhibition in a Calu6 xenograft model when dosed orally at 50 mg/kg twice daily, while compound <b>46</b> (at 20 mg/kg twice daily) did not result in statistically significant reductions in tumor volume (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>). In contrast to the observation of marked increases in capillary leakiness in murine lungs, we did not observe statistically significant increases in EBD accumulation in tumor tissue obtained from either Calu6 or Colo205 xenograft-bearing mice treated with these compounds (data not shown), suggesting that these agents do not substantially affect vascular integrity within the tumor. Even though decreases in plasma exposure (1 h postdose) over time were observed with <b>47</b>, both compounds achieved plasma exposures throughout the duration of these studies comparable to those observed in the previously described <i>in vivo</i> experiments (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S6). Therefore, given the disparity between the activity we observed in the pharmacodynamic models and the various tumor xenograft studies, we conclude that a selective S1P<sub>1</sub> antagonist would have only minimal effects on tumor growth inhibition as a single agent.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0010.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Evaluation of antitumor activity of lead S1P<sub>1</sub> antagonists in a Calu6 xenograft model in female NcR-nude mice. (A) Compound <b>46</b>, dosed orally at 20 mg/kg BID (<i>n</i> = 14) on days 13–32, does not result in statistically significant tumor growth inhibition relative to vehicle (HPMC)-treated controls (<i>n</i> = 20). (B) Compound <b>47</b>, dosed orally at 50 mg/kg BID (<i>n</i> = 14) on days 11–33, results in 32% tumor growth inhibition (<i>p</i> = 0.008) relative to controls (<i>n</i> = 20).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71087" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71087" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The benzimidazole sulfonamides discussed in this paper were prepared as described in the schemes below. The sulfonamide moiety was typically installed in the last step, by the reaction of the chiral amine with commercially available or readily prepared sulfonyl chlorides. The amine reactant was derived from the cyclocondensation of an appropriately substituted aromatic diamine with an alanine derivative. For example, benzimidazole <b>2</b> was obtained by refluxing <i>N</i>-ethyl-1,2-phenylenediamine and <span class="smallcaps smallerCapital">d</span>-alanine in 6 N HCl for several days, followed by coupling with 4-chlorobenzenesulfonyl chloride (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of benzimidazole <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd/C, H<sub>2</sub>, EtOH, rt; (b) <span class="smallcaps smallerCapital">d</span>-Ala-OH, 6 N HCl, 100 °C; (c) 4-chlorobenzenesulfonyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C.</p></p></figure><div class="NLM_p">For the preparation of benzimidazoles containing substituents on the carbocyclic ring, it was necessary to obtain the appropriately substituted 1,2-phenylenediamine derivatives. While in principle the <i>N</i>-ethyl group could be installed following benzimidazole ring formation through alkylation, we were concerned about the prospect of inseparable mixtures of regioisomers and thus sought to install this group prior to cyclization. In many cases, this was conveniently achieved through nucleophilic aromatic substitution on a substituted <i>ortho</i>-halo nitroarene, followed by reduction of the nitro group (as in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Given the harsh cyclization conditions employed in the preparation of <b>2</b>, we chose to pursue a stepwise approach for future analogues to ensure functional group compatibility. Thus, using compound <b>4</b> as a representative example, coupling of the aryl diamine <b>49</b> with Boc-<span class="smallcaps smallerCapital">d</span>-alanine under standard amide bond formation conditions yielded intermediate <b>50</b>. Cyclization to <b>51</b> occurred with heating in glacial HOAc, avoiding excessive reaction temperatures in order to minimize Boc-deprotection or loss in optical activity. Removal of the Boc group followed by sulfonamide installation as above afforded the target compound. While other methods of benzimidazole formation were employed for select cases, the chemistry described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> could be readily applied to most of the compounds prepared in this series. Similarly, variation of the sulfonyl chloride used in the final step (with either commercially available or previously described reagents) afforded the compounds depicted in <a class="ref internalNav" href="#tbl4" aria-label="Tables 4">Tables 4</a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>.</div><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthesis of a Substituted Benzimidazole Sulfonamide<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethylamine (2 M in THF), 100 °C (microwave irradiation); (b) 10% Pd/C, H<sub>2</sub>, EtOH, rt; (c) Boc-<span class="smallcaps smallerCapital">d</span>-Ala-OH, HATU, NEt<sub>3</sub>, DMF, 0 °C to rt; (d) glacial HOAc, 65 °C; (e) 4 N HCl/dioxane, rt; (f) 4-chlorobenzenesulfonyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C.</p></p></figure><div class="NLM_p">For the preparation of azabenzimidazoles from pyridine-derived diamines (as for compounds <b>14</b>–<b>17</b>), the cyclization conditions described above were less effective. As a result, more forcing conditions needed to be employed. For instance, we found that even prolonged heating in refluxing acetic acid failed to convert any of the intermediate amide to the cyclized product. However, when heated at 150 °C under microwave irradiation, the desired products were isolable in low yield. Similarly, we found that the cyclization could be effected at this high temperature using a stoichiometric amount of Lawesson’s reagent. Given the requisite forcing conditions, we intentionally prepared these initial compounds as racemates to alleviate concerns over epimerization during the reaction.</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Forcing Conditions Required for Cyclization of Azabenzimidazoles <b>14</b>–<b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glacial HOAc, 150 °C (microwave irradiation); (b) Lawesson’s reagent, dioxane, 150 °C (microwave irradiation).</p></p></figure><div class="NLM_p">For the preparation of subsequent project compounds containing a substituted azabenzimidazole ring (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>), the requisite pyridine 3,4-diamines were obtained following the chemistry detailed in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Thus, the methoxy- and cyclopropyl-substituted pyridines were obtained from the common precursor <b>53</b>, which in turn was obtained from 4-chloro-3-nitropyridine through a sequence of vicarious nucleophilic substitution of hydrogen<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> followed by chlorination. To prepare the trifluoromethyl-substituted diamine <b>60</b>, 5-bromo-2-(trifluoromethyl)pyridine was deprotonated with LDA, and the resultant anion was quenched with iodine to give <b>58</b>. Displacement of the iodide with ethylamine afforded <b>59</b>, which was converted to the diamine <b>60</b> by palladium-catalyzed amination with benzophenone imine followed by hydrolysis.</div><figure id="sch4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0014.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Diaminopyridine Precursors to Compounds <b>42</b>–<b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Potassium <i>tert</i>-butoxide, <i>tert</i>-butylhydroperoxide (5 M in decane), NH<sub>3</sub>(l), THF, −35 °C; (b) POCl<sub>3</sub>, toluene, 100 °C; (c) ethylamine (2 M in THF), THF, 0 °C; (d) NaOMe, MeOH, 65 °C; (e) SnCl<sub>2</sub>·2 H<sub>2</sub>O, EtOAc, 80 °C; (f) cyclopropylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, toluene, water, 100 °C; (g) H<sub>2</sub> (5 bar), 5% Pd/C, MeOH, rt; (h) LDA, THF, −78 °C, then I<sub>2</sub>; (i) ethylamine (70% in water), EtOH, 80 °C; (j) benzophenone imine, sodium <i>tert</i>-butoxide, Pd<sub>2</sub>(dba)<sub>3</sub>, <i>rac</i>-BINAP, toluene, 110 °C; (k) 2 M HCl, THF, rt.</p></p></figure><div class="NLM_p">Because of the electron-deficient nature of these pyridine substrates, the standard amide bond coupling with Boc-<span class="smallcaps smallerCapital">d</span>-alanine (as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) proved to be troublesome and typically resulted in very low yields. In addition to concerns surrounding the stereochemical integrity of the chiral center that would result from more forcing conditions, most attempts to push these reactions to completion through heating often resulted in unwanted side products. For these particular substrates, we found it advantageous to generate the acylimidazolide of the protected amino acid, which in our hands seemed to be more stable toward gentle heating and resulted in minimal byproduct formation. Thus, pretreatment of Boc-<span class="smallcaps smallerCapital">d</span>-alanine with CDI in CH<sub>2</sub>Cl<sub>2</sub> followed by addition of the diaminopyridine (with heating to 40 °C if necessary) afforded the desired amide intermediates with no observable loss in optical activity (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Since the cyclization conditions described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> were anticipated to result in racemization, we sought to identify an alternative cyclization methodology for these electron-deficient substrates. Ultimately, we found that removal of the Boc-protecting group followed by heating under alkaline conditions yielded the cyclized benzimidazole with minimal epimerization (the products isolated were typically 80–90% ee). Prolonged reaction times for this cyclization resulted in further erosion in optical activity, and so reaction progress was carefully monitored in each case. Following introduction of the sulfonamide moiety, the enantiopure materials were obtained through chiral chromatography (to remove the minor enantiomer) or by recrystallization.</div><figure id="sch5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0015.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Representative Synthetic Route to Access Substituted Azabenzimidazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CDI, CH<sub>2</sub>Cl<sub>2</sub>, rt, then <b>55</b>, rt; (b) 4 N HCl/dioxane, rt; (c) NaOH, EtOH, 80 °C; (d) 4-cyanobenzenesulfonyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, then chiral chromatography.</p></p></figure><div class="NLM_p">For compounds <b>45</b>–<b>47</b>, the requisite sulfonyl chloride <b>63</b> was synthesized from 5-aminopicolinonitrile, through reaction of the corresponding diazonium hydrochloride salt with sulfur dioxide (prepared <i>in situ</i> by hydrolysis of thionyl chloride, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0016.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of Sulfonyl Chloride <b>63</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) conc. HCl, NaNO<sub>2</sub>, water, 0 °C; (b) thionyl chloride, water, 0 °C, then CuCl, 0 °C.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have discovered a novel class of benzimidazole sulfonamides that act as S1P<sub>1</sub> antagonists, by scaffold hopping from a lead series we have previously described. Our initial efforts in this series were directed at developing structure–activity relationships and at identifying drivers for improving overall metabolic stability. The early <i>in vivo</i> probe compounds thus obtained appeared to be inducers of metabolic enzymes in mouse, and in subsequent experiments demonstrated potent induction of CYP3A in human hepatocytes. In order to overcome this liability, we utilized a PXR reporter gene assay to prioritize compounds for assessment of CYP3A activity in human hepatocytes. Ultimately, by focusing on reducing compound lipophilicity through the introduction of polar moieties known to be tolerated within this scaffold, we have identified compounds (such as <b>46</b> and <b>47</b>) which are largely free of any human P450 induction issues. These compounds both show indirect evidence of target engagement <i>in vivo</i> when dosed orally, exhibiting pharmacodynamic effects consistent with previously described S1P<sub>1</sub> antagonists. In a variety of xenograft models, we did not see any evidence of antiangiogenic effects in tumor tissue, and only modest antitumor activity was observed. Taken together, these data suggest that selective S1P<sub>1</sub> antagonists would not have significant activity as single agent anticancer therapeutics.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All reagents and solvents used were purchased from commercial sources and were used without further purification. <sup>1</sup>H NMR spectra were obtained using a Bruker 300 or 400 MHz spectrometer at room temperature; chemical shifts are expressed in parts per million (ppm, δ units) and are referenced to the residual protons in the deuterated solvent used. Coupling constants are given in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br s (broad singlet). Mass spectrometry analyses were performed with an Agilent 1100 equipped with Waters columns (Atlantis T3, 2.1 × 50 mm, 3 μm; or Atlantis dC18, 2.1 × 50 mm, 5 μm) eluted with a gradient mixture of water and acetonitrile with either formic acid or ammonium acetate added as a modifier. Reverse-phase chromatography was performed on a Gilson system using an Atlantis Prep T3 OBD reverse-phase HPLC column (19 mm × 100 mm) in water/MeCN with 0.1% TFA as mobile phase. Thin layer chromatography was performed using EMD silica gel 60 F<sub>254</sub> plates, which were visualized using UV light. Column chromatography was performed using SiliCycle Silia<i>Sep</i> preloaded silica gel cartridges on Teledyne ISCO CombiFlash Companion automated purification systems. All final compounds were purified to ≥95% purity as assessed by analytical HPLC using an Agilent 1100 equipped with Waters columns (Atlantis T3, 2.1 × 50 mm, 3 μm; or Atlantis dC18, 2.1 × 50 mm, 5 μm) eluted for >10 min with a gradient mixture of water and acetonitrile with either formic acid or ammonium acetate added as a modifier, monitored at wavelengths of 220, 254, and 280 nm. All <i>in vivo</i> experiments described in this article were conducted in accordance with the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals, and within the protocols approved by the Institute of Animal Care and Use Committee at AstraZeneca.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>R</i>)-1-(1-Ethyl-1<i>H</i>-benzo[d]imidazol-2-yl)ethanamine (<b>48</b>)</h3><div class="NLM_p last">To a solution of 1-ethyl-2-nitroaniline (5.0 g, 30.0 mmol) in EtOH (100 mL) was added 10% Pd on carbon (1.24 g). The mixture was hydrogenated in a Parr apparatus under 50 psi of H<sub>2</sub> gas for 2 h, and the resulting mixture was filtered through Celite. The filter cake was washed with EtOAc, and the combined filtrates were concentrated under reduced pressure to give the diamine as brown oil (4.0 g, quantitative). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.28 (t, <i>J</i> = 7.1 Hz, 3H), 3.12–3.19 (m, 5H), 6.68–6.72 (m, 4H). LC-MS (M + H) 137. A mixture of this material (2.00 g, 14.7 mmol) and <span class="smallcaps smallerCapital">d</span>-alanine (2.2 g, 22.0 mmol) in 6 N aqueous HCl (15.0 mL) was heated at 100 °C for a total of 6 days. The mixture was allowed to cool, was neutralized with 2 N NaOH, and was extracted with EtOAc (3 × 50 mL). The combined organics were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude material was purified by silica gel chromatography (95:5 CHCl<sub>3</sub>:MeOH) to give the title compound as a brown oil (2.25 g, 81%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.45 (t, <i>J</i> = 7.1 Hz, 3H), 1.61 (d, <i>J</i> = 7.1 Hz, 3H), 1.81 (br. s., 2H), 4.17–4.36 (m, 3H), 7.21–7.37 (m, 3H), 7.72–7.78 (m, 1H). LC-MS (M + H) 190.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(1-ethyl-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>2</b>)</h3><div class="NLM_p last">A solution of <b>48</b> (700 mg, 3.70 mmol) and NEt<sub>3</sub> (1.70 mL, 12.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was cooled to 0 °C. A solution of 4-chlorobenzenesulfonyl chloride (820 mg, 3.88 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added dropwise, and the reaction mixture was allowed to stir at room temperature overnight. The mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and water, and the organic layer was washed with brine and was then concentrated under reduced pressure. The crude material was purified by silica gel chromatography (98:2 CHCl<sub>3</sub>:MeOH) to give the title compound as a solid (1.30 g, 97%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.35 (t, <i>J</i> = 7.1 Hz, 3H), 1.56 (d, <i>J</i> = 6.9 Hz, 3H), 3.99–4.24 (m, 2H), 4.75–4.85 (m, 1H), 6.18 (d, <i>J</i> = 8.3 Hz, 1H), 7.16–7.26 (m, 5H), 7.57–7.64 (m, 3H). LC-MS (M+H) 364.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>1-Ethyl-5-(trifluoromethyl)benzene-1,2-diamine (<b>49</b>)</h3><div class="NLM_p last">A microwave reaction tube was charged with a stir bar and with 2-chloro-1-nitro-4-(trifluoromethyl)benzene (776 mg, 3.44 mmol). The tube was then charged with a 2 M MeOH solution of ethylamine (5.0 mL, 10.0 mmol) and was sealed and heated at 150 °C for 2 h in a microwave reactor. The resulting mixture was transferred to a round-bottom flask and was concentrated under reduced pressure. The orange-yellow solid was partitioned between EtOAc and water, and the aqueous layer was extracted with EtOAc. The combined organics were washed with brine and were concentrated under reduced pressure to give the substituted 2-nitroaniline as a yellow-orange solid (811 mg). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.22 (t, <i>J</i> = 7.1 Hz, 3H), 3.41–3.48 (m, 2 H), 6.90–6.95 (m, 1H) 7.25–7.28 (m, 1H), 8.12–8.20 (m, 1H), 8.21–8.26 (m, 1H). LC-MS (M + H) 235. The flask containing this material (811 mg, 3.46 mmol) was charged with absolute EtOH (20 mL). The flask was evacuated and backfilled with N<sub>2</sub> (2x), and then 10% palladium on carbon (115 mg, 0.11 mmol) was added. The flask was then evacuated and backfilled with H<sub>2</sub> via a filled balloon (this was repeated twice), and the resulting mixture was allowed to stir at room temperature under 1 atm H<sub>2</sub>. After being stirred overnight, the flask was evacuated and backfilled with N<sub>2</sub>, and the mixture was suction filtered through a pad of Celite. The reaction flask and filter cake were washed well with EtOH, and the combined filtrates were concentrated under reduced pressure to give the title compound as a gray-colored oil (687 mg, 97% over 2 steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.21 (t, <i>J</i> = 7.1 Hz, 3H), 3.01–3.11 (m, 2H), 4.66–4.75 (m, 1H), 5.19 (br. s., 2H), 6.49–6.53 (m, 1H), 6.56–6.61 (m, 1H), 6.67–6.74 (m, 1H). LC-MS (M + H) 205.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>R</i>)-<i>tert</i>-Butyl (1-((2-(Ethylamino)-4-(trifluoromethyl)phenyl)amino)-1-oxopropan-2-yl)carbamate (<b>50</b>)</h3><div class="NLM_p last">A 250 mL round-bottom flask containing <b>49</b> (687 mg, 3.36 mmol) was charged with (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)propanoic acid (700 mg, 3.70 mmol) and anhydrous DMF (14 mL). The solution was treated with triethylamine (0.52 mL, 3.73 mmol) and was cooled to 0 °C before HATU (1.44 g, 3.79 mmol) was added. Additional DMF (1 mL) was added, and the resulting solution was allowed to stir at 0 °C with slow warming to room temperature. After being stirred overnight, the reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organics were concentrated under reduced pressure. The crude material was purified by silica gel chromatography (gradient elution; <i>R</i><sub><i>f</i></sub> in 60:40 hexanes:EtOAc = 0.43) to give the title compound as a colorless solid (968 mg, 77%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.20 (t, <i>J</i> = 7.0 Hz, 3H), 1.27 (d, <i>J</i> = 7.0 Hz, 3H), 1.39 (s, 9H), 3.07–3.16 (m, 2H), 4.02–4.13 (m, 1H), 5.13–5.21 (m, 1H), 6.77–6.81 (m, 1H), 6.84–6.89 (m, 1H), 7.15–7.20 (m, 1H), 7.27–7.33 (m, 1H), 9.32–9.39 (m, 1H). LC-MS (M + H) 376.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>R</i>)-<i>tert</i>-Butyl (1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)carbamate (<b>51</b>)</h3><div class="NLM_p last">A 250 mL round-bottom flask containing <b>50</b> (603 mg, 1.61 mmol) was charged with glacial HOAc (10 mL), and the resulting mixture was heated in a 65 °C oil bath for 2 h. The reaction was allowed to cool and was concentrated under reduced pressure, and the crude material was purified by silica gel chromatography (gradient elution; <i>R</i><sub><i>f</i></sub> in 60:40 hexanes:EtOAc = 0.47) to give the product as a colorless solid (491 mg, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.0 Hz, 3H), 1.37 (s, 9H), 1.50 (d, <i>J</i> = 7.0 Hz, 3H), 4.28–4.46 (m, 2H), 5.00–5.11 (m, 1H), 7.45–7.51 (m, 1H), 7.54–7.61 (m, 1H), 7.74–7.80 (m, 1H), 7.96–8.02 (m, 1H). LC-MS (M + H) 358.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>4</b>)</h3><div class="NLM_p">A 100 mL round-bottom flask was charged with <b>51</b> (202 mg, 0.57 mmol). A solution of 4 N HCl in dioxane (4.0 mL, 16 mmol) was added, and the resulting solution was allowed to stir at room temperature. After 2 h, the mixture was concentrated under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL) and then was treated with triethylamine (250 μL, 1.79 mmol) before being cooled to 0 °C. The mixture was then treated with 4-chlorobenzenesulfonyl chloride (171 mg, 0.81 mmol) and was allowed to stir at 0 °C. After 2 h, the mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and water. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organics were concentrated under reduced pressure. The crude material was purified by silica gel chromatography (gradient elution; <i>R</i><sub><i>f</i></sub> in 60:40 hexanes:EtOAc = 0.33) to give the title compound as a colorless solid (152 mg, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29 (t, <i>J</i> = 7.5 Hz, 3H), 1.40 (t, <i>J</i> = 7.0 Hz, 3H), 4.26–4.42 (m, 2H), 4.81–4.92 (m, 1H), 7.35–7.42 (m, 2H), 7.43–7.49 (m, 1H), 7.62–7.70 (m, 3H), 7.91–7.97 (m, 1H), 8.59–8.66 (m, 1H). LC-MS (M + H) 432.</div><div class="NLM_p last">The compounds described in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were prepared using procedures analgous to those described above for compound <b>4</b>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(1-ethyl-6-methoxy-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>3</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.33 (t, 3H), 1.52 (d, 3H), 3.86 (s, 3H), 3.98 (m, 1H), 4.15 (m, 1H), 4.82 (m, 1H), 6.60 (m, 1H), 6.86 (m, 1H), 7.15 (m, 1H), 7.25 (m, 2H), 7.51 (m, 1H), 7.69 (m, 2H). LC-MS (M + H) 394.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(6-chloro-1-ethyl-5-fluoro-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>5</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.40 (t, <i>J</i> = 7.5 Hz, 3H), 1.60 (<i>J</i> = 6.0 Hz, 3H), 4.01–4.13 (m, 1H), 4.14–4.26 (m, 1H), 4.75–4.85 (m, 1H), 5.81–5.89 (m, 1H), 7.22–7.30 (m, 2H), 7.31–7.35 (m, 1H), 7.37–7.42 (m, 1H), 7.61–7.68 (m, 2H). LC-MS (M + H) 417.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>R)</i>-4-Chloro-<i>N</i>-(1-(5-cyano-1-ethyl-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>6</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.43 (t, 3H), 1.59 (d, 3H), 4.16 (m, 1H), 4.28 (m, 1H), 4.88 (m, 1H), 6.22 (m, 1H), 7.25 (m, 2H), 7.37 (m, 1H), 7.54 (m, 1H), 7.67 (m, 2H), 7.95 (m, 1H). LC-MS (M + H) 389.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(1-ethyl-5-(hydroxymethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>7</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29 (t, <i>J</i> = 7.2 Hz, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 4.20–4.31 (m, 2H), 4.58 (m, 2H), 4.79–4.90 (m, 1H), 5.12 (br. s., 1H), 7.20 (m, 1H), 7.44 (m, 1H), 7.46 (m, 1H), 7.52 (m, 2H), 7.75 (m, 2H), 8.55 (m, 1H). LC-MS (M + H) 394.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(1-ethyl-6-(hydroxymethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>8</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 4.24 (m, 2H), 4.60 (d, <i>J</i> = 5.8 Hz, 2H), 4.82 (m, 1H), 5.18 (t, <i>J</i> = 5.8 Hz, 1H), 7.11 (m, 1H), 7.41 (m, 1H), 7.45 (m, 1H), 7.51 (m, 2H), 7.74 (m, 2H), 8.52 (m, 1H). LC-MS (M + H) 394.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>R</i>)-2-(1-(4-Chlorophenylsulfonamido)ethyl)-1-ethyl-1<i>H</i>-benzo[d]imidazole-5-carboxamide (<b>9</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 1.40 (d, <i>J</i> = 6.8 Hz, 3H), 4.35 (m, 2H), 4.86–4.97 (m, 1H), 7.34 (br. s., 1H), 7.52 (m, 2H), 7.67 (m, 1H), 7.74 (m, 2H), 7.84–7.95 (m, 1H), 8.00 (br. s., 1H), 8.12 (m, 1H), 8.72 (m, 1H). LC-MS (M + H) 407.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(6-((dimethylamino)methyl)-1-ethyl-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>10</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31–1.44 (m, 6H), 2.74 (m, 6H), 4.31 (m, 2H), 4.39 (m, 2H), 4.90 (m, 1H), 7.33 (m, 1H), 7.49 (m, 2H), 7.63 (m, 1H), 7.71 (m, 3H), 8.70 (m, 1H). LC-MS (M + H) 421.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(1-ethyl-5-morpholino-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>11</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.26 (t, 3H), 1.33 (d, 3H), 3.03 (m, 4H), 3.75 (m, 4H), 4.18 (m, 2H), 4.76 (m, 1H), 6.97 (m, 2H), 7.33 (m, 1H), 7.46 (m, 2H), 7.69 (m, 2H), 8.48 (m, 1H). LC-MS (M + H) 449.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(1-ethyl-6-(methylsulfonyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>12</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.33 (t, <i>J</i> = 7.2 Hz, 3H), 1.39 (d, <i>J</i> = 6.8 Hz, 3H), 3.22 (s, 3H), 4.38 (m, 2H), 4.8 5- 4.94 (m, 1H), 7.41 (m, 2H), 7.66 (m, 2H), 7.69 (m, 2H), 8.10 (m, 1H), 8.65 (m, 1H). LC-MS (M + H) 442.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>R</i>)-4-Chloro-<i>N</i>-(1-(7-chloro-1-ethyl-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>13</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.35–1.39 (m, 6H), 4.39–4.55 (m, 2H), 4.83–4.89 (m, 1H), 7.13–7.26 (m, 2H), 7.43–7.51 (m, 3H), 7.67–7.71 (m, 2H), 8.63 (br. s., 1H). LC-MS (M + H) 399.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-Chloro-<i>N</i>-(1-(3-ethyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>14</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, 3H), 1.40 (d, 3H), 4.30 (q, 2H), 4.81–4.95 (m, 1H), 7.18–7.27 (m, 1H), 7.45 (d, 2H), 7.70 (d, 2H), 7.92–8.00 (m, 1H), 8.32–8.39 (m, 1H), 8.65–8.73 (m, 1H). LC-MS (M + H) 365.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-Chloro-<i>N</i>-(1-(3-ethyl-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>15</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 1.45 (t, <i>J</i> = 7.2 Hz, 3H), 1.52 (d, <i>J</i> = 7.2 Hz, 3H), 4.39–4.49 (m, 2H), 4.90–5.00 (m, 1H), 7.26–7.32 (m 2H), 7.49–7.54 (m, 1H), 7.62–7.68 (m, 2H), 8.27–8.31 (m, 1H), 8.80–8.83 (m, 1H). LC-MS (M + H) 365.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-Chloro-<i>N</i>-(1-(1-ethyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>16</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 1.60 (t, 3H), 1.66 (d, 3H), 4.45 (q, 2H), 5.01 (m, 1H), 7.34 (m, 2H), 7.60 (m, 2H), 7.75 (m, 2H), 8.33 (m, 1H), 8.86 (m, 1 H). LC-MS (M + H) 365.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-Chloro-<i>N</i>-(1-(1-ethyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>17</b>)</h3><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 1.40 (t, 3H), 1.65 (d, 3H), 4.37 (q, 2H), 4.86 (m, 1H), 7.28 (m, 2H), 7.41 (d, 2H), 7.64 (d, 2H), 7.88 (d, 1H), 8.45 (d, 1H). LC-MS (M + H) 365.</div><div class="NLM_p last">The compounds described in <a class="ref internalNav" href="#tbl4" aria-label="Tables 4">Tables 4</a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> were prepared from intermediate <b>51</b> and the appropriate sulfonyl chloride, following the same procedure as that employed for compound <b>4</b>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)cyclopropanesulfonamide (<b>18</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 0.83 (m, 1H), 0.97 (m, 1H), 1.11 (m, 1H), 1.21 (m, 1H), 1.59 (t, 3H), 1.85 (d, 3H), 2.33 (m, 1H), 4.34–4.52 (m, 2H), 5.09 (m, 1H), 6.34 (m, 1H), 7.67 (d, 1H), 7.75 (m, 1H), 7.92 (m, 1H). LC-MS (M + H) 362.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)cyclopentanesulfonamide (<b>19</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.55 (m, 5H), 1.70–1.75 (m, 2H), 1.81 (d, 3H), 1.90–2.01 (m, 4H), 3.36 (m, 1H), 4.30–4.51 (m, 2H), 5.08 (m, 1H), 7.19 (m, 1H), 7.70 (m, 1H), 7.92 (m, 1H). LC-MS (M + H) 390.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>20</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.44 (t, 3H), 1.66 (d, 3H), 4.19 (m, 1H), 4.30 (m, 1H), 4.90 (m, 1H), 6.98 (m, 1H), 7.24–7.35 (m, 3H), 7.54–7.58 (m, 2H), 7.71–7.77 (m, 3H). LC-MS (M + H) 398.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-4-fluorobenzenesulfonamide (<b>21</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.39 (t, 3H), 1.54 (d, 3H), 4.12 (m, 1H), 4.29 (m, 1H), 4.90 (m, 1H), 6.98 (m, 2H), 7.13 (m, 1H), 7.48 (m, 2H), 7.78 (m, 3H). LC-MS (M + H) 416.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-4-methylbenzenesulfonamide (<b>22</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 2.21 (s, 3H), 4.28–4.40 (m, 2H), 4.82 (m, 1H), 7.17 (m, 2H), 7.43–7.53 (m, 1H), 7.58 (m, 2H), 7.69 (m, 1H), 7.94 (m, 1H), 8.39 (m, 1H). LC-MS (M + H) 412.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>R</i>)-4-Cyano-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>23</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.43 (t, 3H), 1.58 (d, 3H), 4.15 (m, 1H), 4.31 (m, 1H), 4.95 (m, 1H), 7.25 (m, 1H), 7.51–7.59 (m, 4H), 7.75 (m, 1H), 7.87 (m, 2H). LC-MS (M + H) 423.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>R</i>)-3-Chloro-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>24</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.48 (t, 3H), 1.68 (d, 3H), 4.14–4.40 (m, 2H), 4.91 (m, 1H), 6.27 (m, 1H), 7.20 (m, 2H), 7.55 (m, 1H), 7.60 (m, 1H), 7.64 (m, 2H), 7.69 (m, 1H). LC-MS (M + H) 433.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>R</i>)-3-Cyano-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)benzenesulfonamide (<b>25</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.46 (t, 3H), 1.65 (d, 3H), 4.14–4.27 (m, 1H), 4.27–4.39 (m, 1H), 4.91 (m, 1H), 6.90 (m, 1H), 7.35 (m, 1H), 7.43 (m, 1H), 7.54 (m, 1H), 7.62 (m, 2H), 7.83 (m, 1H), 7.95 (m, 1H). LC-MS (M + H) 423.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>R</i>)-<i>N</i>-(4-(<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)sulfamoyl)-2-methylphenyl)acetamide (<b>26</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.41 (t, 3H), 1.73 (d, 3H), 1.86 (s, 3H), 2.08 (s, 3H), 4.18 (m, 2H), 4.83 (m, 1H), 6.65 (m, 1H), 7.45–7.58 (m, 4H), 7.75 (m, 1H), 7.83 (m, 1H). LC-MS (M + H) 469.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-4-isobutylbenzenesulfonamide (<b>27</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 0.66 (d, 6H), 1.33 (t, 3H), 1.48–1.60 (m, 1H), 1.57 (d, 3H), 2.19 (d, 2H), 3.99–4.11 (m, 1H), 4.13–4.26 (m, 1H), 4.79 (m, 1H), 6.07 (m, 1H), 6.89 (m, 2H), 7.44 (s, 1H), 7.46 (s, 1H), 7.53 (m, 2H), 7.63 (m, 1H). LC-MS (M + H) 454.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-2,4,6-trifluorobenzenesulfonamide (<b>28</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.39 (t, 3H), 1.67 (d, 3H), 4.17 (m, 1H), 4.35 (m, 1H), 5.02 (m, 1H), 6.27 (m, 1H), 6.32–6.40 (m, 2H), 7.46 (m, 1H), 7.53 (m, 1H), 7.61 (m, 1H). LC-MS (M + H) 452.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)pyridine-2-sulfonamide (<b>29</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.49 (t, 3H), 1.65 (d, 3H), 4.23 (m, 1H), 4.42 (m, 1H), 5.20 (m, 1H), 7.13 (m, 1H), 7.22 (m, 1H), 7.44 (m, 1H), 7.65–7.75 (m, 2H), 7.90 (m, 1H), 8.32 (m, 1H). LC-MS (M + H) 399.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)pyridine-3-sulfonamide (<b>30</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.40 (t, 3H), 1.58 (d, 3H), 4.06–4.36 (m, 2H), 4.87–4.98 (m, 1H), 6.96–7.05 (m, 1H), 7.14–7.21 (m, 1H), 7.44–7.51 (m, 2H), 7.68–7.74 (m, 1H), 7.96–8.02 (m, 1H), 8.51–8.55 (m, 1H), 8.98–9.02 (m, 1H). LC-MS (M + H) 399.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)pyridine-4-sulfonamide (<b>31</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.41 (t, 3H), 1.57 (d, 3H), 1.86–1.95 (m, 1H), 4.07–4.36 (m, 2H), 4.93 (d, 1H), 7.46–7.54 (m, 2H), 7.59 (m, 2H), 7.68–7.74 (m, 1H), 8.63 (m, 2H). LC-MS (M + H) 399.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-1,3-dimethyl-1<i>H</i>-pyrazole-4-sulfonamide (<b>32</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.29 (s, 3H), 1.31 (s, 3H), 1.51 (t, 3H), 1.77 (d, 3H), 4.32 (m, 1H), 4.43 (m, 1H), 5.01 (m, 1H), 6.67 (m, 1H), 7.62 (m, 1H), 7.69 (m, 1H), 7.89 (m, 1H). LC-MS (M + H) 416.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-3-methyl-1-propyl-1<i>H</i>-pyrazole-4-sulfonamide (<b>33</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 0.81 (t, 3H), 1.51 (t, 3H), 1.66 (m, 2H), 1.73 (m, 3H), 2.39 (s, 3H), 3.77 (t, 2H), 4.30 (m, 1H), 4.38 (m, 1H), 4.95 (m, 1H), 6.28 (m, 1H), 7.63 (m, 2H), 7.67 (m, 1H), 7.87 (m, 1H). LC-MS (M + H) 444.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>R</i>)-1-Ethyl-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-1<i>H</i>-pyrazole-4-sulfonamide (<b>34</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.21 (t, 3H), 1.50 (t, 3H), 1.74 (d, 3H), 3.84 (q, 2H), 4.22–4.40 (m, 2H), 4.97 (m, 1H), 6.65 (m, 1H), 7.59 (m, 1H), 7.61 (m, 1H), 7.63 (m, 1H), 7.71 (m, 1H), 7.86 (1, H). LC-MS (M + H) 416.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>R</i>)-1-Ethyl-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-5-methyl-<i>1H-</i>pyrazole-4-sulfonamide (<b>35</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.22 (t, 3H), 1.67 (t, 3H), 1.90 (d, 3H), 2.57 (s, 3H), 3.90 (m, 2H), 4.45 (m, 1H), 4.59 (m, 1H), 5.12 (m, 1H), 7.40 (m, 1H), 7.80–7.84 (m, 3H), 7.98 (m, 1H). LC-MS (M + H) 430.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-5-methyl-1-propyl-1<i>H</i>-pyrazole-4-sulfonamide (<b>36</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 0.58 (t, 3H), 1.27 (m, 2H), 1.37 (t, 3H), 1.60 (d, 3H), 2.28 (s, 3H), 3.49 (m, 2H), 4.16 (m, 2H), 4.75 (m, 1H), 6.17 (m, 1H), 7.49–7.53 (m, 3H), 7.71 (m, 1H). LC-MS (M + H) 444.</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-1-isopropyl-5-methyl-1<i>H</i>-pyrazole-4-sulfonamide (<b>37</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 0.80 (d, 3H), 1.19 (d, 3H), 1.40 (t, 3H), 1.62 (d, 3H), 2.31 (s, 3H), 3.96–4.04 (m, 1H), 4.09–4.31 (m, 2H), 4.80 (m, 1H), 6.38 (m, 1H), 7.46 (m, 1H), 7.51 (m, 1H), 7.55 (m, 1H), 7.70 (m, 1H). LC-MS (M + H) 444.</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-1,2-dimethyl-1<i>H</i>-imidazole-4-sulfonamide (<b>38</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.42 (t, 3H), 1.65 (d, 3H), 1.85 (s, 3H), 3.60 (s, 3H), 4.18 (m, 2H), 4.76 (m, 1H), 6.57 (m, 1H), 7.41 (m, 1H), 7.54 (m, 1H), 7.60 (m, 1H), 7.78 (m, 1H). LC-MS (M + H) 416.</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>R</i>)-<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)-1,2-dimethyl-1<i>H</i>-imidazole-5-sulfonamide (<b>39</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.58 (t, 3H), 1.80 (d, 3H), 2.39 (s, 3H), 3.67 (s, 3H), 4.35–4.51 (m, 2H), 5.05 (m, 1H), 7.71–7.76 (m, 3H), 7.94 (m, 1H). LC-MS (M + H) 416.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>R</i>)-<i>N</i>-(5-(<i>N</i>-(1-(1-Ethyl-6-(trifluoromethyl)-1<i>H</i>-benzo[d]imidazol-2-yl)ethyl)sulfamoyl)thiazol-2-yl)acetamide (<b>40</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.55 (t, 3H), 1.74 (d, 3H), 2.12 (s, 3H), 4.38 (m, 2H), 5.09 (m, 1H), 7.59–7.67 (m, 2H), 7.77 (m, 2H). LC-MS (M + H) 462.</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 2,4-Dichloro-5-nitropyridine (<b>52</b>)</h3><div class="NLM_p last">Anhydrous THF (50 mL) was cooled to −78 °C, and NH<sub>3</sub> (gas, about 30 mL) was condensed into the THF. Potassium <i>tert</i>-butoxide (9.3 g, 79 mmol) was added, and the mixture was allowed to warm to −35 °C. In a separate flask, 4-chloro-3-nitropyridine (4.1 g, 26 mmol) was dissolved in anhydrous THF (40 mL), and the solution was cooled to 0 °C before <i>tert</i>-butylhydroperoxide (5 M in decane; 7.0 mL, 35 mmol) was added. The resulting solution was added dropwise to the solution of potassium <i>tert</i>-butoxide mixtrue over 30 min. The resulting mixture was allowed to stir at −35 °C for an additional 30 min and was then cooled to −78 °C before slowly quenching with saturated NH<sub>4</sub>Cl solution (20 mL). The mixture was allowed to warm to room temperature open to the atmosphere overnight and was then concentrated to small volume under reduced pressure. The resulting suspension was filtered, and the solid was washed wih cold water (3 × 10 mL) and dried <i>in vacuo</i> to afford 4-chloro-5-nitropyridin-2-ol as a yellow solid (2.7 g, 60%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 5.95 (s, 1H), 8.80 (s, 1H). LC-MS (M-H) 173. This material was suspended in toluene (60 mL), and POCl<sub>3</sub> (14.2 mL, 156 mmol) was added. The mixture was heated at reflux for 6 h and was then heated at 60 °C overnight. Upon cooling, the mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc and saturated K<sub>2</sub>CO<sub>3</sub>, and the organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered through a short pad of silica gel (eluting with 1:1 hexanes:EtOAc), and concentrated under reduced pressure to give the title compound as a brown solid (2.2 g, 75%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.23 (s, 1H), 9.18 (s, 1H). LC-MS (M – H) 193.</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-Chloro-<i>N</i>-ethyl-5-nitropyridin-4-amine (<b>53</b>)</h3><div class="NLM_p last">A solution of <b>52</b> (1.7 g, 8.8 mmol) in THF (10 mL) was cooled to 0 °C, and then ethylamine (2 M solution in THF; 10 mL, 20 mmol) was slowly added. Upon completion of the reaction (as judged by TLC), the mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc and water, and the organic layer was concentrated to give the title compound as a yellow solid (1.44 g, 81%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.17 (m, 3H), 3.44 (m, 2H), 7.10 (s, 1H), 8.51 (s, 1H), 8.87 (s, 1H). LC-MS (M – H) 202.</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-Ethyl-2-methoxy-5-nitropyridin-4-amine (<b>54</b>)</h3><div class="NLM_p last">A 250 mL round-bottom flask containing <b>53</b> (986 mg, 4.89 mmol) was charged with MeOH (25 mL) and NaOMe (1.12 g, 20.7 mmol). The mixture was heated overnight in a 65 °C oil bath and then allowed to cool and was concentrated under reduced pressure. The residue was partitioned between EtOAc and water, and the aqueous layer was further extracted with EtOAc. The combined organics were washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated to give the product as a pale yellow solid (827 mg, 86%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.37 (t, <i>J</i> = 7.2 Hz, 3H), 3.26–3.35 (m, 2H), 3.99 (s, 3H), 5.95 (s, 1H), 7.90 (br. s., 1H), 9.01 (s, 1H). LC-MS (M + H) 198.</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>4-Ethyl-6-methoxypyridine-3,4-diamine (<b>55</b>)</h3><div class="NLM_p last">A 250 mL round-bottom flask containing <b>54</b> (827 mg, 4.19 mmol) was charged with tin(II) chloride dihydrate (3.82 g, 16.9 mmol) and EtOAc (15 mL). The resulting mixture was heated to 80 °C. After 4 h, the mixture was allowed to cool and was treated with aqueous NaHCO<sub>3</sub>, precipitating a colorless solid. The mixture was suction filtered through a pad of diatomaceous earth, and the reaction flask and filter were thoroughly washed with water and EtOAc. The filtrate layers were separated, and the aqueous layer was further extracted with EtOAc. The combined organics were washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated to give the product as a dark red solid (465 mg, 66%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.30 (t, <i>J</i> = 7.2 Hz, 3H), 2.77 (br. s., 2H), 3.11–3.22 (m, 2H), 3.86 (s, 3H), 4.34 (br. s., 1H), 5.90 (s, 1H), 7.50 (s, 1H). LC-MS (M + H) 168.</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 2-Cyclopropyl-<i>N</i>-ethyl-5-nitropyridin-4-amine (<b>56</b>)</h3><div class="NLM_p last">A 100 mL round-bottom flask was charged with <b>53</b> (0.60 g, 2.9 mmol), cyclopropylboronic acid (0.65 g, 7.5 mmol), and K<sub>3</sub>PO<sub>4</sub> (1.92 g, 15.0 mmol). Toluene (45 mL) and water (5 mL) were added, and N<sub>2</sub> was bubbled into the mixture for 20 min before Pd(PPh<sub>3</sub>)<sub>4</sub> (0.85 g, 0.75 mmol) was added. The reaction was heated at 100 °C overnight and was then allowed to cool. The mixture was partitioned between EtOAc and water, and the aqueous layer was further extracted with EtOAc. The combined organics were concentrated under reduced pressure, and the crude material was purified by silica gel chromatography (0–80% EtOAc:hexane gradient) to give the title compound as a solid (270 mg, 45%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.97 (m, 4H), 1.21 (t, <i>J</i> = 7.2 Hz, 3H), 2.10 (m, 1H), 3.43 (m, 2H), 6.92 (s, 1H), 8.30 (m, 1H), 8.90 (s, 1H). LC-MS (M + H) 208.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 6-Cyclopropyl-<i>N</i>4-ethylpyridine-3,4-diamine (<b>57</b>)</h3><div class="NLM_p last">A mixture of <b>56</b> (0.50 g, 2.4 mmol) and 5% Pd/C (100 mg) in MeOH (50 mL) was stirred under 5 bar H<sub>2</sub> at room temperature. After 3 h, the mixture was filtered through Celite, and filter pad was washed with MeOH. Concentration of the filtrate afforded the title compound as a purple solid (380 mg, 89%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.72 (m, 2H), 0.75 (m, 2H), 1.20 (t, <i>J</i> = 7.2 Hz, 3H), 1.82 (m, 1H), 3.13 (m, 2H), 4.43 (s, 2H), 5.40 (s, 1H), 6.25 (s, 1H), 7.46 (s, 1H). LC-MS (M + H) 178.</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 5-Bromo-4-iodo-2-(trifluoromethyl)pyridine (<b>58</b>)</h3><div class="NLM_p last">A solution of 5-bromo-2-(trifluoromethyl)pyridine (4.06 g, 18.0 mmol) in THF (25 mL) was dropwise added to a solution of lithium diisopropylamide (9.0 mL, 18.0 mmol) in THF/heptane/ethylbenzene over 15 min at −78 °C under N<sub>2</sub>. After 2 h at −78 °C, a solution of iodine (4.65 g, 18.3 mmol) in THF (25 mL) was added dropwise over 20 min. The mixture was held at −78 °C for 15 min and was then poured into a mixture of 2 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (10 mL) and diethyl ether (20 mL). The layers were separated, and the aqueous layer was further extracted with ether. The combined organics were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to give the crude product (5.08 g, 80%). This was used directly without further purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 7.56 (s, 1H), 8.99 (s, 1H). LC-MS (M + H) 352.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 5-Bromo-<i>N</i>-ethyl-2-(trifluoromethyl)pyridin-4-amine (<b>59</b>)</h3><div class="NLM_p last">A 250 mL round-bottom flask was charged with <b>58</b> (4.52 g, 12.8 mmol) and EtOH (25 mL). Ethylamine (70% in water; 4.0 mL, 50 mmol) was added, and the resulting suspension was placed in an 80 °C oil bath. After heating overnight, additional ethylamine (4.0 mL, 50 mmol) was added, and heating was continued. After an additional 24 h, the reaction was allowed to cool and was concentrated under reduced pressure. The residue was partitioned between EtOAc and water, and the aqueous layer was extracted with EtOAc. The combined organics were concentrated and the residue was purified by silica gel chromatography (gradient elution; <i>R</i><sub><i>f</i></sub> in 95:5 hexanes:EtOAc = 0.22) to give the product as a colorless solid (2.21 g, 64%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.37 (t, <i>J</i> = 7.2 Hz, 3H), 3.27–3.40 (m, 2H), 5.01 (br. s., 2H), 6.82 (s, 1H), 8.44 (s, 1H). LC-MS (M + H) 270.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i>4-Ethyl-6-(trifluoromethyl)pyridine-3,4-diamine (<b>60</b>)</h3><div class="NLM_p last">An oven-dried sealable tube equipped with magnetic stir bar and rubber septum was cooled under N<sub>2</sub>. The tube was charged with Pd<sub>2</sub>(dba)<sub>3</sub> (5.55 g, 6.1 mmol), <i>rac</i>-BINAP (7.55 g, 12.1 mmol), and anhydrous toluene (200 mL). The mixture was degassed, the rubber septum was replaced with a Teflon screw cap, and the mixture was heated at 110 °C in an oil bath for 30 min. The solution was then allowed to cool to room temparature, and benzophenone imine (6.61 mL, 39.5 mmol), <b>59</b> (8.16 g, 30.3 mmol) dissolved in toluene (100 mL), and sodium <i>tert-</i>butoxide (3.8 g, 39.5 mmol) were added. The mixture was degassed, the rubber septum was replaced with Teflon cap, and the mixture was heated at 110 °C for 16 h. The solution was then allowed to cool to room temperature, was diluted with ether, filtered through a pad of Celite, and concentrated under reduced pressure to give the imine adduct as a dark green oil. This was dissolved in THF (240 mL) and the solution was treated with 2 M HCl (80 mL), and the resulting mixture was allowed to stir at room temperature for 20 h. The volatile components were evaporated under reduced pressure, and the residue was partitioned between EtOAc and 2 M HCl. The aqueous layer was cooled to 0 °C and was basified with NaOH to pH 14. This mixture was extracted with EtOAc (2×), and the combined organics were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to give the title compound as a colorless solid (4.09 g, 64%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.21 (t, <i>J</i> = 7.2 Hz, 3H), 3.12–3.21 (m, 2H), 5.23 (br. s., 1H), 5.65 (m, 1H), 6.65 (s, 1H), 7.69 (s, 1H). LC-MS (M + H) 206.</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>R</i>)-<i>tert</i>-Butyl 1-(4-(ethylamino)-6-methoxypyridin-3-ylamino)-1-oxopropan-2-ylcarbamate (<b>61</b>)</h3><div class="NLM_p last">A 250 mL round-bottom flask was charged with Boc-<span class="smallcaps smallerCapital">d</span>-Ala-OH (1.56 g, 8.24 mmol) and CDI (1.34 g, 8.26 mmol). CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added (gas evolution observed), and the resulting solution was allowed to stir at room temperature. After 30 min, <b>55</b> (1.05 g, 6.28 mmol) was added, and the resulting solution was allowed to stir at room temperature. After 90 min, the reaction was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (gradient elution; R<sub>f</sub> in 20:80 hexanes:EtOAc = 0.21) to give the product as a light purple-colored foam (1.73 g, 62%). Chiral LC analysis indicated >98% ee. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.14 (t, <i>J</i> = 7.1 Hz, 3H), 1.24 (d, <i>J</i> = 7.1 Hz, 3H), 1.39 (s, 9H), 3.01–3.13 (m, 2H), 3.73 (s, 3H), 3.94–4.03 (m, 1H), 5.49–5.55 (m, 1H), 5.84 (s, 1H), 7.20–7.25 (m, 1H), 7.48 (s, 1H), 9.11 (s, 1H). LC-MS (M + H) 339.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>R</i>)-1-(1-Ethyl-6-methoxy-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethanamine (<b>62</b>)</h3><div class="NLM_p last">A 250 mL round-bottom flask containing <b>61</b> (1.46 g, 4.31 mmol) was charged with 4 N HCl/dioxane (15 mL), and the resulting mixture was allowed to stir at room temperature. After 2 h, the dioxane and excess HCl were evaporated under reduced pressure. The residue was dissolved in absolute EtOH (15 mL), and then a solution of NaOH (726 mg, 18.2 mmol) in water (3 mL) was added. The mixture was heated in an 80 °C oil bath for 5.5 h, and was then allowed to cool to room temperature. The mixture was concentrated under reduced pressure, and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and a minimum volume of water. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organics were washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated to give the cyclized product as a dark purple oil. Conversion of a portion of this material to the Boc-protected intermediate allowed for determination of chirality; the compound was shown to have 80% ee, suggesting partial epimerization of the chiral center occurs during the cyclization. This material was used directly without further purification. LC-MS (M + H) 221.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>R</i>)-4-Cyano-<i>N</i>-(1-(1-ethyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>41</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, 3H), 1.44 (d, 3H), 4.31 (m, 2H), 4.98 (m, 1H), 7.60 (m, 1H), 7.85 (m, 2H), 8.30 (m, 2H), 8.80 (m, 1H), 8.91 (m, 1H). LC-MS (M + H) 356.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (<i>R</i>)-4-Cyano-<i>N</i>-(1-(1-ethyl-6-methoxy-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>42</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.25 (t, <i>J</i> = 7.2 Hz, 3H), 1.37 (d, <i>J</i> = 6.8 Hz, 3H), 3.87 (s, 3H), 4.17 (m, 2H), 4.81–4.90 (m, 1H), 6.84 (m, 1H), 7.79–7.87 (m, 4H), 8.36 (m, 1H), 8.83 (m, 1H). LC-MS (M + H) 386.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (<i>R</i>)-4-Cyano-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>43</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 1.42 (d, <i>J</i> = 6.8 Hz, 3H), 4.33–4.45 (m, 2H), 4.98 (m, 1H), 7.75–7.85 (m, 4H), 8.20 (m, 1H), 8.90 (m, 1H), 8.97 (m, 1H). LC-MS (M + H) 424.</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>R</i>)-4-Cyano-<i>N</i>-(1-(6-cyclopropyl-1-ethyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)benzenesulfonamide (<b>44</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.87–0.99 (m, 4H), 1.30 (t, <i>J</i> = 7.2 Hz, 3H), 1.38 (d, <i>J</i> = 6.9 Hz, 3H), 2.07–2.24 (m, 1H), 4.19–4.28 (m, 2H), 4.83–4.96 (m, 1H), 7.41 (m, 1H), 7.80–7.88 (m, 4H), 8.58 (m, 1H), 8.86 (m, 1H). LC-MS (M+H) 396.</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 6-Cyanopyridine-3-sulfonyl Chloride (<b>63</b>)</h3><div class="NLM_p last">A 500 mL round-bottom flask was charged with water (90 mL) and was cooled to 0 °C. Thionyl chloride (17.0 mL, 233 mmol) was added dropwise via addition funnel over 2 h. The resulting solution was allowed to slowly warm to room temperature overnight. After stirring overnight, CuCl (66 mg, 0.67 mmol) was added, forming a yellow-colored solution. This was cooled to 0 °C. Meanwhile, a separate 250 mL round-bottom flask was charged with 5-aminopicolinonitrile (4.99 g, 41.89 mmol) and concentrated HCl (50 mL). The solution was cooled to −5 °C, and then a solution of sodium nitrite (4.11 g, 59.6 mmol) in water (25 mL) was added dropwise over 20 min. The resulting mixture was allowed to stir at −5 °C for another 15 min and was then added in small portions to the chilled aqueous sulfur dioxide solution over 30 min (gas evolution occurs). The resulting mixture was allowed to stir at 0 °C for an additional hour, and was then suction filtered. The filter cake was washed well with cold water, and was dried in air and then <i>in vacuo</i> to give the product as a tan solid (5.52 g, 65%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 7.95–7.99 (m, 1H), 8.45–8.52 (m, 1H), 9.32 (s, 1H).</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (<i>R</i>)-6-Cyano-<i>N</i>-(1-(1-ethyl-6-methoxy-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)pyridine-3-sulfonamide (<b>45</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.25 (t, <i>J</i> = 7.2 Hz, 3H), 1.43 (d, <i>J</i> = 6.8 Hz, 3H), 3.87 (s, 3H), 4.18 (m, 2H), 4.92 (m, 1H), 6.85 (m, 1H), 7.98 (m, 1H), 8.18 (m, 1H), 8.30 (m, 1H), 8.86 (m, 1H), 9.11 (m, 1H). LC-MS (M + H) 387.</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (<i>R</i>)-6-Cyano-<i>N</i>-(1-(1-ethyl-6-(trifluoromethyl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)pyridine-3-sulfonamide (<b>46</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 1.46 (d, <i>J</i> = 6.8 Hz, 3H), 4.36–4.46 (m, 2H), 5.05 (m, 1H), 8.00 (m, 1H), 8.18–8.24 (m, 2H), 8.87 (m, 2H), 9.25 (m, 1H). LC-MS (M+H) 425.</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (<i>R</i>)-6-Cyano-<i>N</i>-(1-(6-cyclopropyl-1-ethyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethyl)pyridine-3-sulfonamide (<b>47</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.89–0.98 (m, 4H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H), 1.44 (d, <i>J</i> = 6.9 Hz, 3H), 2.03–2.28 (m, 1H), 4.25 (m, 2H), 4.95 (m, 1H), 7.42 (m, 1H), 7.95 (m, 1H), 8.17 (m, 1H), 8.51 (m, 1H), 8.85 (m, 1H), 9.14 (m, 1H). LC-MS (M + H) 397.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01078">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55808" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55808" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01078" class="ext-link">10.1021/acs.jmedchem.5b01078</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Protocols for physical property, ADMET, and pharmacokinetic assays described in this paper, characterization of mode of inhibition for compound <b>2</b>, protocol for S1P<sub>1</sub> receptor internalization assay, procedures for Matrigel plug angiogenesis and Evans blue dye pharmacodynamic experiments along with accompanying pharmacokinetic data and photographs, pharmacokinetic data from Calu6 tumor xenograft studies, and crystallographic collection and refinement data for PXR-compound <b>4</b> complex (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Spreadsheet of molecular formula strings for compounds in this article (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_001.pdf">jm5b01078_si_001.pdf (319.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_002.csv">jm5b01078_si_002.csv (3.64 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates for the structure of compound <b>4</b> bound to human PXR have been deposited in the Protein Data Bank (PDB) under accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.5b01078" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73771" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73771" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward J. Hennessy</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ddb8b9aabcafb9f3b5b8b3b3b8aeaea49dbcaea9afbca7b8b3b8bebcf3beb2b0"><span class="__cf_email__" data-cfemail="85e0e1f2e4f7e1abede0ebebe0f6f6fcc5e4f6f1f7e4ffe0ebe0e6e4abe6eae8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vibha Oza</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ammar Adam</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kate Byth</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lillian Castriotta</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gurmit Grewal</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Geraldine A. Hamilton</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor M. Kamhi</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paula Lewis</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danyang Li</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Lyne</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Öster</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, Innovative Medicines and Early Development, AstraZeneca R&D Mölndal, S-43183, Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael T. Rooney</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jamal C. Saeh</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Sha</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qibin Su</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shengua Wen</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yafeng Xue</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, Innovative Medicines and Early Development, AstraZeneca R&D Mölndal, S-43183, Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Yang</span> - <span class="hlFld-Affiliation affiliation">Oncology
iMed, Innovative Medicines and Early Development, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d6059e4561-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Erika Keeton, Meghan Scarpitti, Vicki Racicot, and Mali Wold for conducting the S1P<sub>1</sub> translocation assay, to Nancy DeGrace and Kanayo Azogu for analytical chemistry support, to Adrian Fretland and Helen Rollison for helpful discussions around CYP3A induction and PXR activation, to Karen Stams, Suzette Haney, and Dave Ayres for human hepatocyte induction studies, and to Frank Kilty for assistance in data analysis.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i84" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i84"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> Abbreviations Used</h2><tr><td class="NLM_term">S1P</td><td class="NLM_def"><p class="first last">sphingosine 1-phosphate</p></td></tr><tr><td class="NLM_term">S1P<sub>1</sub></td><td class="NLM_def"><p class="first last">sphingosine 1-phosphate receptor 1</p></td></tr><tr><td class="NLM_term">GIRK</td><td class="NLM_def"><p class="first last">G protein-coupled inwardly rectifying potassium channel</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">F%</td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">PXR</td><td class="NLM_def"><p class="first last">pregnane X receptor</p></td></tr><tr><td class="NLM_term">CAR</td><td class="NLM_def"><p class="first last">constitutive androstane receptor</p></td></tr><tr><td class="NLM_term">FGF</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">HPMC</td><td class="NLM_def"><p class="first last">hydroxypropyl methylcellulose</p></td></tr><tr><td class="NLM_term">EBD</td><td class="NLM_def"><p class="first last">Evans blue dye</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">(dimethylamino)-<i>N</i>,<i>N</i>-dimethyl(3<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyridin-3-yloxy)methaniminium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisoprpylamide</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2007.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.pharmthera.2007.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17561264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2007&pages=84-105&author=V.+Brinkmann&title=Sphingosine+1-phosphate+receptors+in+health+and+disease%3A+Mechanistic+insights+from+gene+deletion+studies+and+reverse+pharmacology&doi=10.1016%2Fj.pharmthera.2007.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology</span></div><div class="casAuthors">Brinkmann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that is critically involved in the embryonic development of the cardiovascular and central nervous systems.  In the adult, S1P can produce cytoskeletal re-arrangements in many cell types to regulate immune cell trafficking, vascular homeostasis and cell communication in the central nervous system.  S1P is contained in body fluids and tissues at different concns., and excessive prodn. of the pleiotropic mediator at inflammatory sites may participate in various pathol. conditions.  Gene deletion studies and reverse pharmacol. (techniques aiming to identify both ligands and function of receptors) provided evidence that many effects of S1P are mediated via five G-protein-coupled S1P receptor subtypes, and novel therapeutic strategies based on interaction with these receptors are being initiated.  The prototype S1P receptor modulator, FTY720 (fingolimod), targets four of the five S1P receptor subtypes and may act at several levels to modulate lymphocyte trafficking via lymphocytic and endothelial S1P1 and, perhaps, other inflammatory processes through addnl. S1P receptor subtypes.  A recently completed Phase II clin. trial suggested that the drug may provide an effective treatment of relapsing-remitting multiple sclerosis.  FTY720 is currently being evaluated in larger-scale, longer-term, Phase III studies.  This review provides an overview on S1P activities and S1P receptor function in health and disease, and summarizes the clin. experience with FTY720 in transplantation and multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGbwKhZo2vLrVg90H21EOLACvtfcHk0lhAwwLT_Cx3fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D&md5=cacdb374439270734f34a0ca4771ca3d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26atitle%3DSphingosine%25201-phosphate%2520receptors%2520in%2520health%2520and%2520disease%253A%2520Mechanistic%2520insights%2520from%2520gene%2520deletion%2520studies%2520and%2520reverse%2520pharmacology%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D115%26spage%3D84%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2007.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Adachi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, T.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Structure-Activity Relationships of 2-Substituted-2-Amino-1,3-Propanediols: Discovery of a Novel Immunosuppressant, FTY720</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">856</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00127-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2F0960-894X%2895%2900127-F" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=853-856&author=K.+Adachiauthor=T.+Koharaauthor=N.+Nakaoauthor=M.+Aritaauthor=K.+Chibaauthor=T.+Mishinaauthor=S.+Sasakiauthor=T.+Fujita&title=Design%2C+Synthesis%2C+and+Structure-Activity+Relationships+of+2-Substituted-2-Amino-1%2C3-Propanediols%3A+Discovery+of+a+Novel+Immunosuppressant%2C+FTY720&doi=10.1016%2F0960-894X%2895%2900127-F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900127-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900127-F%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DKohara%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DArita%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DMishina%26aufirst%3DT.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DT.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Structure-Activity%2520Relationships%2520of%25202-Substituted-2-Amino-1%252C3-Propanediols%253A%2520Discovery%2520of%2520a%2520Novel%2520Immunosuppressant%252C%2520FTY720%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D853%26epage%3D856%26doi%3D10.1016%2F0960-894X%2895%2900127-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hof, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieschl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiestand, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span> </span><span class="NLM_article-title">The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">21453</span><span class="NLM_x">–</span> <span class="NLM_lpage">21457</span><span class="refDoi"> DOI: 10.1074/jbc.C200176200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.C200176200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11967257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=21453-21457&author=V.+Brinkmannauthor=M.+D.+Davisauthor=C.+E.+Heiseauthor=R.+Albertauthor=S.+Cottensauthor=R.+Hofauthor=C.+Brunsauthor=E.+Prieschlauthor=T.+Baumrukerauthor=P.+Hiestandauthor=C.+A.+Fosterauthor=M.+Zollingerauthor=K.+R.+Lynch&title=The+Immune+Modulator+FTY720+Targets+Sphingosine+1-Phosphate+Receptors&doi=10.1074%2Fjbc.C200176200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Brinkmann, Volker; Davis, Michael D.; Heise, Christopher E.; Albert, Rainer; Cottens, Sylvain; Hof, Robert; Bruns, Christian; Prieschl, Eva; Baumruker, Thomas; Hiestand, Peter; Foster, Carolyn A.; Zollinger, Markus; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">21453-21457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis.  In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation.  FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms.  Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compd. is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis.  Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6zyZnHOYNbVg90H21EOLACvtfcHk0lhAwwLT_Cx3fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D&md5=b59856fffa9ebae7fb8182d18daa025f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C200176200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C200176200%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DCottens%26aufirst%3DS.%26aulast%3DHof%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPrieschl%26aufirst%3DE.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHiestand%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DC.%2BA.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DThe%2520Immune%2520Modulator%2520FTY720%2520Targets%2520Sphingosine%25201-Phosphate%2520Receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D21453%26epage%3D21457%26doi%3D10.1074%2Fjbc.C200176200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mandala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupprecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.-J.+Sheiauthor=D.+Cardauthor=C.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+Lymphocyte+Trafficking+by+Sphingosine-1-Phosphate+Receptor+Agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0lgZKA1JwzNT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520Lymphocyte%2520Trafficking%2520by%2520Sphingosine-1-Phosphate%2520Receptor%2520Agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heining, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aradhye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burtin, P.</span><span> </span><span class="NLM_article-title">Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">897</span><span class="refDoi"> DOI: 10.1038/nrd3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnrd3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=21031003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=883-897&author=V.+Brinkmannauthor=A.+Billichauthor=T.+Baumrukerauthor=P.+Heiningauthor=R.+Schmouderauthor=G.+Francisauthor=S.+Aradhyeauthor=P.+Burtin&title=Fingolimod+%28FTY720%29%3A+discovery+and+development+of+an+oral+drug+to+treat+multiple+sclerosis&doi=10.1038%2Fnrd3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis</span></div><div class="casAuthors">Brinkmann, Volker; Billich, Andreas; Baumruker, Thomas; Heining, Peter; Schmouder, Robert; Francis, Gordon; Aradhye, Shreeram; Burtin, Pascale</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">883-897</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system.  Elucidation of the effects of fingolimod - mediated by the modulation of sphingosine 1-phosphate (S1P) receptors - has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct effects on neural cells, particularly astrocytes.  An improved understanding of the biol. of S1P receptors has also been gained.  This article describes the discovery and development of fingolimod, which was approved by the US Food and Drug Administration in Sept. 2010 as a first-line treatment for relapsing forms of multiple sclerosis, thereby becoming the first oral disease-modifying therapy to be approved for multiple sclerosis in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80U6QfXSJMbVg90H21EOLACvtfcHk0lgZKA1JwzNT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL&md5=0f6dd60ef115079f3652e9d12d82e215</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3248%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DSchmouder%26aufirst%3DR.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DAradhye%26aufirst%3DS.%26aulast%3DBurtin%26aufirst%3DP.%26atitle%3DFingolimod%2520%2528FTY720%2529%253A%2520discovery%2520and%2520development%2520of%2520an%2520oral%2520drug%2520to%2520treat%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D883%26epage%3D897%26doi%3D10.1038%2Fnrd3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gräler, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetzl, E. J.</span><span> </span><span class="NLM_article-title">The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1096/fj.03-0910fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1096%2Ffj.03-0910fje" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=551-553&author=M.+H.+Gr%C3%A4lerauthor=E.+J.+Goetzl&title=The+immunosuppressant+FTY720+down-regulates+sphingosine+1-phosphate+G-protein-coupled+receptors&doi=10.1096%2Ffj.03-0910fje"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1096%2Ffj.03-0910fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.03-0910fje%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A4ler%26aufirst%3DM.%2BH.%26aulast%3DGoetzl%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520immunosuppressant%2520FTY720%2520down-regulates%2520sphingosine%25201-phosphate%2520G-protein-coupled%2520receptors%26jtitle%3DFASEB%2520J.%26date%3D2004%26volume%3D18%26spage%3D551%26epage%3D553%26doi%3D10.1096%2Ffj.03-0910fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Mapping Pathways Downstream of Sphingosine 1-Phosphate Subtype 1 by Differential Chemical Perturbation and Proteomics</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">7254</span><span class="NLM_x">–</span> <span class="NLM_lpage">7264</span><span class="refDoi"> DOI: 10.1074/jbc.M610581200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M610581200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=7254-7264&author=P.+J.+Gonzalez-Cabreraauthor=T.+Hlaauthor=H.+Rosen&title=Mapping+Pathways+Downstream+of+Sphingosine+1-Phosphate+Subtype+1+by+Differential+Chemical+Perturbation+and+Proteomics&doi=10.1074%2Fjbc.M610581200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M610581200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M610581200%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DMapping%2520Pathways%2520Downstream%2520of%2520Sphingosine%25201-Phosphate%2520Subtype%25201%2520by%2520Differential%2520Chemical%2520Perturbation%2520and%2520Proteomics%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D7254%26epage%3D7264%26doi%3D10.1074%2Fjbc.M610581200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Oo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thangada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">9082</span><span class="NLM_x">–</span> <span class="NLM_lpage">9089</span><span class="refDoi"> DOI: 10.1074/jbc.M610318200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M610318200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=9082-9089&author=M.+L.+Ooauthor=S.+Thangadaauthor=M.-T.+Wuauthor=C.+H.+Liuauthor=T.+L.+Macdonaldauthor=K.+R.+Lynchauthor=C.-Y.+Linauthor=T.+Hla&title=Immunosuppressive+and+Anti-angiogenic+Sphingosine+1-Phosphate+Receptor-1+Agonists+Induce+Ubiquitinylation+and+Proteasomal+Degradation+of+the+Receptor&doi=10.1074%2Fjbc.M610318200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M610318200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M610318200%26sid%3Dliteratum%253Aachs%26aulast%3DOo%26aufirst%3DM.%2BL.%26aulast%3DThangada%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DLin%26aufirst%3DC.-Y.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DImmunosuppressive%2520and%2520Anti-angiogenic%2520Sphingosine%25201-Phosphate%2520Receptor-1%2520Agonists%2520Induce%2520Ubiquitinylation%2520and%2520Proteasomal%2520Degradation%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D9082%26epage%3D9089%26doi%3D10.1074%2Fjbc.M610318200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeldt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nava, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span> </span><span class="NLM_article-title">Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">951</span><span class="NLM_x">–</span> <span class="NLM_lpage">961</span><span class="refDoi"> DOI: 10.1172/JCI10905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1172%2FJCI10905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11032855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVeisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2000&pages=951-961&author=Y.+Liuauthor=R.+Wadaauthor=T.+Yamashitaauthor=Y.+Miauthor=C.-X.+Dengauthor=J.+P.+Hobsonauthor=H.+M.+Rosenfeldtauthor=V.+E.+Navaauthor=S.-S.+Chaeauthor=M.-J.+Leeauthor=C.+H.+Liuauthor=T.+Hlaauthor=S.+Spiegelauthor=R.+L.+Proia&title=Edg-1%2C+the+G+protein-coupled+receptor+for+sphingosine-1-phosphate%2C+is+essential+for+vascular+maturation&doi=10.1172%2FJCI10905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation</span></div><div class="casAuthors">Liu, Yujing; Wada, Ryuichi; Yamashita, Tadashi; Mi, Yide; Deng, Chu-Xia; Hobson, John P.; Rosenfeldt, Hans M.; Nava, Victor E.; Chae, Sung-Suk; Lee, Menq-Jer; Liu, Catherine H.; Hla, Timothy; Spiegel, Sarah; Proia, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">951-961</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Sphingolipid signaling pathways have been implicated in many crit. cellular events.  Sphingosine-1-phosphate (SPP), a sphingolipid metabolite found in high concns. in platelets and blood, stimulates members of the endothelial differentiation gene (Edg) family of G protein-coupled receptors and triggers diverse effects, including cell growth, survival, migration, and morphogenesis.  To det. the in vivo functions of the SPP/Edg signaling pathway, the authors disrupted the Edg1 gene in mice.  Edg1-/- mice exhibited embryonic hemorrhage leading to intrauterine death between E12.5 and E14.5.  Vasculogenesis and angiogenesis appeared normal in the mutant embryos.  However, vascular maturation was incomplete due to a deficiency of vascular smooth muscle cells/pericytes.  The authors also show that Edg-1 mediates an SPP-induced migration response that is defective in mutant cells due to an inability to activate the small GTPase, Rac.  The authors' data reveal Edg-1 to be the first G protein-coupled receptor required for blood vessel formation and show that sphingolipid signaling is essential during mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruF19rW-FkA7Vg90H21EOLACvtfcHk0liqSWrcdgp36Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVeisbw%253D&md5=939c81aeb6374e6827953ab94be2a42b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1172%2FJCI10905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI10905%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DR.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DC.-X.%26aulast%3DHobson%26aufirst%3DJ.%2BP.%26aulast%3DRosenfeldt%26aufirst%3DH.%2BM.%26aulast%3DNava%26aufirst%3DV.%2BE.%26aulast%3DChae%26aufirst%3DS.-S.%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DProia%26aufirst%3DR.%2BL.%26atitle%3DEdg-1%252C%2520the%2520G%2520protein-coupled%2520receptor%2520for%2520sphingosine-1-phosphate%252C%2520is%2520essential%2520for%2520vascular%2520maturation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D106%26spage%3D951%26epage%3D961%26doi%3D10.1172%2FJCI10905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Chae, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furneaux, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1089</span><span class="refDoi"> DOI: 10.1172/JCI200422716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1172%2FJCI200422716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=1082-1089&author=S.-S.+Chaeauthor=J.-H.+Paikauthor=H.+Furneauxauthor=T.+Hla&title=Requirement+for+sphingosine+1-phosphate+receptor-1+in+tumor+angiogenesis+demonstrated+by+in+vivo+RNA+interference&doi=10.1172%2FJCI200422716"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI200422716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200422716%26sid%3Dliteratum%253Aachs%26aulast%3DChae%26aufirst%3DS.-S.%26aulast%3DPaik%26aufirst%3DJ.-H.%26aulast%3DFurneaux%26aufirst%3DH.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DRequirement%2520for%2520sphingosine%25201-phosphate%2520receptor-1%2520in%2520tumor%2520angiogenesis%2520demonstrated%2520by%2520in%2520vivo%2520RNA%2520interference%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D1082%26epage%3D1089%26doi%3D10.1172%2FJCI200422716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">LaMontagne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Antagonism of Sphingosine-1-Phosphate Receptors by FTY720 Inhibits Angiogenesis and Tumor Vascularization</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1158%2F0008-5472.CAN-05-2001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=221-231&author=K.+LaMontagneauthor=A.+Littlewood-Evansauthor=C.+Schnellauthor=T.+O%E2%80%99Reillyauthor=L.+Wyderauthor=T.+Sanchezauthor=B.+Probstauthor=J.+Butlerauthor=A.+Woodauthor=G.+Liauauthor=E.+Billyauthor=A.+Theuerauthor=T.+Hlaauthor=J.+Wood&title=Antagonism+of+Sphingosine-1-Phosphate+Receptors+by+FTY720+Inhibits+Angiogenesis+and+Tumor+Vascularization&doi=10.1158%2F0008-5472.CAN-05-2001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2001%26sid%3Dliteratum%253Aachs%26aulast%3DLaMontagne%26aufirst%3DK.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DWyder%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DProbst%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DLiau%26aufirst%3DG.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DTheuer%26aufirst%3DA.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAntagonism%2520of%2520Sphingosine-1-Phosphate%2520Receptors%2520by%2520FTY720%2520Inhibits%2520Angiogenesis%2520and%2520Tumor%2520Vascularization%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D221%26epage%3D231%26doi%3D10.1158%2F0008-5472.CAN-05-2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Budde, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunkhorst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nashan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lücker, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skerjanec, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumayer, H. H.</span><span> </span><span class="NLM_article-title">First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients</span> <span class="citation_source-journal">J. Am. Soc. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1073</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11912269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFSntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1073-1083&author=K.+Buddeauthor=R.+L.+Schmouderauthor=R.+Brunkhorstauthor=B.+Nashanauthor=P.+W.+L%C3%BCckerauthor=T.+Mayerauthor=S.+Choudhuryauthor=A.+Skerjanecauthor=G.+Krausauthor=H.+H.+Neumayer&title=First+Human+Trial+of+FTY720%2C+a+Novel+Immunomodulator%2C+in+Stable+Renal+Transplant+Patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients</span></div><div class="casAuthors">Budde, Klemens; Schmouder, Robert L.; Brunkhorst, Reinhard; Nashan, Bjorn; Lucker, Peter W.; Mayer, Thomas; Choudhury, Somesh; Skerjanec, Andrej; Kraus, Gerolf; Neumayer, Hans H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1073-1083</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">FTY720 is a novel immunomodulator to be developed for use in organ transplantation.  The primary objective of this study was to measure safety, single-dose pharmacokinetics, and pharmacodynamics in stable renal transplant patients-the first human use of FTY720.  This study used a randomized, double-blind, placebo-controlled design that explored single oral doses of FTY720 from 0.25 to 3.5 mg in 20 stable renal transplant patients on a cyclosporine-based regimen.  Safety assessments and blood samples were taken predose and at multiple time points during a 96-h period postdose.  Std. pharmacokinetic parameters were derived from the FTY720 whole blood concns., measured by HPLC/MS/MS.  FTY720 was well tolerated, with no serious adverse events.  Transient, asymptomatic bradycardia occurred after administration in 10 of 24 doses of FTY720.  Pharmacokinetics are characterized by a prolonged absorption phase; the terminal elimination phase started 36 h after the administration, with elimination half-life (t1/2) ranging from 89 to 157 h independent of dose.  Maximum plasma concn. and AUC were proportional to dose with low intersubject variability, the apparent vol. of distribution (Vd/F) ranged from 1116 to 1737 L.  FTY pharmacodynamics were characterized by a reversible transient lymphopenia within 6 h, the nadir being 42% of baseline.  The lymphocyte count returned to baseline within 72 h in all dosing cohorts except the highest.  Single oral doses of FTY720 ranging from 0.25 to 3.5 mg were well tolerated and caused a reversible selective lymphopenia.  Transient, but asymptomatic bradycardia was the most common adverse event.  The long t1/2 suggests less frequent dosing intervals.  The size of Vd/F is in excess of blood vol., consistent with widespread tissue distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jzPXTdVJrrVg90H21EOLACvtfcHk0liqSWrcdgp36Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFSntbw%253D&md5=2c30d91109c7c25fe9a17ab0ac8ae969</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBudde%26aufirst%3DK.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26aulast%3DBrunkhorst%26aufirst%3DR.%26aulast%3DNashan%26aufirst%3DB.%26aulast%3DL%25C3%25BCcker%26aufirst%3DP.%2BW.%26aulast%3DMayer%26aufirst%3DT.%26aulast%3DChoudhury%26aufirst%3DS.%26aulast%3DSkerjanec%26aufirst%3DA.%26aulast%3DKraus%26aufirst%3DG.%26aulast%3DNeumayer%26aufirst%3DH.%2BH.%26atitle%3DFirst%2520Human%2520Trial%2520of%2520FTY720%252C%2520a%2520Novel%2520Immunomodulator%252C%2520in%2520Stable%2520Renal%2520Transplant%2520Patients%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2002%26volume%3D13%26spage%3D1073%26epage%3D1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents are Mediated via Distinct Receptor Subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">758</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fjpet.103.062828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=14747617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=758-768&author=M.+Forrestauthor=S.-Y.+Sunauthor=R.+Hajduauthor=J.+Bergstromauthor=D.+Cardauthor=G.+Dohertyauthor=J.+Haleauthor=C.+Keohaneauthor=C.+Meyersauthor=J.+Milliganauthor=S.+Millsauthor=N.+Nomuraauthor=H.+Rosenauthor=M.+Rosenbachauthor=G.-J.+Sheiauthor=I.+I.+Singerauthor=M.+Tianauthor=S.+Westauthor=V.+Whiteauthor=J.+Xieauthor=R.+L.+Proiaauthor=S.+Mandala&title=Immune+Cell+Regulation+and+Cardiovascular+Effects+of+Sphingosine+1-Phosphate+Receptor+Agonists+in+Rodents+are+Mediated+via+Distinct+Receptor+Subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span></div><div class="casAuthors">Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">758-768</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive lysolipid with pleiotropic functions mediated through a family of G protein-coupled receptors, S1P1,2,3,4,5.  Physiol. effects of S1P receptor agonists include regulation of cardiovascular function and immunosuppression via redistribution of lymphocytes from blood to secondary lymphoid organs.  The phosphorylated metabolite of the immunosuppressant agent FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) and other phosphonate analogs with differential receptor selectivity were investigated.  No significant species differences in compd. potency or rank order of activity on receptors cloned from human, murine, and rat sources were obsd.  All synthetic analogs were high-affinity agonists on S1P1, with IC50 values for ligand binding between 0.3 and 14 nM.  The correlation between S1P1 receptor activation and the ED50 for lymphocyte redn. was highly significant (p < 0.001) and lower for the other receptors.  In contrast to S1P1-mediated effects on lymphocyte recirculation, three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compd. potency on S1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia vs. bradycardia and hypertension was consistent with affinity for S1P1 relative to S1P3; and toxicity, bradycardia, and hypertension were absent in S1P3-/- mice.  Blood pressure effects of agonists in anesthetized rats were complex, whereas hypertension was the predominant effect in conscious rats and mice.  Immunolocalization of S1P3 in rodent heart revealed abundant expression on myocytes and perivascular smooth muscle cells consistent with regulation of bradycardia and hypertension, whereas S1P1 expression was restricted to the vascular endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo2vpih4eoLVg90H21EOLACvtfcHk0lj7yZopdzBLzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D&md5=27183d4991bffbc5d2b88174b1386d5a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.062828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.062828%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.-Y.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DMeyers%26aufirst%3DC.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DSinger%26aufirst%3DI.%2BI.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DImmune%2520Cell%2520Regulation%2520and%2520Cardiovascular%2520Effects%2520of%2520Sphingosine%25201-Phosphate%2520Receptor%2520Agonists%2520in%2520Rodents%2520are%2520Mediated%2520via%2520Distinct%2520Receptor%2520Subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D758%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P<sub>1</sub> and S1P<sub>3</sub>, Respectively, Regulate Lymphocyte Recirculation and Heart Rate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">13839</span><span class="NLM_x">–</span> <span class="NLM_lpage">13848</span><span class="refDoi"> DOI: 10.1074/jbc.M311743200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M311743200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=14732717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=13839-13848&author=M.+G.+Sannaauthor=J.+Liaoauthor=E.+Joauthor=C.+Alfonsoauthor=M.-Y.+Ahnauthor=M.+S.+Petersonauthor=B.+Webbauthor=S.+Lefebvreauthor=J.+Chunauthor=N.+Grayauthor=H.+Rosen&title=Sphingosine+1-Phosphate+%28S1P%29+Receptor+Subtypes+S1P1+and+S1P3%2C+Respectively%2C+Regulate+Lymphocyte+Recirculation+and+Heart+Rate&doi=10.1074%2Fjbc.M311743200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate</span></div><div class="casAuthors">Sanna, M. Germana; Liao, Jiayu; Jo, Euijung; Alfonso, Christopher; Ahn, Min-Young; Peterson, Melissa S.; Webb, Bill; Lefebvre, Sophie; Chun, Jerold; Gray, Nathanael; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">13839-13848</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) influences heart rate, coronary artery caliber, endothelial integrity, and lymphocyte recirculation through five related high affinity G-protein-coupled receptors.  Inhibition of lymphocyte recirculation by non-selective S1P receptor agonists produces clin. immunosuppression preventing transplant rejection but is assocd. with transient bradycardia.  Understanding the contribution of individual receptors has been limited by the embryonic lethality of the S1P1 knock-out and the unavailability of selective agonists or antagonists.  A potent, S1P1-receptor selective agonist structurally unrelated to S1P was found to activate multiple signals triggered by S1P, including guanosine 5'-3-O-(thio)triphosphate binding, calcium flux, Akt and ERK1/2 phosphorylation, and stimulation of migration of S1P1- but not S1P3-expressing cells in vitro.  The agonist also alters lymphocyte trafficking in vivo.  Use of selective agonism together with deletant mice lacking S1P3 receptor reveals that agonism of S1P1 receptor alone is sufficient to control lymphocyte recirculation.  Moreover, S1P1 receptor agonist plasma levels are causally assocd. with induction and maintenance of lymphopenia.  S1P3, and not S1P1, is directly implicated in sinus bradycardia.  The sustained bradycardia induced by S1P receptor non-selective immunosuppressive agonists in wild-type mice is abolished in S1P3-/- mice, whereas S1P1-selective agonist does not produce bradycardia.  Sepn. of receptor subtype usage for control of lymphocyte recirculation and heart rate may allow the identification of selective immunosuppressive S1P1 receptor agonists with an enhanced therapeutic window.  S1P1-selective agonists will be of broad utility in understanding cell functions in vitro, and vascular physiol. in vivo, and the success of the chem. approach for S1P1 suggests that selective tools for the resoln. of function across this broad lipid receptor family are now possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoztTB58pXPA7Vg90H21EOLACvtfcHk0lj7yZopdzBLzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D&md5=5b720513c7c550bfdf55e5344efc8f16</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311743200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311743200%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-Phosphate%2520%2528S1P%2529%2520Receptor%2520Subtypes%2520S1P1%2520and%2520S1P3%252C%2520Respectively%252C%2520Regulate%2520Lymphocyte%2520Recirculation%2520and%2520Heart%2520Rate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D13839%26epage%3D13848%26doi%3D10.1074%2Fjbc.M311743200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Koyrakh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickman, K.</span><span> </span><span class="NLM_article-title">The Heart Rate Decrease Caused by Acute FTY720 Administration is Mediated by the G Protein-Gated Potassium Channel I<sub>KACh</sub></span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span><span class="refDoi"> DOI: 10.1111/j.1600-6143.2005.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1111%2Fj.1600-6143.2005.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=15707407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFSitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=529-536&author=L.+Koyrakhauthor=M.+I.+Romanauthor=V.+Brinkmannauthor=K.+Wickman&title=The+Heart+Rate+Decrease+Caused+by+Acute+FTY720+Administration+is+Mediated+by+the+G+Protein-Gated+Potassium+Channel+IKACh&doi=10.1111%2Fj.1600-6143.2005.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh</span></div><div class="casAuthors">Koyrakh, Lev; Roman, Maria I.; Brinkmann, Volker; Wickman, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">529-536</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Sphingosine-1-phosphate (S1P) is an endogenous agonist for a family of five G protein-coupled receptors (S1P1-5) involved in cell proliferation, cardiovascular development and lymphocyte trafficking.  The sphingolipid drug FTY720 displays structural similarity to S1P and efficacy as an immunosuppressant in models of autoimmune disease and in solid organ transplantation.  While FTY720 is well-tolerated in humans, it produces a transient redn. of heart rate (HR).  As S1P activates the cardiac G protein-gated potassium channel IKACh, we speculated that the FTY720-induced HR redn. reflects IKACh activation.  We examd. FTY720 effects on atrial myocytes from wild-type and IKACh-deficient mice.  In wild-type myocytes, the active phosphate metabolite of FTY720 (FTY720-P) induced single channel activity with conductance, open time, GTP sensitivity and rectification identical to that of IKACh.  In whole-cell recordings, FTY720-P evoked an inwardly rectifying potassium current in ∼90% of myocytes responding to acetylcholine.  Comparable channel activity was never obsd. in myocytes from IKACh-deficient mice.  In wild-type mice, acute FTY720 administration produced a dose-dependent, robust HR redn.  In contrast, the HR redn. induced by FTY720 in IKACh-deficient mice was blunted.  We conclude that the effect of acute FTY720 administration on HR is mediated primarily by IKACh activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLvv1lgLdAbVg90H21EOLACvtfcHk0lj7yZopdzBLzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFSitrg%253D&md5=c6d2e7d8fea9f64ec0793693b596c1c6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2005.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2005.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DKoyrakh%26aufirst%3DL.%26aulast%3DRoman%26aufirst%3DM.%2BI.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DWickman%26aufirst%3DK.%26atitle%3DThe%2520Heart%2520Rate%2520Decrease%2520Caused%2520by%2520Acute%2520FTY720%2520Administration%2520is%2520Mediated%2520by%2520the%2520G%2520Protein-Gated%2520Potassium%2520Channel%2520IKACh%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2005%26volume%3D5%26spage%3D529%26epage%3D536%26doi%3D10.1111%2Fj.1600-6143.2005.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gergley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groenewegen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaliti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttringer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumb, W. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallström, E.</span><span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=22646698" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergleyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstr%C3%B6m&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergley%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstr%25C3%25B6m%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Kunkel, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maceyka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milstien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, S.</span><span> </span><span class="NLM_article-title">Targeting the sphingosine-1-phosphate axis in cancer, inflammation, and beyond</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">688</span><span class="NLM_x">–</span> <span class="NLM_lpage">702</span><span class="refDoi"> DOI: 10.1038/nrd4099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnrd4099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=688-702&author=G.+T.+Kunkelauthor=M.+Maceykaauthor=S.+Milstienauthor=S.+Spiegel&title=Targeting+the+sphingosine-1-phosphate+axis+in+cancer%2C+inflammation%2C+and+beyond&doi=10.1038%2Fnrd4099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd4099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4099%26sid%3Dliteratum%253Aachs%26aulast%3DKunkel%26aufirst%3DG.%2BT.%26aulast%3DMaceyka%26aufirst%3DM.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520sphingosine-1-phosphate%2520axis%2520in%2520cancer%252C%2520inflammation%252C%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D688%26epage%3D702%26doi%3D10.1038%2Fnrd4099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemens, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span> </span><span class="NLM_article-title">Sphingosine 1-Phosphate Analogs as Receptor Antagonists</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">9833</span><span class="NLM_x">–</span> <span class="NLM_lpage">9841</span><span class="refDoi"> DOI: 10.1074/jbc.M412356200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M412356200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=9833-9841&author=M.+D.+Davisauthor=J.+J.+Clemensauthor=T.+L.+Macdonaldauthor=K.+R.+Lynch&title=Sphingosine+1-Phosphate+Analogs+as+Receptor+Antagonists&doi=10.1074%2Fjbc.M412356200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M412356200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M412356200%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DClemens%26aufirst%3DJ.%2BJ.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DSphingosine%25201-Phosphate%2520Analogs%2520as%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D9833%26epage%3D9841%26doi%3D10.1074%2Fjbc.M412356200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wei, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheu, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, M. D.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">–</span> <span class="NLM_lpage">1235</span><span class="refDoi"> DOI: 10.1038/ni1269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fni1269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=16273098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=1228-1235&author=S.+H.+Weiauthor=H.+Rosenauthor=M.+P.+Matheuauthor=M.+G.+Sannaauthor=S.-K.+Wangauthor=E.+Joauthor=C.-H.+Wongauthor=I.+Parkerauthor=M.+D.+Cahalan&title=Sphingosine+1-phosphate+type+1+receptor+agonism+inhibits+transendothelial+migration+of+medullary+T+cells+to+lymphatic+sinuses&doi=10.1038%2Fni1269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span></div><div class="casAuthors">Wei, Sindy H.; Rosen, Hugh; Matheu, Melanie P.; Sanna, M. Germana; Wang, Sheng-Kai; Jo, Euijung; Wong, Chi-Huey; Parker, Ian; Cahalan, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1228-1235</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate type 1 (S1P1) receptor agonists cause sequestration of lymphocytes in secondary lymphoid organs by a mechanism that is not well understood.  One hypothesis proposes that agonists act as "functional antagonists" by binding and internalizing S1P1 receptors on lymphocytes; a second hypothesis proposes instead that S1P1 agonists act on endothelial cells to prevent lymphocyte egress from lymph nodes.  Here, 2-photon imaging of living T cells in explanted lymph nodes after treatment with S1P1 agonists or antagonists has provided insight into the mechanism by which S1P1 agonists function.  The selective S1P1 agonist SEW2871 caused reversible slowing and "log-jamming" of T cells between filled medullary cords and empty sinuses, whereas motility was unaltered in diffuse cortex.  Removal or antagonist competition of SEW2871 permitted recovery of T cell motility in the parenchyma of the medulla and resumption of migration across the stromal endothelial barrier, leading to refilling of sinuses.  The authors' results provide visualization of transendothelial migration of T cells into lymphatic sinuses and suggest that S1P1 agonists act mainly on endothelial cell S1P1 receptors to inhibit lymphocyte migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT6yH1S8NBXbVg90H21EOLACvtfcHk0lheFKCkhATJ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E&md5=1e8e381a3808c9231937e05a0c010b73</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fni1269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1269%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%2BH.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMatheu%26aufirst%3DM.%2BP.%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DS.-K.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DParker%26aufirst%3DI.%26aulast%3DCahalan%26aufirst%3DM.%2BD.%26atitle%3DSphingosine%25201-phosphate%2520type%25201%2520receptor%2520agonism%2520inhibits%2520transendothelial%2520migration%2520of%2520medullary%2520T%2520cells%2520to%2520lymphatic%2520sinuses%26jtitle%3DNat.%2520Immunol.%26date%3D2005%26volume%3D6%26spage%3D1228%26epage%3D1235%26doi%3D10.1038%2Fni1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Don, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsolais, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheu, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P<sub>1</sub> antagonist in vivo</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">434</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1038/nchembio804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnchembio804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=16829954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=434-441&author=M.+G.+Sannaauthor=S.-K.+Wangauthor=P.+J.+Gonzalez-Cabreraauthor=A.+Donauthor=D.+Marsolaisauthor=M.+P.+Matheuauthor=S.+H.+Weiauthor=I.+Parkerauthor=E.+Joauthor=W.-C.+Chengauthor=M.+D.+Cahalanauthor=C.-H.+Wongauthor=H.+Rosen&title=Enhancement+of+capillary+leakage+and+restoration+of+lymphocyte+egress+by+a+chiral+S1P1+antagonist+in+vivo&doi=10.1038%2Fnchembio804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo</span></div><div class="casAuthors">Sanna, M. Germana; Wang, Sheng-Kai; Gonzalez-Cabrera, Pedro J.; Don, Anthony; Marsolais, David; Matheu, Melanie P.; Wei, Sindy H.; Parker, Ian; Jo, Euijung; Cheng, Wei-Chieh; Cahalan, Michael D.; Wong, Chi-Huey; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">434-441</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P, 1) regulates vascular barrier and lymphoid development, as well as lymphocyte egress from lymphoid organs, by activating high-affinity S1P1 receptors.  The authors used reversible chem. probes (i) to gain mechanistic insights into S1P systems organization not accessible through genetic manipulations and (ii) to investigate their potential for therapeutic modulation.  Vascular (but not airway) administration of the preferred R enantiomer of an in vivo-active chiral S1P11 receptor antagonist induced loss of capillary integrity in mouse skin and lung.  In contrast, the antagonist did not affect the no. of constitutive blood lymphocytes.  Instead, alteration of lymphocyte trafficking and phenotype required supraphysiol. elevation of S1P1 tone and was reversed by the antagonist.  In vivo two-photon imaging of lymph nodes confirmed requirements for obligate agonism, and the data were consistent with the presence of a stromal barrier mechanism for gating lymphocyte egress.  Thus, chem. modulation reveals differences in S1P-S1P1 'set points' among tissues and highlights both mechanistic advantages (lymphocyte sequestration) and risks (pulmonary edema) of therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3H_AoUm7AkrVg90H21EOLACvtfcHk0lheFKCkhATJ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrw%253D&md5=c7cf6472393abe2d43851c5cd329e968</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnchembio804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio804%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DS.-K.%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DDon%26aufirst%3DA.%26aulast%3DMarsolais%26aufirst%3DD.%26aulast%3DMatheu%26aufirst%3DM.%2BP.%26aulast%3DWei%26aufirst%3DS.%2BH.%26aulast%3DParker%26aufirst%3DI.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DW.-C.%26aulast%3DCahalan%26aufirst%3DM.%2BD.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DEnhancement%2520of%2520capillary%2520leakage%2520and%2520restoration%2520of%2520lymphocyte%2520egress%2520by%2520a%2520chiral%2520S1P1%2520antagonist%2520in%2520vivo%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D434%26epage%3D441%26doi%3D10.1038%2Fnchembio804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukahara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goitsuka, R.</span><span> </span><span class="NLM_article-title">Amelioration of Collagen-Induced Arthritis by a Novel S1P<sub>1</sub> Antagonist with Immunomodulatory Activities</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">188</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.4049/jimmunol.1101537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.4049%2Fjimmunol.1101537" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=206-215&author=Y.+Fujiiauthor=T.+Hirayamaauthor=H.+Ohtakeauthor=N.+Onoauthor=T.+Inoueauthor=T.+Sakuraiauthor=T.+Takayamaauthor=K.+Matsumotoauthor=N.+Tsukaharaauthor=S.+Hidanoauthor=N.+Harimaauthor=K.+Nakazawaauthor=Y.+Igarashiauthor=R.+Goitsuka&title=Amelioration+of+Collagen-Induced+Arthritis+by+a+Novel+S1P1+Antagonist+with+Immunomodulatory+Activities&doi=10.4049%2Fjimmunol.1101537"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101537%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHirayama%26aufirst%3DT.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DOno%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DTsukahara%26aufirst%3DN.%26aulast%3DHidano%26aufirst%3DS.%26aulast%3DHarima%26aufirst%3DN.%26aulast%3DNakazawa%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DY.%26aulast%3DGoitsuka%26aufirst%3DR.%26atitle%3DAmelioration%2520of%2520Collagen-Induced%2520Arthritis%2520by%2520a%2520Novel%2520S1P1%2520Antagonist%2520with%2520Immunomodulatory%2520Activities%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D206%26epage%3D215%26doi%3D10.4049%2Fjimmunol.1101537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ibrahim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolfrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banica, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattheakis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipway, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, G.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1368</span><span class="NLM_x">–</span> <span class="NLM_lpage">1381</span><span class="refDoi"> DOI: 10.1021/jm201533b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201533b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1368-1381&author=M.+A.+Ibrahimauthor=H.+W.+B.+Johnsonauthor=J.+W.+Jeongauthor=G.+L.+Lewisauthor=X.+Shiauthor=R.+T.+Noguchiauthor=M.+Williamsauthor=J.+W.+Leahyauthor=J.+M.+Nussauthor=J.+Woolfreyauthor=M.+Banicaauthor=F.+Bentzienauthor=Y.-C.+Chouauthor=A.+Gibsonauthor=N.+Healdauthor=P.+Lambauthor=L.+Mattheakisauthor=D.+Matthewsauthor=A.+Shipwayauthor=X.+Wuauthor=W.+Zhangauthor=S.+Zhouauthor=G.+Shankar&title=Discovery+of+a+Novel+Class+of+Potent+and+Orally+Bioavailable+Sphingosine+1-Phosphate+Receptor+1+Antagonists&doi=10.1021%2Fjm201533b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists</span></div><div class="casAuthors">Ibrahim, Mohamed A.; Johnson, Henry W. B.; Jeong, Joon Won; Lewis, Gary L.; Shi, Xian; Noguchi, Robin T.; Williams, Matthew; Leahy, James W.; Nuss, John M.; Woolfrey, John; Banica, Monica; Bentzien, Frauke; Chou, Yu-Chien; Gibson, Anna; Heald, Nathan; Lamb, Peter; Mattheakis, Larry; Matthews, David; Shipway, Aaron; Wu, Xiang; Zhang, WenTao; Zhou, Sihong; Shankar, Geetha</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1368-1381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of subtype selective sphingosine 1-phosphate receptor 1 (S1P1) antagonists are disclosed.  Our high-throughput screening campaign revealed hit I for which an increase in potency and mouse oral exposure was achieved with minor modifications to the chem. scaffold.  In vivo efficacy revealed that at high doses compds. II(X = F, Cl) inhibited tumor growth.  Further optimization of our lead series led to the discovery of proline derivs. III(R = 1,2,3-triazol-1yl) (XL541) and III(R = 1,2,3-triazol-2yl) which had similar efficacy as our first generation analogs at significantly lower doses.  Analog III(R = 1,2,3-triazol-1yl) displayed excellent pharmacokinetics and oral exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1zBOwMD_ld7Vg90H21EOLACvtfcHk0lgbNWp0s5DgDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVChsA%253D%253D&md5=78755c4ffeda0e3bec4a150b9b59ddc9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm201533b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201533b%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DLewis%26aufirst%3DG.%2BL.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DNoguchi%26aufirst%3DR.%2BT.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DBanica%26aufirst%3DM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DChou%26aufirst%3DY.-C.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DHeald%26aufirst%3DN.%26aulast%3DLamb%26aufirst%3DP.%26aulast%3DMattheakis%26aufirst%3DL.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DShipway%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DShankar%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Class%2520of%2520Potent%2520and%2520Orally%2520Bioavailable%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1368%26epage%3D1381%26doi%3D10.1021%2Fjm201533b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Angst, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janser, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quancard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buehlmayer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berst, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beerli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pally, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersperger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassilana, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollbuck, B.</span><span> </span><span class="NLM_article-title">An Oral Sphingosine 1-Phosphate Receptor 1 (S1P<sub>1</sub>) Antagonist Prodrug with Efficacy in Vivo: Discovery, Synthesis, and Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9722</span><span class="NLM_x">–</span> <span class="NLM_lpage">9734</span><span class="refDoi"> DOI: 10.1021/jm3009508</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009508" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9722-9734&author=D.+Angstauthor=P.+Janserauthor=J.+Quancardauthor=P.+Buehlmayerauthor=F.+Berstauthor=L.+Obererauthor=C.+Beerliauthor=M.+Streiffauthor=C.+Pallyauthor=R.+Herspergerauthor=C.+Brunsauthor=F.+Bassilanaauthor=B.+Bollbuck&title=An+Oral+Sphingosine+1-Phosphate+Receptor+1+%28S1P1%29+Antagonist+Prodrug+with+Efficacy+in+Vivo%3A+Discovery%2C+Synthesis%2C+and+Evaluation&doi=10.1021%2Fjm3009508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm3009508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009508%26sid%3Dliteratum%253Aachs%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DQuancard%26aufirst%3DJ.%26aulast%3DBuehlmayer%26aufirst%3DP.%26aulast%3DBerst%26aufirst%3DF.%26aulast%3DOberer%26aufirst%3DL.%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DPally%26aufirst%3DC.%26aulast%3DHersperger%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DBassilana%26aufirst%3DF.%26aulast%3DBollbuck%26aufirst%3DB.%26atitle%3DAn%2520Oral%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520%2528S1P1%2529%2520Antagonist%2520Prodrug%2520with%2520Efficacy%2520in%2520Vivo%253A%2520Discovery%252C%2520Synthesis%252C%2520and%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9722%26epage%3D9734%26doi%3D10.1021%2Fjm3009508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hennessy, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamhi, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronco, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Q.</span><span> </span><span class="NLM_article-title">Discovery of Heterocyclic Sulfonamides as Sphingosine 1-Phosphate Receptor 1 (S1P<sub>1</sub>) Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2045</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.bmcl.2015.03.095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2041-2045&author=E.+J.+Hennessyauthor=G.+Grewalauthor=K.+Bythauthor=V.+M.+Kamhiauthor=D.+Liauthor=P.+Lyneauthor=V.+Ozaauthor=L.+Roncoauthor=M.+T.+Rooneyauthor=J.+C.+Saehauthor=Q.+Su&title=Discovery+of+Heterocyclic+Sulfonamides+as+Sphingosine+1-Phosphate+Receptor+1+%28S1P1%29+Antagonists&doi=10.1016%2Fj.bmcl.2015.03.095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.095%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DGrewal%26aufirst%3DG.%26aulast%3DByth%26aufirst%3DK.%26aulast%3DKamhi%26aufirst%3DV.%2BM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DOza%26aufirst%3DV.%26aulast%3DRonco%26aufirst%3DL.%26aulast%3DRooney%26aufirst%3DM.%2BT.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DSu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520Heterocyclic%2520Sulfonamides%2520as%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520%2528S1P1%2529%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2041%26epage%3D2045%26doi%3D10.1016%2Fj.bmcl.2015.03.095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Oakley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruickshank, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhem, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loomis, C. R.</span><span> </span><span class="NLM_article-title">The Cellular Distribution of Fluorescently Labeled Arrestins Provides a Robust, Sensitive, and Universal Assay for Screening G Protein-Coupled Receptors</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1089/154065802761001275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1089%2F154065802761001275" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=21-30&author=R.+H.+Oakleyauthor=C.+C.+Hudsonauthor=R.+D.+Cruickshankauthor=D.+M.+Meyersauthor=R.+E.+Payneauthor=S.+M.+Rhemauthor=C.+R.+Loomis&title=The+Cellular+Distribution+of+Fluorescently+Labeled+Arrestins+Provides+a+Robust%2C+Sensitive%2C+and+Universal+Assay+for+Screening+G+Protein-Coupled+Receptors&doi=10.1089%2F154065802761001275"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1089%2F154065802761001275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065802761001275%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DR.%2BH.%26aulast%3DHudson%26aufirst%3DC.%2BC.%26aulast%3DCruickshank%26aufirst%3DR.%2BD.%26aulast%3DMeyers%26aufirst%3DD.%2BM.%26aulast%3DPayne%26aufirst%3DR.%2BE.%26aulast%3DRhem%26aufirst%3DS.%2BM.%26aulast%3DLoomis%26aufirst%3DC.%2BR.%26atitle%3DThe%2520Cellular%2520Distribution%2520of%2520Fluorescently%2520Labeled%2520Arrestins%2520Provides%2520a%2520Robust%252C%2520Sensitive%252C%2520and%2520Universal%2520Assay%2520for%2520Screening%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2002%26volume%3D1%26spage%3D21%26epage%3D30%26doi%3D10.1089%2F154065802761001275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0liXr7fGg4bBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, A. Y. H.</span><span> </span><span class="NLM_article-title">Inhibition and Induction of Cytochrome P450 and the Clinical Implications</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span><span class="refDoi"> DOI: 10.2165/00003088-199835050-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.2165%2F00003088-199835050-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=9839089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1998&pages=361-390&author=J.+H.+Linauthor=A.+Y.+H.+Lu&title=Inhibition+and+Induction+of+Cytochrome+P450+and+the+Clinical+Implications&doi=10.2165%2F00003088-199835050-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and induction of cytochrome P450 and the clinical implications</span></div><div class="casAuthors">Lin, Jiunn H.; Lu, Anthony Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-390</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 192 refs.  The cytochrome P450s (CYPs) constitute a superfamily of isoforms that play an important role in the oxidative metab. of drugs.  Each CYP isoform possesses a characteristic broad spectrum of catalytic activities of substrates.  Whenever 2 or more drugs are administered concurrently, the possibility of drug interactions exists.  The ability of a single CYP to metabolize multiple substrates is responsible for a large no. of documented drug interactions assocd. with CYP inhibition.  In addn., drug interactions can also occur as a result of the induction of several human CYPs following long term drug treatment.  The mechanisms of CYP inhibition can be divided into 3 categories: (a) reversible inhibition; (b) quasi-irreversible inhibition; and (c) irreversible inhibition.  In mechanistic terms, reversible interactions arise as a result of competition at the CYP active site and probably involve only the first step of the CYP catalytic cycle.  On the other hand, drugs that act during and subsequent to the oxygen transfer step are generally irreversible or quasi-irreversible inhibitors.  Irreversible and quasi-irreversible inhibition require at least one cycle of the CYP catalytic process.  Because human liver samples and recombinant human CYPs are now readily available, in vitro systems have been used as screening tools to predict the potential for in vivo drug interaction.  Although it is easy to det. in vitro metabolic drug interactions, the proper interpretation and extrapolation of in vitro interaction data to in vivo situations require a good understanding of pharmacokinetic principles.  From the viewpoint of drug therapy, to avoid potential drug-drug interactions, it is desirable to develop a new drug candidate that is not a potent CYP inhibitor or inducer and the metab. of which is not readily inhibited by other drugs.  In reality, drug interaction by mutual inhibition between drugs is almost inevitable, because CYP-mediated metab. represents a major route of elimination of many drugs, which can compete for the same CYP enzyme.  The clin. significance of a metabolic drug interaction depends on the magnitude of the change in the concn. of active species (parent drug and/or active metabolites) at the site of pharmacol. action and the therapeutic index of the drug.  The smaller the difference between toxic and effective concn., the greater the likelihood that a drug interaction will have serious clin. consequences.  Thus, careful evaluation of potential drug interactions of a new drug candidate during the early stage of drug development is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdqTupUCBbLVg90H21EOLACvtfcHk0liXr7fGg4bBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D&md5=18993123e2cdad5517962664e986a5b4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003088-199835050-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199835050-00003%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DLu%26aufirst%3DA.%2BY.%2BH.%26atitle%3DInhibition%2520and%2520Induction%2520of%2520Cytochrome%2520P450%2520and%2520the%2520Clinical%2520Implications%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1998%26volume%3D35%26spage%3D361%26epage%3D390%26doi%3D10.2165%2F00003088-199835050-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kocarek, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuetz, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strom, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzelian, P. S.</span><span> </span><span class="NLM_article-title">Comparative Analysis of Cytochrome P4503A Induction in Primary Cultures of Rat, Rabbit, and Human Hepatocytes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=415-421&author=T.+A.+Kocarekauthor=E.+G.+Schuetzauthor=S.+C.+Stromauthor=R.+A.+Fisherauthor=P.+S.+Guzelian&title=Comparative+Analysis+of+Cytochrome+P4503A+Induction+in+Primary+Cultures+of+Rat%2C+Rabbit%2C+and+Human+Hepatocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKocarek%26aufirst%3DT.%2BA.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26aulast%3DStrom%26aufirst%3DS.%2BC.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DGuzelian%26aufirst%3DP.%2BS.%26atitle%3DComparative%2520Analysis%2520of%2520Cytochrome%2520P4503A%2520Induction%2520in%2520Primary%2520Cultures%2520of%2520Rat%252C%2520Rabbit%252C%2520and%2520Human%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D415%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomkinson, N. C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCluyse, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. T.</span><span> </span><span class="NLM_article-title">The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution</span> <span class="citation_source-journal">Mol. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1210/mend.14.1.0409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1210%2Fmend.14.1.0409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10628745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=27-39&author=S.+A.+Jonesauthor=L.+B.+Mooreauthor=J.+L.+Shenkauthor=G.+B.+Wiselyauthor=G.+A.+Hamiltonauthor=D.+D.+McKeeauthor=N.+C.+O.+Tomkinsonauthor=E.+L.+LeCluyseauthor=M.+H.+Lambertauthor=T.+M.+Willsonauthor=S.+A.+Kliewerauthor=J.+T.+Moore&title=The+Pregnane+X+Receptor%3A+A+Promiscuous+Xenobiotic+Receptor+That+Has+Diverged+during+Evolution&doi=10.1210%2Fmend.14.1.0409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution</span></div><div class="casAuthors">Jones, Stacey A.; Moore, Linda B.; Shenk, Jennifer L.; Wisely, G. Bruce; Hamilton, Geraldine A.; McKee, David D.; Tomkinson, Nicholas C. O.; LeCluyse, Edward L.; Lambert, Millard H.; Willson, Timothy M.; Kliewer, Steven A.; Moore, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-39</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Transcription of genes encoding cytochrome P 450 3A (CYP3A) monooxygenases is induced by a variety of xenobiotics and natural steroids.  There are marked differences in the compds. that induce CYP3A gene expression between species.  Recently, the mouse and human pregnane X receptor (PXR) were shown to be activated by compds. that induce CYP3A expression.  However, most studies of CYP3A regulation have been performed using rabbit and rat hepatocytes.  Here, the authors report the cloning and characterization of PXR from these two species.  PXR is remarkably divergent between species, with the rabbit, rat, and human receptors sharing only approx. 80% amino acid identity in their ligand-binding domains.  This sequence divergence is reflected by marked pharmacol. differences in PXR activation profiles.  For example, the macrolide antibiotic rifampicin, the antidiabetic drug troglitazone, and the hypocholesterolemic drug SR12813 are efficacious activators of the human and rabbit PXR but have little activity on the rat and mouse PXR.  Conversely, pregnane 16α-carbonitrile is a more potent activator of the rat and mouse PXR than the human and rabbit receptor.  The activities of xenobiotics in PXR activation assays correlate well with their ability to induce CYP3A expression in primary hepatocytes.  Through the use of a novel scintillation proximity binding assay, the authors demonstrate that many of the compds. that induce CYP3A expression bind directly to human PXR.  These data establish PXR as a promiscuous xenobiotic receptor that has diverged during evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4cu4x3jOH8rVg90H21EOLACvtfcHk0ljsq4VZu2dVTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D&md5=50bbd39e3285b9293b8a452798b5cffd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1210%2Fmend.14.1.0409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.14.1.0409%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DShenk%26aufirst%3DJ.%2BL.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DTomkinson%26aufirst%3DN.%2BC.%2BO.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Pregnane%2520X%2520Receptor%253A%2520A%2520Promiscuous%2520Xenobiotic%2520Receptor%2520That%2520Has%2520Diverged%2520during%2520Evolution%26jtitle%3DMol.%2520Endocrinol.%26date%3D2000%26volume%3D14%26spage%3D27%26epage%3D39%26doi%3D10.1210%2Fmend.14.1.0409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Burk, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raucy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hustert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockmöller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanger, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojnowski, L.</span><span> </span><span class="NLM_article-title">The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">38379</span><span class="NLM_x">–</span> <span class="NLM_lpage">38385</span><span class="refDoi"> DOI: 10.1074/jbc.M404949200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M404949200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=38379-38385&author=O.+Burkauthor=I.+Kochauthor=J.+Raucyauthor=E.+Hustertauthor=M.+Eichelbaumauthor=J.+Brockm%C3%B6llerauthor=U.+M.+Zangerauthor=L.+Wojnowski&title=The+Induction+of+Cytochrome+P450+3A5+%28CYP3A5%29+in+the+Human+Liver+and+Intestine+Is+Mediated+by+the+Xenobiotic+Sensors+Pregnane+X+Receptor+%28PXR%29+and+Constitutively+Activated+Receptor+%28CAR%29&doi=10.1074%2Fjbc.M404949200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M404949200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M404949200%26sid%3Dliteratum%253Aachs%26aulast%3DBurk%26aufirst%3DO.%26aulast%3DKoch%26aufirst%3DI.%26aulast%3DRaucy%26aufirst%3DJ.%26aulast%3DHustert%26aufirst%3DE.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DBrockm%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DZanger%26aufirst%3DU.%2BM.%26aulast%3DWojnowski%26aufirst%3DL.%26atitle%3DThe%2520Induction%2520of%2520Cytochrome%2520P450%25203A5%2520%2528CYP3A5%2529%2520in%2520the%2520Human%2520Liver%2520and%2520Intestine%2520Is%2520Mediated%2520by%2520the%2520Xenobiotic%2520Sensors%2520Pregnane%2520X%2520Receptor%2520%2528PXR%2529%2520and%2520Constitutively%2520Activated%2520Receptor%2520%2528CAR%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D38379%26epage%3D38385%26doi%3D10.1074%2Fjbc.M404949200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bertilsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Åsman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jendeberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sydow-Bäckman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postlind, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomquist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkenstam, A.</span><span> </span><span class="NLM_article-title">Identification of a human nuclear receptor defines a new signaling pathway for <i>CYP3A</i> induction</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12208</span><span class="NLM_x">–</span> <span class="NLM_lpage">12213</span><span class="refDoi"> DOI: 10.1073/pnas.95.21.12208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1073%2Fpnas.95.21.12208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12208-12213&author=G.+Bertilssonauthor=J.+Heidrichauthor=K.+Svenssonauthor=M.+%C3%85smanauthor=L.+Jendebergauthor=M.+Sydow-B%C3%A4ckmanauthor=R.+Ohlssonauthor=H.+Postlindauthor=P.+Blomquistauthor=A.+Berkenstam&title=Identification+of+a+human+nuclear+receptor+defines+a+new+signaling+pathway+for+CYP3A+induction&doi=10.1073%2Fpnas.95.21.12208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.21.12208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.21.12208%26sid%3Dliteratum%253Aachs%26aulast%3DBertilsson%26aufirst%3DG.%26aulast%3DHeidrich%26aufirst%3DJ.%26aulast%3DSvensson%26aufirst%3DK.%26aulast%3D%25C3%2585sman%26aufirst%3DM.%26aulast%3DJendeberg%26aufirst%3DL.%26aulast%3DSydow-B%25C3%25A4ckman%26aufirst%3DM.%26aulast%3DOhlsson%26aufirst%3DR.%26aulast%3DPostlind%26aufirst%3DH.%26aulast%3DBlomquist%26aufirst%3DP.%26aulast%3DBerkenstam%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520human%2520nuclear%2520receptor%2520defines%2520a%2520new%2520signaling%2520pathway%2520for%2520CYP3A%2520induction%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12208%26epage%3D12213%26doi%3D10.1073%2Fpnas.95.21.12208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Lehmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span> </span><span class="NLM_article-title">The Human Orphan Nuclear Receptor PXR Is Activated by Compounds That Regulate <i>CYP3A4</i> Gene Expression and Cause Drug Interactions</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1016</span><span class="NLM_x">–</span> <span class="NLM_lpage">1023</span><span class="refDoi"> DOI: 10.1172/JCI3703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1172%2FJCI3703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=9727070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1016-1023&author=J.+M.+Lehmannauthor=D.+D.+McKeeauthor=M.+A.+Watsonauthor=T.+M.+Willsonauthor=J.+T.+Mooreauthor=S.+A.+Kliewer&title=The+Human+Orphan+Nuclear+Receptor+PXR+Is+Activated+by+Compounds+That+Regulate+CYP3A4+Gene+Expression+and+Cause+Drug+Interactions&doi=10.1172%2FJCI3703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</span></div><div class="casAuthors">Lehmann, Jurgen M.; McKee, David D.; Watson, Michael A.; Willson, Timothy M.; Moore, John T.; Kliewer, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1016-1023</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The cytochrome P 450 monooxygenase 3A4 (CYP3A4) is responsible for the oxidative metab. of a wide variety of xenobiotics including an estd. 60% of all clin. used drugs.  Although expression of the CYP3A4 gene is known to be induced in response to a variety of compds., the mechanism underlying this induction, which represents a basis for drug interactions in patients, has remained unclear.  The authors report the identification of a human (h) orphan nuclear receptor, termed the pregnane X receptor (PXR), that binds to a response element in the CYP3A4 promoter and is activated by a range of drugs known to induce CYP3A4 expression.  Comparison of hPXR with the recently cloned mouse PXR reveals marked differences in their activation by certain drugs, which may account in part for the species-specific effects of compds. on CYP3A gene expression.  These findings provide a mol. explanation for the ability of disparate chems. to induce CYP3A4 levels and, furthermore, provide a basis for developing in vitro assays to aid in predicting whether drugs will interact in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7B4VVObDCH7Vg90H21EOLACvtfcHk0ljsq4VZu2dVTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D&md5=536bd0a0a80d2d6b36cdc7747a8e0fd0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1172%2FJCI3703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3703%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26atitle%3DThe%2520Human%2520Orphan%2520Nuclear%2520Receptor%2520PXR%2520Is%2520Activated%2520by%2520Compounds%2520That%2520Regulate%2520CYP3A4%2520Gene%2520Expression%2520and%2520Cause%2520Drug%2520Interactions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1016%26epage%3D1023%26doi%3D10.1172%2FJCI3703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kliewer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterström, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, J. M.</span><span> </span><span class="NLM_article-title">An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)80900-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2FS0092-8674%2800%2980900-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=9489701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=73-82&author=S.+A.+Kliewerauthor=J.+T.+Mooreauthor=L.+Wadeauthor=J.+L.+Staudingerauthor=M.+A.+Watsonauthor=S.+A.+Jonesauthor=D.+D.+McKeeauthor=B.+B.+Oliverauthor=T.+M.+Willsonauthor=R.+H.+Zetterstr%C3%B6mauthor=T.+Perlmannauthor=J.+M.+Lehmann&title=An+Orphan+Nuclear+Receptor+Activated+by+Pregnanes+Defines+a+Novel+Steroid+Signaling+Pathway&doi=10.1016%2FS0092-8674%2800%2980900-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway</span></div><div class="casAuthors">Kliewer, Steven A.; Moore, John T.; Wade, Laura; Staudinger, Jeff L.; Watson, Michael A.; Jones, Stacey A.; McKee, David D.; Oliver, Beverly B.; Willson, Timothy M.; Zetterstrom, Rolf H.; Perlmann, Thomas; Lehmann, Jurgen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Steroid hormones exert profound effects on differentiation, development, and homeostasis in higher eukaryotes through interactions with nuclear receptors.  We describe a novel orphan nuclear receptor, termed the pregnane X receptor (PXR), that is activated by naturally occurring steroids such as pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids.  PXR exists as two isoforms, PXR.1 and PXR.2, that are differentially activated by steroids.  Notably, PXR.1 is efficaciously activated by pregnenolone 16α-carbonitrile, a glucocorticoid receptor antagonist that induces the expression of the CYP3A family of steroid hydroxylases and modulates sterol and bile acid biosynthesis in vivo.  Our results provide evidence for the existence of a novel steroid hormone signaling pathway with potential implications in the regulation of steroid hormone and sterol homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcj-Q4c6TTLVg90H21EOLACvtfcHk0lg5Z_Zna2Z9-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D&md5=1c24d97b161b497c4d2503e7b7adb778</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980900-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980900-9%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWade%26aufirst%3DL.%26aulast%3DStaudinger%26aufirst%3DJ.%2BL.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZetterstr%25C3%25B6m%26aufirst%3DR.%2BH.%26aulast%3DPerlmann%26aufirst%3DT.%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26atitle%3DAn%2520Orphan%2520Nuclear%2520Receptor%2520Activated%2520by%2520Pregnanes%2520Defines%2520a%2520Novel%2520Steroid%2520Signaling%2520Pathway%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D73%26epage%3D82%26doi%3D10.1016%2FS0092-8674%2800%2980900-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Baes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinoli, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, D. D.</span><span> </span><span class="NLM_article-title">A New Orphan Member of the Nuclear Hormone Receptor Superfamily That Interacts with a Subset of Retinoic Acid Response Elements</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1128%2FMCB.14.3.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=8114692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK2cXis1ais7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1994&pages=1544-1552&author=M.+Baesauthor=T.+Gulickauthor=H.-S.+Choiauthor=M.+G.+Martinoliauthor=D.+Simhaauthor=D.+D.+Moore&title=A+New+Orphan+Member+of+the+Nuclear+Hormone+Receptor+Superfamily+That+Interacts+with+a+Subset+of+Retinoic+Acid+Response+Elements"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements</span></div><div class="casAuthors">Baes, Myriam; Gulick, Tod; Choi, Hueng Sik; Martinoli, Maria Grazia; Simha, Devendranath; Moore, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1544-52</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The authors have identified and characterized a new orphan member of the nuclear hormone receptor superfamily, called MB67, which is predominantly expressed in liver.  MB67 binds and trans-activates the retinoic acid response elements that control expression of the retinoic acid receptor β2 and alc. dehydrogenase 3 genes, both of which consist of direct repeat hexamers related to the consensus AGGTCA, sepd. by 5 bp.  MB67 binds these elements as a heterodimer with the 9-cis-retinoic acid receptor, RXR.  However, MB67 does not bind or activate other retinoic acid response elements with alternative hexamer arrangements or any of several other wild-type and synthetic hormone response elements examd.  The transactivation of retinoic acid response elements by MB67 is weaker than that conferred by the retinoic acid receptors but does not require the presence of all-trans retinoic acid, 9-cis-retinoic acid, or any exogenously added ligand.  The authors propose that MB67 plays an important role in the complex network of proteins that govern response to retinoic acid and its metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSjESKOun4vLVg90H21EOLACvtfcHk0lg5Z_Zna2Z9-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1ais7Y%253D&md5=7ff455f386465512605f9f0ad27abca8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FMCB.14.3.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.14.3.1544%26sid%3Dliteratum%253Aachs%26aulast%3DBaes%26aufirst%3DM.%26aulast%3DGulick%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DH.-S.%26aulast%3DMartinoli%26aufirst%3DM.%2BG.%26aulast%3DSimha%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DD.%2BD.%26atitle%3DA%2520New%2520Orphan%2520Member%2520of%2520the%2520Nuclear%2520Hormone%2520Receptor%2520Superfamily%2520That%2520Interacts%2520with%2520a%2520Subset%2520of%2520Retinoic%2520Acid%2520Response%2520Elements%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1994%26volume%3D14%26spage%3D1544%26epage%3D1552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Raucy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yueh, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, S. W.</span><span> </span><span class="NLM_article-title">A Cell-Based Reporter Gene Assay for Determining Induction of CYP3A4 in a High-Volume System</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span><span class="refDoi"> DOI: 10.1124/jpet.102.038653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fjpet.102.038653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=12235278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsV2qtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=412-423&author=J.+Raucyauthor=L.+Warfeauthor=M.-F.+Yuehauthor=S.+W.+Allen&title=A+Cell-Based+Reporter+Gene+Assay+for+Determining+Induction+of+CYP3A4+in+a+High-Volume+System&doi=10.1124%2Fjpet.102.038653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system</span></div><div class="casAuthors">Raucy, Judy; Warfe, Lyndon; Yueh, Mei-Fei; Allen, Scott W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">412-423</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Assessing the inducibility of CYP3A4 by various xenobiotics can predict potential drug interactions.  In the present investigation, human hepatoma cells were stably integrated with either the CYP3A4 enhancer region and a luciferase reporter gene or the CYP3A4-luciferase construct and the human pregnane X receptor (PXR).  Several colonies contg. one to three copies of luciferase per cell were identified by Southern blot anal.  Those transformants producing high luciferase activity in response to rifampicin were used to standardize a 96-well plate screening system with minimal inter- and intraplate variability.  Standardization also consisted of assessing viability of cells cultured in medium contg. various serum concns.  In cells maintained for 48 h in medium with less than 5% serum, a significant (p < 0.01) decline was obsd. in viability accompanied by altered induction.  A defined serum-free medium also produced less viable cells but did not alter the inductive response.  Treatment of transformants with various concns. of rifampicin produced a dose-response curve with maximal induction at 10 μM (5.6±0.18- and 2.1±0.3-fold above DMSO (DMSO)-treated cells in transformants with and without PXR, resp.).  Of addnl. agents examd. for their ability to induce CYP3A4, omeprazole (200 μM) was the most potent inducer (12.8±1.9- and 2.4±0.2-fold above DMSO-treated cells in transformants with and without PXR, resp.).  Mifepristone and mevastatin produced modest induction (∼3-fold) in the cell line contg. exogenous PXR, but produced less than 1.2-fold increases in cells lacking PXR.  Thus, only potent inducers can be identified in the cell line without PXR.  In contrast, cells contg. the receptor can be used to rank CYP3A4 induction.  Because a high vol. of chems. can be readily and accurately screened for their ability to induce CYP3A4 with this format, such a system could be valuable in the initial stages of preclin. drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZyXqBDWRWLVg90H21EOLACvtfcHk0lg5Z_Zna2Z9-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsV2qtrc%253D&md5=433cb89b72745771e8df9c07df65632f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.038653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.038653%26sid%3Dliteratum%253Aachs%26aulast%3DRaucy%26aufirst%3DJ.%26aulast%3DWarfe%26aufirst%3DL.%26aulast%3DYueh%26aufirst%3DM.-F.%26aulast%3DAllen%26aufirst%3DS.%2BW.%26atitle%3DA%2520Cell-Based%2520Reporter%2520Gene%2520Assay%2520for%2520Determining%2520Induction%2520of%2520CYP3A4%2520in%2520a%2520High-Volume%2520System%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D412%26epage%3D423%26doi%3D10.1124%2Fjpet.102.038653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Lemaire, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Sousa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahmani, R.</span><span> </span><span class="NLM_article-title">A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYB2B6 induction by pesticides</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2347</span><span class="NLM_x">–</span> <span class="NLM_lpage">2358</span><span class="refDoi"> DOI: 10.1016/j.bcp.2004.07.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.bcp.2004.07.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=2347-2358&author=G.+Lemaireauthor=G.+de+Sousaauthor=R.+Rahmani&title=A+PXR+reporter+gene+assay+in+a+stable+cell+culture+system%3A+CYP3A4+and+CYB2B6+induction+by+pesticides&doi=10.1016%2Fj.bcp.2004.07.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.07.041%26sid%3Dliteratum%253Aachs%26aulast%3DLemaire%26aufirst%3DG.%26aulast%3Dde%2BSousa%26aufirst%3DG.%26aulast%3DRahmani%26aufirst%3DR.%26atitle%3DA%2520PXR%2520reporter%2520gene%2520assay%2520in%2520a%2520stable%2520cell%2520culture%2520system%253A%2520CYP3A4%2520and%2520CYB2B6%2520induction%2520by%2520pesticides%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D2347%26epage%3D2358%26doi%3D10.1016%2Fj.bcp.2004.07.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Gao, Y.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkovec, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabut, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span> </span><span class="NLM_article-title">Attenuating pregnane X receptor (PXR) activation: A molecular modelling approach</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">124</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1080/00498250601050412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1080%2F00498250601050412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17484516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=124-138&author=Y.-D.+Gaoauthor=S.+H.+Olsonauthor=J.+M.+Balkovecauthor=Y.+Zhuauthor=I.+Royoauthor=J.+Yabutauthor=R.+Eversauthor=E.+Y.+Tanauthor=W.+Tangauthor=D.+P.+Hartleyauthor=R.+T.+Mosley&title=Attenuating+pregnane+X+receptor+%28PXR%29+activation%3A+A+molecular+modelling+approach&doi=10.1080%2F00498250601050412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach</span></div><div class="casAuthors">Gao, Y.-D.; Olson, S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. Y.; Tang, W.; Hartley, D. P.; Mosley, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that the pregnane X receptor (PXR) is a key regulator of cytochromes P 450 3A (e.g. CYP3A4 in human) gene expression.  As a result, activation of PXR may lead to CYP3A4 protein over-expression.  Because induction of CYP3A4 could result in clin. important drug-drug interactions, there has been a great interest in reducing the possibility of PXR activation by drug candidates in drug-discovery programs.  In order to provide structural insight for attenuating drug candidate-mediated PXR activation, we used a docking approach to study the structure-activity relationship for PXR activators.  Based on our docking models, it is proposed that introducing polar groups to the end of an activator should reduce its human PXR (hPXR) activity via destabilizing interactions in the hydrophobic areas of the PXR ligand-binding pocket.  A no. of analogs that incorporate these structural features then were designed and synthesized, and they exhibited significantly lower hPXR activation in a transactivation assay and decreased CYP3A4 induction in a human hepatocytes-based assay.  In addn., an example in which attenuating hPXR activation was achieved by sterically destabilizing the helixes 11 and 12 of the receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBZSC0secQoLVg90H21EOLACvtfcHk0liEE75BqNItSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D&md5=400688510dd165a4a9632b6ba10bf267</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F00498250601050412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250601050412%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DOlson%26aufirst%3DS.%2BH.%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DRoyo%26aufirst%3DI.%26aulast%3DYabut%26aufirst%3DJ.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DE.%2BY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26atitle%3DAttenuating%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520activation%253A%2520A%2520molecular%2520modelling%2520approach%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26spage%3D124%26epage%3D138%26doi%3D10.1080%2F00498250601050412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Salonen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellermann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span> </span><span class="NLM_article-title">Aromatic Rings in Chemical and Biological Recognition: Energetics and Structures</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4808</span><span class="NLM_x">–</span> <span class="NLM_lpage">4842</span><span class="refDoi"> DOI: 10.1002/anie.201007560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1002%2Fanie.201007560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVekt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=4808-4842&author=L.+M.+Salonenauthor=M.+Ellermannauthor=F.+Diederich&title=Aromatic+Rings+in+Chemical+and+Biological+Recognition%3A+Energetics+and+Structures&doi=10.1002%2Fanie.201007560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatic rings in chemical and biological recognition: energetics and structures</span></div><div class="casAuthors">Salonen, Laura M.; Ellermann, Manuel; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4808-4842</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes a multidimensional treatment of mol. recognition phenomena involving arom. rings in chem. and biol. systems.  It summarizes new results reported since the appearance of an earlier review in 2003 in host-guest chem., biol. affinity assays and biostructural anal., data base mining in the Cambridge Structural Database (CSD) and the Protein Data Bank (PDB), and advanced computational studies.  Topics addressed are arene-arene, perfluoroarene-arene, S···arom., cation-π, and anion-π interactions, as well as hydrogen bonding to π systems.  The generated knowledge benefits, in particular, structure-based hit-to-lead development and lead optimization both in the pharmaceutical and in the crop protection industry.  It equally facilitates the development of new advanced materials and supramol. systems, and should inspire further utilization of interactions with arom. rings to control the stereochem. outcome of synthetic transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8vdN7B4v_aLVg90H21EOLACvtfcHk0liEE75BqNItSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVekt70%253D&md5=3684d00abc320d1ea0c71565495d5d5c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fanie.201007560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201007560%26sid%3Dliteratum%253Aachs%26aulast%3DSalonen%26aufirst%3DL.%2BM.%26aulast%3DEllermann%26aufirst%3DM.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DAromatic%2520Rings%2520in%2520Chemical%2520and%2520Biological%2520Recognition%253A%2520Energetics%2520and%2520Structures%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D4808%26epage%3D4842%26doi%3D10.1002%2Fanie.201007560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Bjornsson, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snikeris, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span> </span><span class="NLM_article-title">The Conduct of in vitro and in vivo Drug-Drug Interaction Studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) Perspective</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1124/dmd.31.7.815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fdmd.31.7.815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=12814957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=815-832&author=T.+D.+Bjornssonauthor=J.+T.+Callaghanauthor=H.+J.+Einolfauthor=V.+Fischerauthor=L.+Ganauthor=S.+Grimmauthor=J.+Kaoauthor=S.+P.+Kingauthor=G.+Miwaauthor=L.+Niauthor=G.+Kumarauthor=J.+McLeodauthor=R.+S.+Obachauthor=S.+Robertsauthor=A.+Roeauthor=A.+Shahauthor=F.+Snikerisauthor=J.+T.+Sullivanauthor=D.+Tweedieauthor=J.+M.+Vegaauthor=J.+Walshauthor=S.+A.+Wrighton&title=The+Conduct+of+in+vitro+and+in+vivo+Drug-Drug+Interaction+Studies%3A+A+Pharmaceutical+Research+and+Manufacturers+of+America+%28PhRMA%29+Perspective&doi=10.1124%2Fdmd.31.7.815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective</span></div><div class="casAuthors">Bjornsson, Thorir D.; Callaghan, John T.; Einolf, Heidi J.; Fischer, Volker; Gan, Lawrence; Grimm, Scott; Kao, John; King, S. Peter; Miwa, Gerald; Ni, Lan; Kumar, Gondi; McLeod, James; Obach, R. Scott; Roberts, Stanley; Roe, Amy; Shah, Anita; Snikeris, Fred; Sullivan, John T.; Tweedie, Donald; Vega, Jose M.; Walsh, John; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-832</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies.  There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs.  There is also a growing consensus for the standardization of cytochrome P 450 (P 450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients.  While existing guidances cover mainly P 450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed.  This article was prepd. by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metab. and Clin. Pharmacol. Tech. Working Groups and represents the current industry position.  The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compd. registration dossiers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogi0LDV4FgLVg90H21EOLACvtfcHk0liEE75BqNItSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D&md5=2a41b5f54f65504448656ac7f7409aea</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.7.815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.7.815%26sid%3Dliteratum%253Aachs%26aulast%3DBjornsson%26aufirst%3DT.%2BD.%26aulast%3DCallaghan%26aufirst%3DJ.%2BT.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DGrimm%26aufirst%3DS.%26aulast%3DKao%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DS.%2BP.%26aulast%3DMiwa%26aufirst%3DG.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMcLeod%26aufirst%3DJ.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DRoe%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DSnikeris%26aufirst%3DF.%26aulast%3DSullivan%26aufirst%3DJ.%2BT.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DThe%2520Conduct%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520Drug-Drug%2520Interaction%2520Studies%253A%2520A%2520Pharmaceutical%2520Research%2520and%2520Manufacturers%2520of%2520America%2520%2528PhRMA%2529%2520Perspective%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D815%26epage%3D832%26doi%3D10.1124%2Fdmd.31.7.815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selling, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecluyse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.-S.</span><span> </span><span class="NLM_article-title">CYP3A4 Induction by Drugs: Correlation Between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">804</span><span class="refDoi"> DOI: 10.1124/dmd.30.7.795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fdmd.30.7.795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=12065438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=795-804&author=G.+Luoauthor=M.+Cunninghamauthor=S.+Kimauthor=T.+Burnauthor=J.+Linauthor=M.+Sinzauthor=G.+Hamiltonauthor=C.+Rizzoauthor=S.+Jolleyauthor=D.+Gilbertauthor=A.+Downeyauthor=D.+Mudraauthor=R.+Grahamauthor=K.+Carrollauthor=J.+Xieauthor=A.+Madanauthor=A.+Parkinsonauthor=D.+Christauthor=B.+Sellingauthor=E.+Lecluyseauthor=L.-S.+Gan&title=CYP3A4+Induction+by+Drugs%3A+Correlation+Between+a+Pregnane+X+Receptor+Reporter+Gene+Assay+and+CYP3A4+Expression+in+Human+Hepatocytes&doi=10.1124%2Fdmd.30.7.795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</span></div><div class="casAuthors">Luo, Gang; Cunningham, Mark; Kim, Sean; Burn, Tim; Lin, Jianrong; Sinz, Michael; Hamilton, Geraldine; Rizzo, Christopher; Jolley, Summer; Gilbert, Darryl; Downey, April; Mudra, Daniel; Graham, Richard; Carroll, Kathy; Xie, Jindong; Madan, Ajay; Parkinson, Andrew; Christ, Dave; Selling, Bernard; Lecluyse, Edward; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Induction of cytochrome P 450 3A4 (CYP3A4) is detd. typically by employing primary culture of human hepatocytes and measuring CYP3A4 mRNA, protein and microsomal activity.  Recently a pregnane X receptor (PXR) reporter gene assay was established to screen CYP3A4 inducers.  To evaluate results from the PXR reporter gene assay with those from the aforementioned conventional assays, 14 drugs were evaluated for their ability to induce CYP3A4 and activate PXR.  Sandwiched primary cultures of human hepatocytes from six donors were used and CYP3A4 activity was assessed by measuring microsomal testosterone 6β-hydroxylase activity.  Hepatic CYP3A4 mRNA and protein levels were also analyzed using branched DNA technol./Northern blotting and Western blotting, resp.  In general, PXR activation correlated with the induction potential obsd. in human hepatocyte cultures.  Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.  Ritonavir and troleandomycin showed marked PXR activation but no increase (in the case of troleandomycin) or a significant decrease (in the case of ritonavir) in microsomal CYP3A4 activity.  It is concluded that the PXR reporter gene assay is a reliable and complementary method to assess the CYP3A4 induction potential of drugs and other xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoJw2uJawzuLVg90H21EOLACvtfcHk0lhMSQXiJU9adQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D&md5=0de8fb68ebce41eed8d634cff33fad20</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.7.795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.7.795%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DCunningham%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DG.%26aulast%3DRizzo%26aufirst%3DC.%26aulast%3DJolley%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DDowney%26aufirst%3DA.%26aulast%3DMudra%26aufirst%3DD.%26aulast%3DGraham%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DParkinson%26aufirst%3DA.%26aulast%3DChrist%26aufirst%3DD.%26aulast%3DSelling%26aufirst%3DB.%26aulast%3DLecluyse%26aufirst%3DE.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DCYP3A4%2520Induction%2520by%2520Drugs%253A%2520Correlation%2520Between%2520a%2520Pregnane%2520X%2520Receptor%2520Reporter%2520Gene%2520Assay%2520and%2520CYP3A4%2520Expression%2520in%2520Human%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D795%26epage%3D804%26doi%3D10.1124%2Fdmd.30.7.795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Lee, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thangada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancellin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha’afi, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81661-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2FS0092-8674%2800%2981661-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=301-312&author=M.-J.+Leeauthor=S.+Thangadaauthor=K.+P.+Claffeyauthor=N.+Ancellinauthor=C.+H.+Liuauthor=M.+Klukauthor=M.+Volpiauthor=R.+I.+Sha%E2%80%99afiauthor=T.+Hla&title=Vascular+Endothelial+Cell+Adherens+Junction+Assembly+and+Morphogenesis+Induced+by+Sphingosine-1-Phosphate&doi=10.1016%2FS0092-8674%2800%2981661-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981661-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981661-X%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DThangada%26aufirst%3DS.%26aulast%3DClaffey%26aufirst%3DK.%2BP.%26aulast%3DAncellin%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DKluk%26aufirst%3DM.%26aulast%3DVolpi%26aufirst%3DM.%26aulast%3DSha%25E2%2580%2599afi%26aufirst%3DR.%2BI.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DVascular%2520Endothelial%2520Cell%2520Adherens%2520Junction%2520Assembly%2520and%2520Morphogenesis%2520Induced%2520by%2520Sphingosine-1-Phosphate%26jtitle%3DCell%26date%3D1999%26volume%3D99%26spage%3D301%26epage%3D312%26doi%3D10.1016%2FS0092-8674%2800%2981661-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Foss, F. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusa, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.bmc.2006.10.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17113298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtleisL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=663-677&author=F.+W.+Fossauthor=A.+H.+Snyderauthor=M.+D.+Davisauthor=M.+Rouseauthor=M.+D.+Okusaauthor=K.+R.+Lynchauthor=T.+L.+Macdonald&title=Synthesis+and+biological+evaluation+of+%CE%B3-aminophosphonates+as+potent%2C+subtype-selective+sphingosine+1-phosphate+receptor+agonists+and+antagonists&doi=10.1016%2Fj.bmc.2006.10.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists</span></div><div class="casAuthors">Foss, Frank W.; Snyder, Ashley H.; Davis, Michael D.; Rouse, Michael; Okusa, Mark D.; Lynch, Kevin R.; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">663-677</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis of N-arylamide phosphonates and related aryl ether and arylamine analogs provided potent, subtype-selective agonists and antagonists of the five known sphingosine 1-phosphate (S1P) receptors (S1P1-5).  To this end, the syntheses of phosphoserine mimetics, i.e., selectively protected and optically active phosphonoserines, are described.  In vitro binding assays showed that the implementation of phosphonates as phosphate mimetics provided compds. with similar receptor binding affinities as compared to their phosphate precursors.  Meta-substituted arylamide phosphonates were discovered to be antagonists of the S1P1 and S1P3 receptors.  When administered to mice, an antagonist blocked the lymphopenia evoked by a S1P receptor agonist and caused capillary leakage in both lung and kidney.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqJ9NyWRyVe7Vg90H21EOLACvtfcHk0lhMSQXiJU9adQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtleisL%252FP&md5=b50ee5f8179209124fae41960fc7b0b4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DSnyder%26aufirst%3DA.%2BH.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DRouse%26aufirst%3DM.%26aulast%3DOkusa%26aufirst%3DM.%2BD.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520%25CE%25B3-aminophosphonates%2520as%2520potent%252C%2520subtype-selective%2520sphingosine%25201-phosphate%2520receptor%2520agonists%2520and%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D663%26epage%3D677%26doi%3D10.1016%2Fj.bmc.2006.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilburn, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span> </span><span class="NLM_article-title">AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4400</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-4409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1158%2F0008-5472.CAN-04-4409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4389-4400&author=S.+R.+Wedgeauthor=J.+Kendrewauthor=L.+F.+Hennequinauthor=P.+J.+Valentineauthor=S.+T.+Barryauthor=S.+R.+Braveauthor=N.+R.+Smithauthor=N.+H.+Jamesauthor=M.+Dukesauthor=J.+O.+Curwenauthor=R.+Chesterauthor=J.+A.+Jacksonauthor=S.+J.+Boffeyauthor=L.+L.+Kilburnauthor=S.+Barnettauthor=G.+H.+P.+Richmondauthor=P.+F.+Wadsworthauthor=M.+Walkerauthor=A.+L.+Bigleyauthor=S.+T.+Taylorauthor=L.+Cooperauthor=S.+Beckauthor=J.+M.+J%C3%BCrgensmeierauthor=D.+J.+Ogilvie&title=AZD2171%3A+A+Highly+Potent%2C+Orally+Bioavailable%2C+Vascular+Endothelial+Growth+Factor+Receptor-2+Tyrosine+Kinase+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1158%2F0008-5472.CAN-04-4409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4409%26sid%3Dliteratum%253Aachs%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DValentine%26aufirst%3DP.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DChester%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DJ.%2BA.%26aulast%3DBoffey%26aufirst%3DS.%2BJ.%26aulast%3DKilburn%26aufirst%3DL.%2BL.%26aulast%3DBarnett%26aufirst%3DS.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DWadsworth%26aufirst%3DP.%2BF.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DBigley%26aufirst%3DA.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BT.%26aulast%3DCooper%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26atitle%3DAZD2171%253A%2520A%2520Highly%2520Potent%252C%2520Orally%2520Bioavailable%252C%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor-2%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4389%26epage%3D4400%26doi%3D10.1158%2F0008-5472.CAN-04-4409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakley, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womersley, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2198</span><span class="NLM_x">–</span> <span class="NLM_lpage">2208</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1158%2F1535-7163.MCT-07-0142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17699717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2198-2208&author=N.+R.+Smithauthor=N.+H.+Jamesauthor=I.+Oakleyauthor=A.+Wainwrightauthor=C.+Copleyauthor=J.+Kendrewauthor=L.+M.+Womersleyauthor=J.+M.+J%C3%BCrgensmeierauthor=S.+R.+Wedgeauthor=S.+T.+Barry&title=Acute+pharmacodynamic+and+antivascular+effects+of+the+vascular+endothelial+growth+factor+signaling+inhibitor+AZD2171+in+Calu-6+human+lung+tumor+xenografts&doi=10.1158%2F1535-7163.MCT-07-0142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span></div><div class="casAuthors">Smith, Neil R.; James, Neil H.; Oakley, Ian; Wainwright, Anna; Copley, Clive; Kendrew, Jane; Womersley, Lynsey M.; Juergensmeier, Juliane M.; Wedge, Stephen R.; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2198-2208</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The vascular endothelial growth factor-A (VEGF-A) signaling pathway, a key stimulant of solid tumor vascularization, is primarily dependent on the activation of the endothelial cell surface receptor VEGF receptor-2 (VEGFR-2).  AZD2171 is an oral, highly potent small-mol. inhibitor of VEGFR tyrosine kinase activity that inhibits angiogenesis and the growth of human tumor xenografts in vivo.  Here, we show pharmacodynamic changes in VEGFR-2 phosphorylation induced by AZD2171.  In mouse lung tissue, a single dose of AZD2171 at 6 mg/kg inhibited VEGF-A-stimulated VEGFR-2 phosphorylation by 87% at 2 h with significant inhibition (≥60%) maintained to 24 h.  To examine inhibition of VEGFR-2 phosphorylation in tumor vasculature by immunohistochem., a comprehensive assessment of antibodies to various phosphorylation sites on the receptor was undertaken.  Antibodies to the phosphotyrosine epitopes pY1175/1173 and pY1214/1212 were found suitable for this application.  Calu-6 human lung tumor xenografts, from mice receiving AZD2171 or vehicle treatment (p.o., once daily), were examd. by immunohistochem.  A significant redn. in tumor vessel staining of phosphorylated VEGFR-2 (pVEGFR-2) was evident within 28 h of AZD2171 treatment (6 mg/kg).  This effect preceded a significant redn. in tumor microvessel d., which was detectable following 52 h of AZD2171 treatment.  These data show that AZD2171 is a potent inhibitor of VEGFR-2 activation in vivo and suggest that AZD2171 delivers therapeutic benefit in Calu-6 tumors by targeting vessels dependent on VEGFR-2 signaling for survival.  In addn., this work highlights the utility of measuring either pY1175/1173 or pY1214/1212 on VEGFR-2 as a pharmacodynamic marker of VEGFR-2 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVvyqU1WR9bVg90H21EOLACvtfcHk0ljiqsspYX948w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D&md5=a6bef539c30c6cefc41a8d0eb433e418</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0142%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DOakley%26aufirst%3DI.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DCopley%26aufirst%3DC.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DWomersley%26aufirst%3DL.%2BM.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DAcute%2520pharmacodynamic%2520and%2520antivascular%2520effects%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520signaling%2520inhibitor%2520AZD2171%2520in%2520Calu-6%2520human%2520lung%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2198%26epage%3D2208%26doi%3D10.1158%2F1535-7163.MCT-07-0142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Makosza, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sienkiewicz, K.</span><span> </span><span class="NLM_article-title">Hydroxylation of Nitroarenes with Alkyl Hydroperoxide Anions via Vicarious Nucleophilic Substitution of Hydrogen</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">4199</span><span class="NLM_x">–</span> <span class="NLM_lpage">4208</span><span class="refDoi"> DOI: 10.1021/jo970726m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo970726m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=4199-4208&author=M.+Makoszaauthor=K.+Sienkiewicz&title=Hydroxylation+of+Nitroarenes+with+Alkyl+Hydroperoxide+Anions+via+Vicarious+Nucleophilic+Substitution+of+Hydrogen&doi=10.1021%2Fjo970726m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjo970726m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo970726m%26sid%3Dliteratum%253Aachs%26aulast%3DMakosza%26aufirst%3DM.%26aulast%3DSienkiewicz%26aufirst%3DK.%26atitle%3DHydroxylation%2520of%2520Nitroarenes%2520with%2520Alkyl%2520Hydroperoxide%2520Anions%2520via%2520Vicarious%2520Nucleophilic%2520Substitution%2520of%2520Hydrogen%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1998%26volume%3D63%26spage%3D4199%26epage%3D4208%26doi%3D10.1021%2Fjo970726m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Adrian Hall, Hugues Chanteux, Karelle Ménochet, Marie Ledecq, <span class="NLM_string-name hlFld-ContribAuthor">Monika-Sarah E. D. Schulze</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6413-6522. <a href="https://doi.org/10.1021/acs.jmedchem.0c02245" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02245%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252BOut%252BPXR%252BActivity%252Bon%252BDrug%252BDiscovery%252BProjects%25253A%252BA%252BReview%252Bof%252BStructure-Based%252BMethods%25252C%252BEmpirical%252Band%252BComputational%252BApproaches%26aulast%3DHall%26aufirst%3DAdrian%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D27122020%26date%3D18052021%26volume%3D64%26issue%3D10%26spage%3D6413%26epage%3D6522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael J. Bower, Alex M. Aronov, Thomas Cleveland, Niresh Hariparsad, Georgia B. McGaughey, Daniel R. McMasters, Xiaodan Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Brian Goldman</span>. </span><span class="cited-content_cbyCitation_article-title">Smallest Maximum Intramolecular Distance: A Novel Method to Mitigate Pregnane Xenobiotic Receptor Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (4)
                                     , 2091-2099. <a href="https://doi.org/10.1021/acs.jcim.9b00692" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00692</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00692%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSmallest%252BMaximum%252BIntramolecular%252BDistance%25253A%252BA%252BNovel%252BMethod%252Bto%252BMitigate%252BPregnane%252BXenobiotic%252BReceptor%252BActivation%26aulast%3DBower%26aufirst%3DMichael%2BJ.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D20082019%26date%3D16032020%26date%3D04032020%26volume%3D60%26issue%3D4%26spage%3D2091%26epage%3D2099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Thilo Focken, Kristen Burford, Michael E. Grimwood, Alla Zenova, Jean-Christophe Andrez, Wei Gong, Michael Wilson, Matt Taron, Shannon Decker, Verner Lofstrand, Sultan Chowdhury, Noah Shuart, Sophia Lin, Samuel J. Goodchild, Clint Young, Maegan Soriano, Parisa K. Tari, Matthew Waldbrook, Karen Nelkenbrecher, Rainbow Kwan, Andrea Lindgren, Gina de Boer, Stephanie Lee, Luis Sojo, Robert J. DeVita, Charles J. Cohen, Steven S. Wesolowski, J. P. Johnson, Jr., Christoph M. Dehnhardt, <span class="NLM_string-name hlFld-ContribAuthor">James R. Empfield</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9618-9641. <a href="https://doi.org/10.1021/acs.jmedchem.9b01032" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01032%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BCNS-Penetrant%252BAryl%252BSulfonamides%252Bas%252BIsoform-Selective%252BNaV1.6%252BInhibitors%252Bwith%252BEfficacy%252Bin%252BMouse%252BModels%252Bof%252BEpilepsy%26aulast%3DFocken%26aufirst%3DThilo%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28062019%26date%3D03102019%26date%3D17092019%26volume%3D62%26issue%3D21%26spage%3D9618%26epage%3D9641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Martín
J. Riveira, Cintia M. Diez, Mirta P. Mischne, <span class="NLM_string-name hlFld-ContribAuthor">Ernesto G. Mata</span>. </span><span class="cited-content_cbyCitation_article-title">[2 + 2 + 2]-Cycloaddition Reactions Using Immobilized Alkynes. A Proof of Concept for an Integral Use of the Outcoming Products in Solid-Phase Synthetic Methodologies. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (17)
                                     , 10001-10014. <a href="https://doi.org/10.1021/acs.joc.8b01378" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01378</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01378%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3D%25255B2%252B%25252B%252B2%252B%25252B%252B2%25255D-Cycloaddition%252BReactions%252BUsing%252BImmobilized%252BAlkynes.%252BA%252BProof%252Bof%252BConcept%252Bfor%252Ban%252BIntegral%252BUse%252Bof%252Bthe%252BOutcoming%252BProducts%252Bin%252BSolid-Phase%252BSynthetic%252BMethodologies%26aulast%3DRiveira%26aufirst%3DMart%25C3%25ADn%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01062018%26date%3D11072018%26date%3D29062018%26volume%3D83%26issue%3D17%26spage%3D10001%26epage%3D10014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan-Mei  Yan</span>, <span class="hlFld-ContribAuthor ">Yong  Rao</span>, and <span class="hlFld-ContribAuthor ">Ming-Wu  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of Multisubstituted Benzimidazoles via Sequential Ugi and Catalytic Aza-Wittig Reaction Starting from 2-Aminobenzoyl Azides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (3)
                                     , 1263-1268. <a href="https://doi.org/10.1021/acs.joc.5b02575" title="DOI URL">https://doi.org/10.1021/acs.joc.5b02575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b02575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b02575%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BMultisubstituted%252BBenzimidazoles%252Bvia%252BSequential%252BUgi%252Band%252BCatalytic%252BAza-Wittig%252BReaction%252BStarting%252Bfrom%252B2-Aminobenzoyl%252BAzides%26aulast%3DYan%26aufirst%3DYan-Mei%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D09112015%26date%3D22012016%26date%3D05022016%26date%3D13012016%26volume%3D81%26issue%3D3%26spage%3D1263%26epage%3D1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shadia A.  Galal</span>, <span class="hlFld-ContribAuthor ">Mohamed A.  Omar</span>, <span class="hlFld-ContribAuthor ">Sarah H. M.  Khairat</span>, <span class="hlFld-ContribAuthor ">Fatma A. F.  Ragab</span>, <span class="hlFld-ContribAuthor ">Sonam  Roy</span>, <span class="hlFld-ContribAuthor ">Ahmad Abu Turab  Naqvi</span>, <span class="hlFld-ContribAuthor ">Md. Imtaiyaz  Hassan</span>, <span class="hlFld-ContribAuthor ">Hoda I.  El Diwani</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of new pyrazolylbenzimidazoles as sphingosine kinase-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.1007/s00044-021-02760-3" title="DOI URL">https://doi.org/10.1007/s00044-021-02760-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-021-02760-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-021-02760-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnew%252Bpyrazolylbenzimidazoles%252Bas%252Bsphingosine%252Bkinase-1%252Binhibitors%26aulast%3DGalal%26aufirst%3DShadia%2BA.%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Namdeo  Bhujbal</span>, <span class="hlFld-ContribAuthor ">Dattatray  Gaikwad</span>, <span class="hlFld-ContribAuthor ">Yuvraj  Jagdale</span>, <span class="hlFld-ContribAuthor ">Chandrakant  Pawar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, antimicrobial and anti‐tubercular activity study of N‐(substituted‐benzyl)‐4‐(trifluoromethyl)thiazole‐2‐sulfonamide and 2‐(N‐(substituted‐benzyl)sulfamoyl)thiazole‐4‐carboxylic acid. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Chinese Chemical Society</span><span> <strong>2021,</strong> <em>430 </em><a href="https://doi.org/10.1002/jccs.202000421" title="DOI URL">https://doi.org/10.1002/jccs.202000421</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jccs.202000421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjccs.202000421%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Chinese%2520Chemical%2520Society%26atitle%3DSynthesis%25252C%252Bantimicrobial%252Band%252Banti%2525E2%252580%252590tubercular%252Bactivity%252Bstudy%252Bof%252BN%2525E2%252580%252590%252528substituted%2525E2%252580%252590benzyl%252529%2525E2%252580%2525904%2525E2%252580%252590%252528trifluoromethyl%252529thiazole%2525E2%252580%2525902%2525E2%252580%252590sulfonamide%252Band%252B2%2525E2%252580%252590%252528N%2525E2%252580%252590%252528substituted%2525E2%252580%252590benzyl%252529sulfamoyl%252529thiazole%2525E2%252580%2525904%2525E2%252580%252590carboxylic%252Bacid%26aulast%3DBhujbal%26aufirst%3DNamdeo%26date%3D2021%26date%3D2021%26volume%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Athi  Welsh</span>, <span class="hlFld-ContribAuthor ">Laa-iqa  Rylands</span>, <span class="hlFld-ContribAuthor ">Vladimir B.  Arion</span>, <span class="hlFld-ContribAuthor ">Sharon  Prince</span>, <span class="hlFld-ContribAuthor ">Gregory S.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antiproliferative activity of benzimidazole-based, trinuclear neutral cyclometallated and cationic, N
              ^
              N-chelated ruthenium(
              ii
              ) complexes. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (4)
                                     , 1143-1156. <a href="https://doi.org/10.1039/C9DT03902C" title="DOI URL">https://doi.org/10.1039/C9DT03902C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9DT03902C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9DT03902C%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DSynthesis%252Band%252Bantiproliferative%252Bactivity%252Bof%252Bbenzimidazole-based%25252C%252Btrinuclear%252Bneutral%252Bcyclometallated%252Band%252Bcationic%25252C%252BN%252B%25255E%252BN-chelated%252Bruthenium%252528%252Bii%252B%252529%252Bcomplexes%26aulast%3DWelsh%26aufirst%3DAthi%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D4%26spage%3D1143%26epage%3D1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Warapong  Senapak</span>, <span class="hlFld-ContribAuthor ">Rungnapha  Saeeng</span>, <span class="hlFld-ContribAuthor ">Jaray  Jaratjaroonphong</span>, <span class="hlFld-ContribAuthor ">Vinich  Promarak</span>, <span class="hlFld-ContribAuthor ">Uthaiwan  Sirion</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free selective synthesis of 2-substituted benzimidazoles catalyzed by Brönsted acidic ionic liquid: Convenient access to one-pot synthesis of N-alkylated 1,2-disubstituted benzimidazoles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (26)
                                     , 3543-3552. <a href="https://doi.org/10.1016/j.tet.2019.05.014" title="DOI URL">https://doi.org/10.1016/j.tet.2019.05.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.05.014%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DMetal-free%252Bselective%252Bsynthesis%252Bof%252B2-substituted%252Bbenzimidazoles%252Bcatalyzed%252Bby%252BBr%2525C3%2525B6nsted%252Bacidic%252Bionic%252Bliquid%25253A%252BConvenient%252Baccess%252Bto%252Bone-pot%252Bsynthesis%252Bof%252BN-alkylated%252B1%25252C2-disubstituted%252Bbenzimidazoles%26aulast%3DSenapak%26aufirst%3DWarapong%26date%3D2019%26volume%3D75%26issue%3D26%26spage%3D3543%26epage%3D3552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Motta</span>, <span class="hlFld-ContribAuthor ">Lara  Callea</span>, <span class="hlFld-ContribAuthor ">Sara  Giani Tagliabue</span>, <span class="hlFld-ContribAuthor ">Laura  Bonati</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the PXR ligand binding mechanism with advanced Molecular Dynamics methods. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-34373-z" title="DOI URL">https://doi.org/10.1038/s41598-018-34373-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-34373-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-34373-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DExploring%252Bthe%252BPXR%252Bligand%252Bbinding%252Bmechanism%252Bwith%252Badvanced%252BMolecular%252BDynamics%252Bmethods%26aulast%3DMotta%26aufirst%3DStefano%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roy J.  Vaz</span>, <span class="hlFld-ContribAuthor ">Yi  Li</span>, <span class="hlFld-ContribAuthor ">Vinolia  Chellaraj</span>, <span class="hlFld-ContribAuthor ">Stephan  Reiling</span>, <span class="hlFld-ContribAuthor ">Theresa  Kuntzweiler</span>, <span class="hlFld-ContribAuthor ">Donglai  Yang</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Joseph D.  Batchelor</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Larry R.  McLean</span>, <span class="hlFld-ContribAuthor ">Raymond  Kosley</span>. </span><span class="cited-content_cbyCitation_article-title">Amelioration of PXR-mediated CYP3A4 induction by mGluR2 modulators. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (19)
                                     , 3194-3196. <a href="https://doi.org/10.1016/j.bmcl.2018.08.022" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.08.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.08.022%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAmelioration%252Bof%252BPXR-mediated%252BCYP3A4%252Binduction%252Bby%252BmGluR2%252Bmodulators%26aulast%3DVaz%26aufirst%3DRoy%2BJ.%26date%3D2018%26volume%3D28%26issue%3D19%26spage%3D3194%26epage%3D3196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cameron D.  Buchman</span>, <span class="hlFld-ContribAuthor ">Sergio C.  Chai</span>, <span class="hlFld-ContribAuthor ">Taosheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">A current structural perspective on PXR and CAR in drug metabolism. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (6)
                                     , 635-647. <a href="https://doi.org/10.1080/17425255.2018.1476488" title="DOI URL">https://doi.org/10.1080/17425255.2018.1476488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2018.1476488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2018.1476488%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DA%252Bcurrent%252Bstructural%252Bperspective%252Bon%252BPXR%252Band%252BCAR%252Bin%252Bdrug%252Bmetabolism%26aulast%3DBuchman%26aufirst%3DCameron%2BD.%26date%3D2018%26date%3D2018%26volume%3D14%26issue%3D6%26spage%3D635%26epage%3D647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffold hopping from triazole to benzimidazole core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Reduction in plasma exposures following repeat dosing. Female CB17 SCID mice (3 animals per cohort) were dosed orally with either compound <b>4</b> or <b>21</b>, at either 50 mg/kg or 100 mg/kg twice daily, for 5 days. Plasma concentrations were measured at 1 h after the first dose on day 1 and day 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>4</b> induces an increase in CYP3A activity in cultured human hepatocytes. Human hepatocytes were seeded onto collagen-coated plates and were cultured in a collagen-Matrigel sandwich configuration. On day 3 of culture, the cells were treated with either DMSO (control), compound <b>4</b>, or a reference compound known to cause induction of various CYP isoforms (3-methylcholanthrene for CYP1A2, phenobarbital for CYP2B6, and rifampicin for CYP3A4/5). After 48 h of treatment, the cultures were then incubated with probe substrates (phenacetin for CYP1A2, bupropion for CYP2B6, and testosterone for CYP3A4/5), and the amount of marker metabolite formed (acetaminophen for CYP1A2, hydroxybupropion for CYP2B6, and 6-β-hydroxytestosterone for CYP3A4/5) was quantified. The amount of CYP activity for <b>4</b> is expressed as a percentage of the activity observed for the individual reference compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Correlation between experimentally determined LogD and extent of PXR activation. Compounds with greater than 30% PXR activation at 10 μM were considered to be at risk for CYP3A induction. (B) Compounds with LogD > 2 are more likely to have >30% PXR activation at 10 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of compound <b>4</b> bound to human PXR obtained at 2.3 Å resolution (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a>). Coloration is as follows: compound <b>4</b> (yellow), Trp299 (green), Tyr306 (cyan), Met246 (brown).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Correlation of PXR activation assay with CYP3A activity in human hepatocytes. Compounds with <40% CYP3A activity observed with rifampicin (both compounds at 10 μM) are colored blue, while those with >40% activity are colored red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0008.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of FGF/S1P-stimulated angiogenesis by compounds <b>46</b> and <b>47</b>. Matrigel (0.5 mL) containing 2 μg/mL β-FGF and 1 μM S1P was injected subcutaneously into the ventral region of female 129s1/SvImJ mice. Compounds <b>46</b> and <b>47</b> were dosed orally at 10 mg/kg, once daily, on days 5–8 postimplant (five animals per cohort). Plasma pharmacokinetics for both compounds was assessed 1 h postdose on day 4 (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S2). The plugs were then harvested, and the amount of hemoglobin per gram of gel was quantified. Treated mice were compared with mice given vehicle used in the dosed groups (0.5% HPMC, 0.1% Tween 80) as a control, as well as mice injected with Matrigel not containing proangiogenic factors. The double asterisk (**) indicates <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0009.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Induction of capillary leakage in mouse lungs by compounds <b>46</b> and <b>47</b>. Female NCr nude mice (four animals per cohort) were dosed orally with either compound <b>46</b> (20 mg/kg), compound <b>47</b> (50 mg/kg), or vehicle alone (0.5% HPMC, 0.1% Tween 80). After 1 h, the mice were injected with a solution of Evans blue dye (20 mg/kg). After an additional 30 min, the mice were anesthetized and perfused with 0.9% normal saline. The lungs were harvested, and the amount of Evans blue dye present was determined by spectrophotometry. The amount of dye present was normalized to the amount found in vehicle-treated animals. The double asterisk (**) indicates <i>p</i> < 0.005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0010.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Evaluation of antitumor activity of lead S1P<sub>1</sub> antagonists in a Calu6 xenograft model in female NcR-nude mice. (A) Compound <b>46</b>, dosed orally at 20 mg/kg BID (<i>n</i> = 14) on days 13–32, does not result in statistically significant tumor growth inhibition relative to vehicle (HPMC)-treated controls (<i>n</i> = 20). (B) Compound <b>47</b>, dosed orally at 50 mg/kg BID (<i>n</i> = 14) on days 11–33, results in 32% tumor growth inhibition (<i>p</i> = 0.008) relative to controls (<i>n</i> = 20).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of benzimidazole <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd/C, H<sub>2</sub>, EtOH, rt; (b) <span class="smallcaps smallerCapital">d</span>-Ala-OH, 6 N HCl, 100 °C; (c) 4-chlorobenzenesulfonyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthesis of a Substituted Benzimidazole Sulfonamide<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethylamine (2 M in THF), 100 °C (microwave irradiation); (b) 10% Pd/C, H<sub>2</sub>, EtOH, rt; (c) Boc-<span class="smallcaps smallerCapital">d</span>-Ala-OH, HATU, NEt<sub>3</sub>, DMF, 0 °C to rt; (d) glacial HOAc, 65 °C; (e) 4 N HCl/dioxane, rt; (f) 4-chlorobenzenesulfonyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Forcing Conditions Required for Cyclization of Azabenzimidazoles <b>14</b>–<b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glacial HOAc, 150 °C (microwave irradiation); (b) Lawesson’s reagent, dioxane, 150 °C (microwave irradiation).</p></p></figure><figure data-id="sch4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0014.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Diaminopyridine Precursors to Compounds <b>42</b>–<b>47</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Potassium <i>tert</i>-butoxide, <i>tert</i>-butylhydroperoxide (5 M in decane), NH<sub>3</sub>(l), THF, −35 °C; (b) POCl<sub>3</sub>, toluene, 100 °C; (c) ethylamine (2 M in THF), THF, 0 °C; (d) NaOMe, MeOH, 65 °C; (e) SnCl<sub>2</sub>·2 H<sub>2</sub>O, EtOAc, 80 °C; (f) cyclopropylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, toluene, water, 100 °C; (g) H<sub>2</sub> (5 bar), 5% Pd/C, MeOH, rt; (h) LDA, THF, −78 °C, then I<sub>2</sub>; (i) ethylamine (70% in water), EtOH, 80 °C; (j) benzophenone imine, sodium <i>tert</i>-butoxide, Pd<sub>2</sub>(dba)<sub>3</sub>, <i>rac</i>-BINAP, toluene, 110 °C; (k) 2 M HCl, THF, rt.</p></p></figure><figure data-id="sch5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0015.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Representative Synthetic Route to Access Substituted Azabenzimidazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CDI, CH<sub>2</sub>Cl<sub>2</sub>, rt, then <b>55</b>, rt; (b) 4 N HCl/dioxane, rt; (c) NaOH, EtOH, 80 °C; (d) 4-cyanobenzenesulfonyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, then chiral chromatography.</p></p></figure><figure data-id="sch6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/medium/jm-2015-01078x_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0016.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of Sulfonyl Chloride <b>63</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b01078/20150904/images/large/jm-2015-01078x_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01078&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) conc. HCl, NaNO<sub>2</sub>, water, 0 °C; (b) thionyl chloride, water, 0 °C, then CuCl, 0 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2007.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.pharmthera.2007.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17561264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2007&pages=84-105&author=V.+Brinkmann&title=Sphingosine+1-phosphate+receptors+in+health+and+disease%3A+Mechanistic+insights+from+gene+deletion+studies+and+reverse+pharmacology&doi=10.1016%2Fj.pharmthera.2007.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology</span></div><div class="casAuthors">Brinkmann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that is critically involved in the embryonic development of the cardiovascular and central nervous systems.  In the adult, S1P can produce cytoskeletal re-arrangements in many cell types to regulate immune cell trafficking, vascular homeostasis and cell communication in the central nervous system.  S1P is contained in body fluids and tissues at different concns., and excessive prodn. of the pleiotropic mediator at inflammatory sites may participate in various pathol. conditions.  Gene deletion studies and reverse pharmacol. (techniques aiming to identify both ligands and function of receptors) provided evidence that many effects of S1P are mediated via five G-protein-coupled S1P receptor subtypes, and novel therapeutic strategies based on interaction with these receptors are being initiated.  The prototype S1P receptor modulator, FTY720 (fingolimod), targets four of the five S1P receptor subtypes and may act at several levels to modulate lymphocyte trafficking via lymphocytic and endothelial S1P1 and, perhaps, other inflammatory processes through addnl. S1P receptor subtypes.  A recently completed Phase II clin. trial suggested that the drug may provide an effective treatment of relapsing-remitting multiple sclerosis.  FTY720 is currently being evaluated in larger-scale, longer-term, Phase III studies.  This review provides an overview on S1P activities and S1P receptor function in health and disease, and summarizes the clin. experience with FTY720 in transplantation and multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGbwKhZo2vLrVg90H21EOLACvtfcHk0lhbeymYSzz1QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D&md5=cacdb374439270734f34a0ca4771ca3d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26atitle%3DSphingosine%25201-phosphate%2520receptors%2520in%2520health%2520and%2520disease%253A%2520Mechanistic%2520insights%2520from%2520gene%2520deletion%2520studies%2520and%2520reverse%2520pharmacology%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D115%26spage%3D84%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2007.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Adachi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, T.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Structure-Activity Relationships of 2-Substituted-2-Amino-1,3-Propanediols: Discovery of a Novel Immunosuppressant, FTY720</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">856</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00127-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2F0960-894X%2895%2900127-F" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=853-856&author=K.+Adachiauthor=T.+Koharaauthor=N.+Nakaoauthor=M.+Aritaauthor=K.+Chibaauthor=T.+Mishinaauthor=S.+Sasakiauthor=T.+Fujita&title=Design%2C+Synthesis%2C+and+Structure-Activity+Relationships+of+2-Substituted-2-Amino-1%2C3-Propanediols%3A+Discovery+of+a+Novel+Immunosuppressant%2C+FTY720&doi=10.1016%2F0960-894X%2895%2900127-F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900127-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900127-F%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DKohara%26aufirst%3DT.%26aulast%3DNakao%26aufirst%3DN.%26aulast%3DArita%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DK.%26aulast%3DMishina%26aufirst%3DT.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DT.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Structure-Activity%2520Relationships%2520of%25202-Substituted-2-Amino-1%252C3-Propanediols%253A%2520Discovery%2520of%2520a%2520Novel%2520Immunosuppressant%252C%2520FTY720%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D853%26epage%3D856%26doi%3D10.1016%2F0960-894X%2895%2900127-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hof, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieschl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiestand, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span> </span><span class="NLM_article-title">The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">21453</span><span class="NLM_x">–</span> <span class="NLM_lpage">21457</span><span class="refDoi"> DOI: 10.1074/jbc.C200176200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.C200176200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11967257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=21453-21457&author=V.+Brinkmannauthor=M.+D.+Davisauthor=C.+E.+Heiseauthor=R.+Albertauthor=S.+Cottensauthor=R.+Hofauthor=C.+Brunsauthor=E.+Prieschlauthor=T.+Baumrukerauthor=P.+Hiestandauthor=C.+A.+Fosterauthor=M.+Zollingerauthor=K.+R.+Lynch&title=The+Immune+Modulator+FTY720+Targets+Sphingosine+1-Phosphate+Receptors&doi=10.1074%2Fjbc.C200176200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Brinkmann, Volker; Davis, Michael D.; Heise, Christopher E.; Albert, Rainer; Cottens, Sylvain; Hof, Robert; Bruns, Christian; Prieschl, Eva; Baumruker, Thomas; Hiestand, Peter; Foster, Carolyn A.; Zollinger, Markus; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">21453-21457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis.  In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation.  FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms.  Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compd. is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis.  Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6zyZnHOYNbVg90H21EOLACvtfcHk0li7rQJos_0iMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D&md5=b59856fffa9ebae7fb8182d18daa025f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C200176200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C200176200%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DCottens%26aufirst%3DS.%26aulast%3DHof%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPrieschl%26aufirst%3DE.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHiestand%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DC.%2BA.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DThe%2520Immune%2520Modulator%2520FTY720%2520Targets%2520Sphingosine%25201-Phosphate%2520Receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D21453%26epage%3D21457%26doi%3D10.1074%2Fjbc.C200176200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mandala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupprecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.-J.+Sheiauthor=D.+Cardauthor=C.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+Lymphocyte+Trafficking+by+Sphingosine-1-Phosphate+Receptor+Agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0li7rQJos_0iMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520Lymphocyte%2520Trafficking%2520by%2520Sphingosine-1-Phosphate%2520Receptor%2520Agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heining, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aradhye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burtin, P.</span><span> </span><span class="NLM_article-title">Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">897</span><span class="refDoi"> DOI: 10.1038/nrd3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnrd3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=21031003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=883-897&author=V.+Brinkmannauthor=A.+Billichauthor=T.+Baumrukerauthor=P.+Heiningauthor=R.+Schmouderauthor=G.+Francisauthor=S.+Aradhyeauthor=P.+Burtin&title=Fingolimod+%28FTY720%29%3A+discovery+and+development+of+an+oral+drug+to+treat+multiple+sclerosis&doi=10.1038%2Fnrd3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis</span></div><div class="casAuthors">Brinkmann, Volker; Billich, Andreas; Baumruker, Thomas; Heining, Peter; Schmouder, Robert; Francis, Gordon; Aradhye, Shreeram; Burtin, Pascale</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">883-897</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system.  Elucidation of the effects of fingolimod - mediated by the modulation of sphingosine 1-phosphate (S1P) receptors - has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct effects on neural cells, particularly astrocytes.  An improved understanding of the biol. of S1P receptors has also been gained.  This article describes the discovery and development of fingolimod, which was approved by the US Food and Drug Administration in Sept. 2010 as a first-line treatment for relapsing forms of multiple sclerosis, thereby becoming the first oral disease-modifying therapy to be approved for multiple sclerosis in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80U6QfXSJMbVg90H21EOLACvtfcHk0li7rQJos_0iMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL&md5=0f6dd60ef115079f3652e9d12d82e215</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3248%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DSchmouder%26aufirst%3DR.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DAradhye%26aufirst%3DS.%26aulast%3DBurtin%26aufirst%3DP.%26atitle%3DFingolimod%2520%2528FTY720%2529%253A%2520discovery%2520and%2520development%2520of%2520an%2520oral%2520drug%2520to%2520treat%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D883%26epage%3D897%26doi%3D10.1038%2Fnrd3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gräler, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetzl, E. J.</span><span> </span><span class="NLM_article-title">The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1096/fj.03-0910fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1096%2Ffj.03-0910fje" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=551-553&author=M.+H.+Gr%C3%A4lerauthor=E.+J.+Goetzl&title=The+immunosuppressant+FTY720+down-regulates+sphingosine+1-phosphate+G-protein-coupled+receptors&doi=10.1096%2Ffj.03-0910fje"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1096%2Ffj.03-0910fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.03-0910fje%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A4ler%26aufirst%3DM.%2BH.%26aulast%3DGoetzl%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520immunosuppressant%2520FTY720%2520down-regulates%2520sphingosine%25201-phosphate%2520G-protein-coupled%2520receptors%26jtitle%3DFASEB%2520J.%26date%3D2004%26volume%3D18%26spage%3D551%26epage%3D553%26doi%3D10.1096%2Ffj.03-0910fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Mapping Pathways Downstream of Sphingosine 1-Phosphate Subtype 1 by Differential Chemical Perturbation and Proteomics</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">7254</span><span class="NLM_x">–</span> <span class="NLM_lpage">7264</span><span class="refDoi"> DOI: 10.1074/jbc.M610581200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M610581200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=7254-7264&author=P.+J.+Gonzalez-Cabreraauthor=T.+Hlaauthor=H.+Rosen&title=Mapping+Pathways+Downstream+of+Sphingosine+1-Phosphate+Subtype+1+by+Differential+Chemical+Perturbation+and+Proteomics&doi=10.1074%2Fjbc.M610581200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M610581200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M610581200%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DMapping%2520Pathways%2520Downstream%2520of%2520Sphingosine%25201-Phosphate%2520Subtype%25201%2520by%2520Differential%2520Chemical%2520Perturbation%2520and%2520Proteomics%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D7254%26epage%3D7264%26doi%3D10.1074%2Fjbc.M610581200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Oo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thangada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">9082</span><span class="NLM_x">–</span> <span class="NLM_lpage">9089</span><span class="refDoi"> DOI: 10.1074/jbc.M610318200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M610318200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=9082-9089&author=M.+L.+Ooauthor=S.+Thangadaauthor=M.-T.+Wuauthor=C.+H.+Liuauthor=T.+L.+Macdonaldauthor=K.+R.+Lynchauthor=C.-Y.+Linauthor=T.+Hla&title=Immunosuppressive+and+Anti-angiogenic+Sphingosine+1-Phosphate+Receptor-1+Agonists+Induce+Ubiquitinylation+and+Proteasomal+Degradation+of+the+Receptor&doi=10.1074%2Fjbc.M610318200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M610318200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M610318200%26sid%3Dliteratum%253Aachs%26aulast%3DOo%26aufirst%3DM.%2BL.%26aulast%3DThangada%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DLin%26aufirst%3DC.-Y.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DImmunosuppressive%2520and%2520Anti-angiogenic%2520Sphingosine%25201-Phosphate%2520Receptor-1%2520Agonists%2520Induce%2520Ubiquitinylation%2520and%2520Proteasomal%2520Degradation%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D9082%26epage%3D9089%26doi%3D10.1074%2Fjbc.M610318200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, C.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeldt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nava, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span> </span><span class="NLM_article-title">Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">951</span><span class="NLM_x">–</span> <span class="NLM_lpage">961</span><span class="refDoi"> DOI: 10.1172/JCI10905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1172%2FJCI10905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11032855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVeisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2000&pages=951-961&author=Y.+Liuauthor=R.+Wadaauthor=T.+Yamashitaauthor=Y.+Miauthor=C.-X.+Dengauthor=J.+P.+Hobsonauthor=H.+M.+Rosenfeldtauthor=V.+E.+Navaauthor=S.-S.+Chaeauthor=M.-J.+Leeauthor=C.+H.+Liuauthor=T.+Hlaauthor=S.+Spiegelauthor=R.+L.+Proia&title=Edg-1%2C+the+G+protein-coupled+receptor+for+sphingosine-1-phosphate%2C+is+essential+for+vascular+maturation&doi=10.1172%2FJCI10905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation</span></div><div class="casAuthors">Liu, Yujing; Wada, Ryuichi; Yamashita, Tadashi; Mi, Yide; Deng, Chu-Xia; Hobson, John P.; Rosenfeldt, Hans M.; Nava, Victor E.; Chae, Sung-Suk; Lee, Menq-Jer; Liu, Catherine H.; Hla, Timothy; Spiegel, Sarah; Proia, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">951-961</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Sphingolipid signaling pathways have been implicated in many crit. cellular events.  Sphingosine-1-phosphate (SPP), a sphingolipid metabolite found in high concns. in platelets and blood, stimulates members of the endothelial differentiation gene (Edg) family of G protein-coupled receptors and triggers diverse effects, including cell growth, survival, migration, and morphogenesis.  To det. the in vivo functions of the SPP/Edg signaling pathway, the authors disrupted the Edg1 gene in mice.  Edg1-/- mice exhibited embryonic hemorrhage leading to intrauterine death between E12.5 and E14.5.  Vasculogenesis and angiogenesis appeared normal in the mutant embryos.  However, vascular maturation was incomplete due to a deficiency of vascular smooth muscle cells/pericytes.  The authors also show that Edg-1 mediates an SPP-induced migration response that is defective in mutant cells due to an inability to activate the small GTPase, Rac.  The authors' data reveal Edg-1 to be the first G protein-coupled receptor required for blood vessel formation and show that sphingolipid signaling is essential during mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruF19rW-FkA7Vg90H21EOLACvtfcHk0lg2D9vemRefOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVeisbw%253D&md5=939c81aeb6374e6827953ab94be2a42b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1172%2FJCI10905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI10905%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DR.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DC.-X.%26aulast%3DHobson%26aufirst%3DJ.%2BP.%26aulast%3DRosenfeldt%26aufirst%3DH.%2BM.%26aulast%3DNava%26aufirst%3DV.%2BE.%26aulast%3DChae%26aufirst%3DS.-S.%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DProia%26aufirst%3DR.%2BL.%26atitle%3DEdg-1%252C%2520the%2520G%2520protein-coupled%2520receptor%2520for%2520sphingosine-1-phosphate%252C%2520is%2520essential%2520for%2520vascular%2520maturation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D106%26spage%3D951%26epage%3D961%26doi%3D10.1172%2FJCI10905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Chae, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furneaux, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1089</span><span class="refDoi"> DOI: 10.1172/JCI200422716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1172%2FJCI200422716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=1082-1089&author=S.-S.+Chaeauthor=J.-H.+Paikauthor=H.+Furneauxauthor=T.+Hla&title=Requirement+for+sphingosine+1-phosphate+receptor-1+in+tumor+angiogenesis+demonstrated+by+in+vivo+RNA+interference&doi=10.1172%2FJCI200422716"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI200422716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200422716%26sid%3Dliteratum%253Aachs%26aulast%3DChae%26aufirst%3DS.-S.%26aulast%3DPaik%26aufirst%3DJ.-H.%26aulast%3DFurneaux%26aufirst%3DH.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DRequirement%2520for%2520sphingosine%25201-phosphate%2520receptor-1%2520in%2520tumor%2520angiogenesis%2520demonstrated%2520by%2520in%2520vivo%2520RNA%2520interference%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D1082%26epage%3D1089%26doi%3D10.1172%2FJCI200422716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">LaMontagne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood-Evans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span> </span><span class="NLM_article-title">Antagonism of Sphingosine-1-Phosphate Receptors by FTY720 Inhibits Angiogenesis and Tumor Vascularization</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1158%2F0008-5472.CAN-05-2001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=221-231&author=K.+LaMontagneauthor=A.+Littlewood-Evansauthor=C.+Schnellauthor=T.+O%E2%80%99Reillyauthor=L.+Wyderauthor=T.+Sanchezauthor=B.+Probstauthor=J.+Butlerauthor=A.+Woodauthor=G.+Liauauthor=E.+Billyauthor=A.+Theuerauthor=T.+Hlaauthor=J.+Wood&title=Antagonism+of+Sphingosine-1-Phosphate+Receptors+by+FTY720+Inhibits+Angiogenesis+and+Tumor+Vascularization&doi=10.1158%2F0008-5472.CAN-05-2001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2001%26sid%3Dliteratum%253Aachs%26aulast%3DLaMontagne%26aufirst%3DK.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DWyder%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DProbst%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DLiau%26aufirst%3DG.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DTheuer%26aufirst%3DA.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DJ.%26atitle%3DAntagonism%2520of%2520Sphingosine-1-Phosphate%2520Receptors%2520by%2520FTY720%2520Inhibits%2520Angiogenesis%2520and%2520Tumor%2520Vascularization%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D221%26epage%3D231%26doi%3D10.1158%2F0008-5472.CAN-05-2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Budde, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunkhorst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nashan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lücker, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skerjanec, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumayer, H. H.</span><span> </span><span class="NLM_article-title">First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients</span> <span class="citation_source-journal">J. Am. Soc. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1073</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=11912269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFSntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1073-1083&author=K.+Buddeauthor=R.+L.+Schmouderauthor=R.+Brunkhorstauthor=B.+Nashanauthor=P.+W.+L%C3%BCckerauthor=T.+Mayerauthor=S.+Choudhuryauthor=A.+Skerjanecauthor=G.+Krausauthor=H.+H.+Neumayer&title=First+Human+Trial+of+FTY720%2C+a+Novel+Immunomodulator%2C+in+Stable+Renal+Transplant+Patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients</span></div><div class="casAuthors">Budde, Klemens; Schmouder, Robert L.; Brunkhorst, Reinhard; Nashan, Bjorn; Lucker, Peter W.; Mayer, Thomas; Choudhury, Somesh; Skerjanec, Andrej; Kraus, Gerolf; Neumayer, Hans H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1073-1083</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">FTY720 is a novel immunomodulator to be developed for use in organ transplantation.  The primary objective of this study was to measure safety, single-dose pharmacokinetics, and pharmacodynamics in stable renal transplant patients-the first human use of FTY720.  This study used a randomized, double-blind, placebo-controlled design that explored single oral doses of FTY720 from 0.25 to 3.5 mg in 20 stable renal transplant patients on a cyclosporine-based regimen.  Safety assessments and blood samples were taken predose and at multiple time points during a 96-h period postdose.  Std. pharmacokinetic parameters were derived from the FTY720 whole blood concns., measured by HPLC/MS/MS.  FTY720 was well tolerated, with no serious adverse events.  Transient, asymptomatic bradycardia occurred after administration in 10 of 24 doses of FTY720.  Pharmacokinetics are characterized by a prolonged absorption phase; the terminal elimination phase started 36 h after the administration, with elimination half-life (t1/2) ranging from 89 to 157 h independent of dose.  Maximum plasma concn. and AUC were proportional to dose with low intersubject variability, the apparent vol. of distribution (Vd/F) ranged from 1116 to 1737 L.  FTY pharmacodynamics were characterized by a reversible transient lymphopenia within 6 h, the nadir being 42% of baseline.  The lymphocyte count returned to baseline within 72 h in all dosing cohorts except the highest.  Single oral doses of FTY720 ranging from 0.25 to 3.5 mg were well tolerated and caused a reversible selective lymphopenia.  Transient, but asymptomatic bradycardia was the most common adverse event.  The long t1/2 suggests less frequent dosing intervals.  The size of Vd/F is in excess of blood vol., consistent with widespread tissue distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jzPXTdVJrrVg90H21EOLACvtfcHk0lhj2skjuGwAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFSntbw%253D&md5=2c30d91109c7c25fe9a17ab0ac8ae969</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBudde%26aufirst%3DK.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26aulast%3DBrunkhorst%26aufirst%3DR.%26aulast%3DNashan%26aufirst%3DB.%26aulast%3DL%25C3%25BCcker%26aufirst%3DP.%2BW.%26aulast%3DMayer%26aufirst%3DT.%26aulast%3DChoudhury%26aufirst%3DS.%26aulast%3DSkerjanec%26aufirst%3DA.%26aulast%3DKraus%26aufirst%3DG.%26aulast%3DNeumayer%26aufirst%3DH.%2BH.%26atitle%3DFirst%2520Human%2520Trial%2520of%2520FTY720%252C%2520a%2520Novel%2520Immunomodulator%252C%2520in%2520Stable%2520Renal%2520Transplant%2520Patients%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2002%26volume%3D13%26spage%3D1073%26epage%3D1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents are Mediated via Distinct Receptor Subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">758</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fjpet.103.062828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=14747617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=758-768&author=M.+Forrestauthor=S.-Y.+Sunauthor=R.+Hajduauthor=J.+Bergstromauthor=D.+Cardauthor=G.+Dohertyauthor=J.+Haleauthor=C.+Keohaneauthor=C.+Meyersauthor=J.+Milliganauthor=S.+Millsauthor=N.+Nomuraauthor=H.+Rosenauthor=M.+Rosenbachauthor=G.-J.+Sheiauthor=I.+I.+Singerauthor=M.+Tianauthor=S.+Westauthor=V.+Whiteauthor=J.+Xieauthor=R.+L.+Proiaauthor=S.+Mandala&title=Immune+Cell+Regulation+and+Cardiovascular+Effects+of+Sphingosine+1-Phosphate+Receptor+Agonists+in+Rodents+are+Mediated+via+Distinct+Receptor+Subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span></div><div class="casAuthors">Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">758-768</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive lysolipid with pleiotropic functions mediated through a family of G protein-coupled receptors, S1P1,2,3,4,5.  Physiol. effects of S1P receptor agonists include regulation of cardiovascular function and immunosuppression via redistribution of lymphocytes from blood to secondary lymphoid organs.  The phosphorylated metabolite of the immunosuppressant agent FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) and other phosphonate analogs with differential receptor selectivity were investigated.  No significant species differences in compd. potency or rank order of activity on receptors cloned from human, murine, and rat sources were obsd.  All synthetic analogs were high-affinity agonists on S1P1, with IC50 values for ligand binding between 0.3 and 14 nM.  The correlation between S1P1 receptor activation and the ED50 for lymphocyte redn. was highly significant (p < 0.001) and lower for the other receptors.  In contrast to S1P1-mediated effects on lymphocyte recirculation, three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compd. potency on S1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia vs. bradycardia and hypertension was consistent with affinity for S1P1 relative to S1P3; and toxicity, bradycardia, and hypertension were absent in S1P3-/- mice.  Blood pressure effects of agonists in anesthetized rats were complex, whereas hypertension was the predominant effect in conscious rats and mice.  Immunolocalization of S1P3 in rodent heart revealed abundant expression on myocytes and perivascular smooth muscle cells consistent with regulation of bradycardia and hypertension, whereas S1P1 expression was restricted to the vascular endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo2vpih4eoLVg90H21EOLACvtfcHk0lhj2skjuGwAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D&md5=27183d4991bffbc5d2b88174b1386d5a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.062828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.062828%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.-Y.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DMeyers%26aufirst%3DC.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DSinger%26aufirst%3DI.%2BI.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DImmune%2520Cell%2520Regulation%2520and%2520Cardiovascular%2520Effects%2520of%2520Sphingosine%25201-Phosphate%2520Receptor%2520Agonists%2520in%2520Rodents%2520are%2520Mediated%2520via%2520Distinct%2520Receptor%2520Subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D758%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P<sub>1</sub> and S1P<sub>3</sub>, Respectively, Regulate Lymphocyte Recirculation and Heart Rate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">13839</span><span class="NLM_x">–</span> <span class="NLM_lpage">13848</span><span class="refDoi"> DOI: 10.1074/jbc.M311743200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M311743200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=14732717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=13839-13848&author=M.+G.+Sannaauthor=J.+Liaoauthor=E.+Joauthor=C.+Alfonsoauthor=M.-Y.+Ahnauthor=M.+S.+Petersonauthor=B.+Webbauthor=S.+Lefebvreauthor=J.+Chunauthor=N.+Grayauthor=H.+Rosen&title=Sphingosine+1-Phosphate+%28S1P%29+Receptor+Subtypes+S1P1+and+S1P3%2C+Respectively%2C+Regulate+Lymphocyte+Recirculation+and+Heart+Rate&doi=10.1074%2Fjbc.M311743200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate</span></div><div class="casAuthors">Sanna, M. Germana; Liao, Jiayu; Jo, Euijung; Alfonso, Christopher; Ahn, Min-Young; Peterson, Melissa S.; Webb, Bill; Lefebvre, Sophie; Chun, Jerold; Gray, Nathanael; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">13839-13848</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) influences heart rate, coronary artery caliber, endothelial integrity, and lymphocyte recirculation through five related high affinity G-protein-coupled receptors.  Inhibition of lymphocyte recirculation by non-selective S1P receptor agonists produces clin. immunosuppression preventing transplant rejection but is assocd. with transient bradycardia.  Understanding the contribution of individual receptors has been limited by the embryonic lethality of the S1P1 knock-out and the unavailability of selective agonists or antagonists.  A potent, S1P1-receptor selective agonist structurally unrelated to S1P was found to activate multiple signals triggered by S1P, including guanosine 5'-3-O-(thio)triphosphate binding, calcium flux, Akt and ERK1/2 phosphorylation, and stimulation of migration of S1P1- but not S1P3-expressing cells in vitro.  The agonist also alters lymphocyte trafficking in vivo.  Use of selective agonism together with deletant mice lacking S1P3 receptor reveals that agonism of S1P1 receptor alone is sufficient to control lymphocyte recirculation.  Moreover, S1P1 receptor agonist plasma levels are causally assocd. with induction and maintenance of lymphopenia.  S1P3, and not S1P1, is directly implicated in sinus bradycardia.  The sustained bradycardia induced by S1P receptor non-selective immunosuppressive agonists in wild-type mice is abolished in S1P3-/- mice, whereas S1P1-selective agonist does not produce bradycardia.  Sepn. of receptor subtype usage for control of lymphocyte recirculation and heart rate may allow the identification of selective immunosuppressive S1P1 receptor agonists with an enhanced therapeutic window.  S1P1-selective agonists will be of broad utility in understanding cell functions in vitro, and vascular physiol. in vivo, and the success of the chem. approach for S1P1 suggests that selective tools for the resoln. of function across this broad lipid receptor family are now possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoztTB58pXPA7Vg90H21EOLACvtfcHk0lhj2skjuGwAoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D&md5=5b720513c7c550bfdf55e5344efc8f16</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311743200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311743200%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-Phosphate%2520%2528S1P%2529%2520Receptor%2520Subtypes%2520S1P1%2520and%2520S1P3%252C%2520Respectively%252C%2520Regulate%2520Lymphocyte%2520Recirculation%2520and%2520Heart%2520Rate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D13839%26epage%3D13848%26doi%3D10.1074%2Fjbc.M311743200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Koyrakh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickman, K.</span><span> </span><span class="NLM_article-title">The Heart Rate Decrease Caused by Acute FTY720 Administration is Mediated by the G Protein-Gated Potassium Channel I<sub>KACh</sub></span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span><span class="refDoi"> DOI: 10.1111/j.1600-6143.2005.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1111%2Fj.1600-6143.2005.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=15707407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFSitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=529-536&author=L.+Koyrakhauthor=M.+I.+Romanauthor=V.+Brinkmannauthor=K.+Wickman&title=The+Heart+Rate+Decrease+Caused+by+Acute+FTY720+Administration+is+Mediated+by+the+G+Protein-Gated+Potassium+Channel+IKACh&doi=10.1111%2Fj.1600-6143.2005.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh</span></div><div class="casAuthors">Koyrakh, Lev; Roman, Maria I.; Brinkmann, Volker; Wickman, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">529-536</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Sphingosine-1-phosphate (S1P) is an endogenous agonist for a family of five G protein-coupled receptors (S1P1-5) involved in cell proliferation, cardiovascular development and lymphocyte trafficking.  The sphingolipid drug FTY720 displays structural similarity to S1P and efficacy as an immunosuppressant in models of autoimmune disease and in solid organ transplantation.  While FTY720 is well-tolerated in humans, it produces a transient redn. of heart rate (HR).  As S1P activates the cardiac G protein-gated potassium channel IKACh, we speculated that the FTY720-induced HR redn. reflects IKACh activation.  We examd. FTY720 effects on atrial myocytes from wild-type and IKACh-deficient mice.  In wild-type myocytes, the active phosphate metabolite of FTY720 (FTY720-P) induced single channel activity with conductance, open time, GTP sensitivity and rectification identical to that of IKACh.  In whole-cell recordings, FTY720-P evoked an inwardly rectifying potassium current in ∼90% of myocytes responding to acetylcholine.  Comparable channel activity was never obsd. in myocytes from IKACh-deficient mice.  In wild-type mice, acute FTY720 administration produced a dose-dependent, robust HR redn.  In contrast, the HR redn. induced by FTY720 in IKACh-deficient mice was blunted.  We conclude that the effect of acute FTY720 administration on HR is mediated primarily by IKACh activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLvv1lgLdAbVg90H21EOLACvtfcHk0ljtE4yf-kGNoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFSitrg%253D&md5=c6d2e7d8fea9f64ec0793693b596c1c6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2005.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2005.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DKoyrakh%26aufirst%3DL.%26aulast%3DRoman%26aufirst%3DM.%2BI.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DWickman%26aufirst%3DK.%26atitle%3DThe%2520Heart%2520Rate%2520Decrease%2520Caused%2520by%2520Acute%2520FTY720%2520Administration%2520is%2520Mediated%2520by%2520the%2520G%2520Protein-Gated%2520Potassium%2520Channel%2520IKACh%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2005%26volume%3D5%26spage%3D529%26epage%3D536%26doi%3D10.1111%2Fj.1600-6143.2005.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gergley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groenewegen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaliti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttringer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumb, W. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallström, E.</span><span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=22646698" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergleyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstr%C3%B6m&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergley%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstr%25C3%25B6m%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Kunkel, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maceyka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milstien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, S.</span><span> </span><span class="NLM_article-title">Targeting the sphingosine-1-phosphate axis in cancer, inflammation, and beyond</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">688</span><span class="NLM_x">–</span> <span class="NLM_lpage">702</span><span class="refDoi"> DOI: 10.1038/nrd4099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnrd4099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=688-702&author=G.+T.+Kunkelauthor=M.+Maceykaauthor=S.+Milstienauthor=S.+Spiegel&title=Targeting+the+sphingosine-1-phosphate+axis+in+cancer%2C+inflammation%2C+and+beyond&doi=10.1038%2Fnrd4099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd4099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4099%26sid%3Dliteratum%253Aachs%26aulast%3DKunkel%26aufirst%3DG.%2BT.%26aulast%3DMaceyka%26aufirst%3DM.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520sphingosine-1-phosphate%2520axis%2520in%2520cancer%252C%2520inflammation%252C%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D688%26epage%3D702%26doi%3D10.1038%2Fnrd4099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemens, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span> </span><span class="NLM_article-title">Sphingosine 1-Phosphate Analogs as Receptor Antagonists</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">9833</span><span class="NLM_x">–</span> <span class="NLM_lpage">9841</span><span class="refDoi"> DOI: 10.1074/jbc.M412356200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M412356200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=9833-9841&author=M.+D.+Davisauthor=J.+J.+Clemensauthor=T.+L.+Macdonaldauthor=K.+R.+Lynch&title=Sphingosine+1-Phosphate+Analogs+as+Receptor+Antagonists&doi=10.1074%2Fjbc.M412356200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M412356200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M412356200%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DClemens%26aufirst%3DJ.%2BJ.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DSphingosine%25201-Phosphate%2520Analogs%2520as%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D9833%26epage%3D9841%26doi%3D10.1074%2Fjbc.M412356200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wei, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheu, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, M. D.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">–</span> <span class="NLM_lpage">1235</span><span class="refDoi"> DOI: 10.1038/ni1269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fni1269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=16273098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=1228-1235&author=S.+H.+Weiauthor=H.+Rosenauthor=M.+P.+Matheuauthor=M.+G.+Sannaauthor=S.-K.+Wangauthor=E.+Joauthor=C.-H.+Wongauthor=I.+Parkerauthor=M.+D.+Cahalan&title=Sphingosine+1-phosphate+type+1+receptor+agonism+inhibits+transendothelial+migration+of+medullary+T+cells+to+lymphatic+sinuses&doi=10.1038%2Fni1269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span></div><div class="casAuthors">Wei, Sindy H.; Rosen, Hugh; Matheu, Melanie P.; Sanna, M. Germana; Wang, Sheng-Kai; Jo, Euijung; Wong, Chi-Huey; Parker, Ian; Cahalan, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1228-1235</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate type 1 (S1P1) receptor agonists cause sequestration of lymphocytes in secondary lymphoid organs by a mechanism that is not well understood.  One hypothesis proposes that agonists act as "functional antagonists" by binding and internalizing S1P1 receptors on lymphocytes; a second hypothesis proposes instead that S1P1 agonists act on endothelial cells to prevent lymphocyte egress from lymph nodes.  Here, 2-photon imaging of living T cells in explanted lymph nodes after treatment with S1P1 agonists or antagonists has provided insight into the mechanism by which S1P1 agonists function.  The selective S1P1 agonist SEW2871 caused reversible slowing and "log-jamming" of T cells between filled medullary cords and empty sinuses, whereas motility was unaltered in diffuse cortex.  Removal or antagonist competition of SEW2871 permitted recovery of T cell motility in the parenchyma of the medulla and resumption of migration across the stromal endothelial barrier, leading to refilling of sinuses.  The authors' results provide visualization of transendothelial migration of T cells into lymphatic sinuses and suggest that S1P1 agonists act mainly on endothelial cell S1P1 receptors to inhibit lymphocyte migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT6yH1S8NBXbVg90H21EOLACvtfcHk0liZA5G3NbUidg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E&md5=1e8e381a3808c9231937e05a0c010b73</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fni1269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1269%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%2BH.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMatheu%26aufirst%3DM.%2BP.%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DS.-K.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DParker%26aufirst%3DI.%26aulast%3DCahalan%26aufirst%3DM.%2BD.%26atitle%3DSphingosine%25201-phosphate%2520type%25201%2520receptor%2520agonism%2520inhibits%2520transendothelial%2520migration%2520of%2520medullary%2520T%2520cells%2520to%2520lymphatic%2520sinuses%26jtitle%3DNat.%2520Immunol.%26date%3D2005%26volume%3D6%26spage%3D1228%26epage%3D1235%26doi%3D10.1038%2Fni1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Don, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsolais, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheu, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P<sub>1</sub> antagonist in vivo</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">434</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1038/nchembio804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnchembio804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=16829954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=434-441&author=M.+G.+Sannaauthor=S.-K.+Wangauthor=P.+J.+Gonzalez-Cabreraauthor=A.+Donauthor=D.+Marsolaisauthor=M.+P.+Matheuauthor=S.+H.+Weiauthor=I.+Parkerauthor=E.+Joauthor=W.-C.+Chengauthor=M.+D.+Cahalanauthor=C.-H.+Wongauthor=H.+Rosen&title=Enhancement+of+capillary+leakage+and+restoration+of+lymphocyte+egress+by+a+chiral+S1P1+antagonist+in+vivo&doi=10.1038%2Fnchembio804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo</span></div><div class="casAuthors">Sanna, M. Germana; Wang, Sheng-Kai; Gonzalez-Cabrera, Pedro J.; Don, Anthony; Marsolais, David; Matheu, Melanie P.; Wei, Sindy H.; Parker, Ian; Jo, Euijung; Cheng, Wei-Chieh; Cahalan, Michael D.; Wong, Chi-Huey; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">434-441</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P, 1) regulates vascular barrier and lymphoid development, as well as lymphocyte egress from lymphoid organs, by activating high-affinity S1P1 receptors.  The authors used reversible chem. probes (i) to gain mechanistic insights into S1P systems organization not accessible through genetic manipulations and (ii) to investigate their potential for therapeutic modulation.  Vascular (but not airway) administration of the preferred R enantiomer of an in vivo-active chiral S1P11 receptor antagonist induced loss of capillary integrity in mouse skin and lung.  In contrast, the antagonist did not affect the no. of constitutive blood lymphocytes.  Instead, alteration of lymphocyte trafficking and phenotype required supraphysiol. elevation of S1P1 tone and was reversed by the antagonist.  In vivo two-photon imaging of lymph nodes confirmed requirements for obligate agonism, and the data were consistent with the presence of a stromal barrier mechanism for gating lymphocyte egress.  Thus, chem. modulation reveals differences in S1P-S1P1 'set points' among tissues and highlights both mechanistic advantages (lymphocyte sequestration) and risks (pulmonary edema) of therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3H_AoUm7AkrVg90H21EOLACvtfcHk0liZA5G3NbUidg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrw%253D&md5=c7cf6472393abe2d43851c5cd329e968</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnchembio804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio804%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DS.-K.%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DDon%26aufirst%3DA.%26aulast%3DMarsolais%26aufirst%3DD.%26aulast%3DMatheu%26aufirst%3DM.%2BP.%26aulast%3DWei%26aufirst%3DS.%2BH.%26aulast%3DParker%26aufirst%3DI.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DW.-C.%26aulast%3DCahalan%26aufirst%3DM.%2BD.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DEnhancement%2520of%2520capillary%2520leakage%2520and%2520restoration%2520of%2520lymphocyte%2520egress%2520by%2520a%2520chiral%2520S1P1%2520antagonist%2520in%2520vivo%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D434%26epage%3D441%26doi%3D10.1038%2Fnchembio804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukahara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goitsuka, R.</span><span> </span><span class="NLM_article-title">Amelioration of Collagen-Induced Arthritis by a Novel S1P<sub>1</sub> Antagonist with Immunomodulatory Activities</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">188</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.4049/jimmunol.1101537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.4049%2Fjimmunol.1101537" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=206-215&author=Y.+Fujiiauthor=T.+Hirayamaauthor=H.+Ohtakeauthor=N.+Onoauthor=T.+Inoueauthor=T.+Sakuraiauthor=T.+Takayamaauthor=K.+Matsumotoauthor=N.+Tsukaharaauthor=S.+Hidanoauthor=N.+Harimaauthor=K.+Nakazawaauthor=Y.+Igarashiauthor=R.+Goitsuka&title=Amelioration+of+Collagen-Induced+Arthritis+by+a+Novel+S1P1+Antagonist+with+Immunomodulatory+Activities&doi=10.4049%2Fjimmunol.1101537"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101537%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHirayama%26aufirst%3DT.%26aulast%3DOhtake%26aufirst%3DH.%26aulast%3DOno%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DTsukahara%26aufirst%3DN.%26aulast%3DHidano%26aufirst%3DS.%26aulast%3DHarima%26aufirst%3DN.%26aulast%3DNakazawa%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DY.%26aulast%3DGoitsuka%26aufirst%3DR.%26atitle%3DAmelioration%2520of%2520Collagen-Induced%2520Arthritis%2520by%2520a%2520Novel%2520S1P1%2520Antagonist%2520with%2520Immunomodulatory%2520Activities%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D206%26epage%3D215%26doi%3D10.4049%2Fjimmunol.1101537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ibrahim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolfrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banica, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattheakis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipway, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, G.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1368</span><span class="NLM_x">–</span> <span class="NLM_lpage">1381</span><span class="refDoi"> DOI: 10.1021/jm201533b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201533b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1368-1381&author=M.+A.+Ibrahimauthor=H.+W.+B.+Johnsonauthor=J.+W.+Jeongauthor=G.+L.+Lewisauthor=X.+Shiauthor=R.+T.+Noguchiauthor=M.+Williamsauthor=J.+W.+Leahyauthor=J.+M.+Nussauthor=J.+Woolfreyauthor=M.+Banicaauthor=F.+Bentzienauthor=Y.-C.+Chouauthor=A.+Gibsonauthor=N.+Healdauthor=P.+Lambauthor=L.+Mattheakisauthor=D.+Matthewsauthor=A.+Shipwayauthor=X.+Wuauthor=W.+Zhangauthor=S.+Zhouauthor=G.+Shankar&title=Discovery+of+a+Novel+Class+of+Potent+and+Orally+Bioavailable+Sphingosine+1-Phosphate+Receptor+1+Antagonists&doi=10.1021%2Fjm201533b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists</span></div><div class="casAuthors">Ibrahim, Mohamed A.; Johnson, Henry W. B.; Jeong, Joon Won; Lewis, Gary L.; Shi, Xian; Noguchi, Robin T.; Williams, Matthew; Leahy, James W.; Nuss, John M.; Woolfrey, John; Banica, Monica; Bentzien, Frauke; Chou, Yu-Chien; Gibson, Anna; Heald, Nathan; Lamb, Peter; Mattheakis, Larry; Matthews, David; Shipway, Aaron; Wu, Xiang; Zhang, WenTao; Zhou, Sihong; Shankar, Geetha</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1368-1381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of subtype selective sphingosine 1-phosphate receptor 1 (S1P1) antagonists are disclosed.  Our high-throughput screening campaign revealed hit I for which an increase in potency and mouse oral exposure was achieved with minor modifications to the chem. scaffold.  In vivo efficacy revealed that at high doses compds. II(X = F, Cl) inhibited tumor growth.  Further optimization of our lead series led to the discovery of proline derivs. III(R = 1,2,3-triazol-1yl) (XL541) and III(R = 1,2,3-triazol-2yl) which had similar efficacy as our first generation analogs at significantly lower doses.  Analog III(R = 1,2,3-triazol-1yl) displayed excellent pharmacokinetics and oral exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1zBOwMD_ld7Vg90H21EOLACvtfcHk0li3aoa_hFZaTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVChsA%253D%253D&md5=78755c4ffeda0e3bec4a150b9b59ddc9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm201533b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201533b%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%2BB.%26aulast%3DJeong%26aufirst%3DJ.%2BW.%26aulast%3DLewis%26aufirst%3DG.%2BL.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DNoguchi%26aufirst%3DR.%2BT.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DBanica%26aufirst%3DM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DChou%26aufirst%3DY.-C.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DHeald%26aufirst%3DN.%26aulast%3DLamb%26aufirst%3DP.%26aulast%3DMattheakis%26aufirst%3DL.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DShipway%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DShankar%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Class%2520of%2520Potent%2520and%2520Orally%2520Bioavailable%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1368%26epage%3D1381%26doi%3D10.1021%2Fjm201533b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Angst, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janser, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quancard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buehlmayer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berst, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beerli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pally, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersperger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassilana, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollbuck, B.</span><span> </span><span class="NLM_article-title">An Oral Sphingosine 1-Phosphate Receptor 1 (S1P<sub>1</sub>) Antagonist Prodrug with Efficacy in Vivo: Discovery, Synthesis, and Evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9722</span><span class="NLM_x">–</span> <span class="NLM_lpage">9734</span><span class="refDoi"> DOI: 10.1021/jm3009508</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009508" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9722-9734&author=D.+Angstauthor=P.+Janserauthor=J.+Quancardauthor=P.+Buehlmayerauthor=F.+Berstauthor=L.+Obererauthor=C.+Beerliauthor=M.+Streiffauthor=C.+Pallyauthor=R.+Herspergerauthor=C.+Brunsauthor=F.+Bassilanaauthor=B.+Bollbuck&title=An+Oral+Sphingosine+1-Phosphate+Receptor+1+%28S1P1%29+Antagonist+Prodrug+with+Efficacy+in+Vivo%3A+Discovery%2C+Synthesis%2C+and+Evaluation&doi=10.1021%2Fjm3009508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm3009508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009508%26sid%3Dliteratum%253Aachs%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DQuancard%26aufirst%3DJ.%26aulast%3DBuehlmayer%26aufirst%3DP.%26aulast%3DBerst%26aufirst%3DF.%26aulast%3DOberer%26aufirst%3DL.%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DPally%26aufirst%3DC.%26aulast%3DHersperger%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DBassilana%26aufirst%3DF.%26aulast%3DBollbuck%26aufirst%3DB.%26atitle%3DAn%2520Oral%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520%2528S1P1%2529%2520Antagonist%2520Prodrug%2520with%2520Efficacy%2520in%2520Vivo%253A%2520Discovery%252C%2520Synthesis%252C%2520and%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9722%26epage%3D9734%26doi%3D10.1021%2Fjm3009508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hennessy, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamhi, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronco, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Q.</span><span> </span><span class="NLM_article-title">Discovery of Heterocyclic Sulfonamides as Sphingosine 1-Phosphate Receptor 1 (S1P<sub>1</sub>) Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2045</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.bmcl.2015.03.095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2041-2045&author=E.+J.+Hennessyauthor=G.+Grewalauthor=K.+Bythauthor=V.+M.+Kamhiauthor=D.+Liauthor=P.+Lyneauthor=V.+Ozaauthor=L.+Roncoauthor=M.+T.+Rooneyauthor=J.+C.+Saehauthor=Q.+Su&title=Discovery+of+Heterocyclic+Sulfonamides+as+Sphingosine+1-Phosphate+Receptor+1+%28S1P1%29+Antagonists&doi=10.1016%2Fj.bmcl.2015.03.095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.095%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DGrewal%26aufirst%3DG.%26aulast%3DByth%26aufirst%3DK.%26aulast%3DKamhi%26aufirst%3DV.%2BM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DOza%26aufirst%3DV.%26aulast%3DRonco%26aufirst%3DL.%26aulast%3DRooney%26aufirst%3DM.%2BT.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DSu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520Heterocyclic%2520Sulfonamides%2520as%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520%2528S1P1%2529%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2041%26epage%3D2045%26doi%3D10.1016%2Fj.bmcl.2015.03.095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Oakley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruickshank, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhem, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loomis, C. R.</span><span> </span><span class="NLM_article-title">The Cellular Distribution of Fluorescently Labeled Arrestins Provides a Robust, Sensitive, and Universal Assay for Screening G Protein-Coupled Receptors</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1089/154065802761001275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1089%2F154065802761001275" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=21-30&author=R.+H.+Oakleyauthor=C.+C.+Hudsonauthor=R.+D.+Cruickshankauthor=D.+M.+Meyersauthor=R.+E.+Payneauthor=S.+M.+Rhemauthor=C.+R.+Loomis&title=The+Cellular+Distribution+of+Fluorescently+Labeled+Arrestins+Provides+a+Robust%2C+Sensitive%2C+and+Universal+Assay+for+Screening+G+Protein-Coupled+Receptors&doi=10.1089%2F154065802761001275"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1089%2F154065802761001275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065802761001275%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DR.%2BH.%26aulast%3DHudson%26aufirst%3DC.%2BC.%26aulast%3DCruickshank%26aufirst%3DR.%2BD.%26aulast%3DMeyers%26aufirst%3DD.%2BM.%26aulast%3DPayne%26aufirst%3DR.%2BE.%26aulast%3DRhem%26aufirst%3DS.%2BM.%26aulast%3DLoomis%26aufirst%3DC.%2BR.%26atitle%3DThe%2520Cellular%2520Distribution%2520of%2520Fluorescently%2520Labeled%2520Arrestins%2520Provides%2520a%2520Robust%252C%2520Sensitive%252C%2520and%2520Universal%2520Assay%2520for%2520Screening%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2002%26volume%3D1%26spage%3D21%26epage%3D30%26doi%3D10.1089%2F154065802761001275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0li3aoa_hFZaTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, A. Y. H.</span><span> </span><span class="NLM_article-title">Inhibition and Induction of Cytochrome P450 and the Clinical Implications</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span><span class="refDoi"> DOI: 10.2165/00003088-199835050-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.2165%2F00003088-199835050-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=9839089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1998&pages=361-390&author=J.+H.+Linauthor=A.+Y.+H.+Lu&title=Inhibition+and+Induction+of+Cytochrome+P450+and+the+Clinical+Implications&doi=10.2165%2F00003088-199835050-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and induction of cytochrome P450 and the clinical implications</span></div><div class="casAuthors">Lin, Jiunn H.; Lu, Anthony Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-390</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 192 refs.  The cytochrome P450s (CYPs) constitute a superfamily of isoforms that play an important role in the oxidative metab. of drugs.  Each CYP isoform possesses a characteristic broad spectrum of catalytic activities of substrates.  Whenever 2 or more drugs are administered concurrently, the possibility of drug interactions exists.  The ability of a single CYP to metabolize multiple substrates is responsible for a large no. of documented drug interactions assocd. with CYP inhibition.  In addn., drug interactions can also occur as a result of the induction of several human CYPs following long term drug treatment.  The mechanisms of CYP inhibition can be divided into 3 categories: (a) reversible inhibition; (b) quasi-irreversible inhibition; and (c) irreversible inhibition.  In mechanistic terms, reversible interactions arise as a result of competition at the CYP active site and probably involve only the first step of the CYP catalytic cycle.  On the other hand, drugs that act during and subsequent to the oxygen transfer step are generally irreversible or quasi-irreversible inhibitors.  Irreversible and quasi-irreversible inhibition require at least one cycle of the CYP catalytic process.  Because human liver samples and recombinant human CYPs are now readily available, in vitro systems have been used as screening tools to predict the potential for in vivo drug interaction.  Although it is easy to det. in vitro metabolic drug interactions, the proper interpretation and extrapolation of in vitro interaction data to in vivo situations require a good understanding of pharmacokinetic principles.  From the viewpoint of drug therapy, to avoid potential drug-drug interactions, it is desirable to develop a new drug candidate that is not a potent CYP inhibitor or inducer and the metab. of which is not readily inhibited by other drugs.  In reality, drug interaction by mutual inhibition between drugs is almost inevitable, because CYP-mediated metab. represents a major route of elimination of many drugs, which can compete for the same CYP enzyme.  The clin. significance of a metabolic drug interaction depends on the magnitude of the change in the concn. of active species (parent drug and/or active metabolites) at the site of pharmacol. action and the therapeutic index of the drug.  The smaller the difference between toxic and effective concn., the greater the likelihood that a drug interaction will have serious clin. consequences.  Thus, careful evaluation of potential drug interactions of a new drug candidate during the early stage of drug development is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdqTupUCBbLVg90H21EOLACvtfcHk0ljq7w-Ed2qfuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvVeqtLo%253D&md5=18993123e2cdad5517962664e986a5b4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003088-199835050-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199835050-00003%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DLu%26aufirst%3DA.%2BY.%2BH.%26atitle%3DInhibition%2520and%2520Induction%2520of%2520Cytochrome%2520P450%2520and%2520the%2520Clinical%2520Implications%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1998%26volume%3D35%26spage%3D361%26epage%3D390%26doi%3D10.2165%2F00003088-199835050-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kocarek, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuetz, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strom, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzelian, P. S.</span><span> </span><span class="NLM_article-title">Comparative Analysis of Cytochrome P4503A Induction in Primary Cultures of Rat, Rabbit, and Human Hepatocytes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=415-421&author=T.+A.+Kocarekauthor=E.+G.+Schuetzauthor=S.+C.+Stromauthor=R.+A.+Fisherauthor=P.+S.+Guzelian&title=Comparative+Analysis+of+Cytochrome+P4503A+Induction+in+Primary+Cultures+of+Rat%2C+Rabbit%2C+and+Human+Hepatocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKocarek%26aufirst%3DT.%2BA.%26aulast%3DSchuetz%26aufirst%3DE.%2BG.%26aulast%3DStrom%26aufirst%3DS.%2BC.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DGuzelian%26aufirst%3DP.%2BS.%26atitle%3DComparative%2520Analysis%2520of%2520Cytochrome%2520P4503A%2520Induction%2520in%2520Primary%2520Cultures%2520of%2520Rat%252C%2520Rabbit%252C%2520and%2520Human%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D415%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomkinson, N. C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCluyse, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. T.</span><span> </span><span class="NLM_article-title">The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution</span> <span class="citation_source-journal">Mol. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1210/mend.14.1.0409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1210%2Fmend.14.1.0409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10628745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=27-39&author=S.+A.+Jonesauthor=L.+B.+Mooreauthor=J.+L.+Shenkauthor=G.+B.+Wiselyauthor=G.+A.+Hamiltonauthor=D.+D.+McKeeauthor=N.+C.+O.+Tomkinsonauthor=E.+L.+LeCluyseauthor=M.+H.+Lambertauthor=T.+M.+Willsonauthor=S.+A.+Kliewerauthor=J.+T.+Moore&title=The+Pregnane+X+Receptor%3A+A+Promiscuous+Xenobiotic+Receptor+That+Has+Diverged+during+Evolution&doi=10.1210%2Fmend.14.1.0409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution</span></div><div class="casAuthors">Jones, Stacey A.; Moore, Linda B.; Shenk, Jennifer L.; Wisely, G. Bruce; Hamilton, Geraldine A.; McKee, David D.; Tomkinson, Nicholas C. O.; LeCluyse, Edward L.; Lambert, Millard H.; Willson, Timothy M.; Kliewer, Steven A.; Moore, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-39</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Transcription of genes encoding cytochrome P 450 3A (CYP3A) monooxygenases is induced by a variety of xenobiotics and natural steroids.  There are marked differences in the compds. that induce CYP3A gene expression between species.  Recently, the mouse and human pregnane X receptor (PXR) were shown to be activated by compds. that induce CYP3A expression.  However, most studies of CYP3A regulation have been performed using rabbit and rat hepatocytes.  Here, the authors report the cloning and characterization of PXR from these two species.  PXR is remarkably divergent between species, with the rabbit, rat, and human receptors sharing only approx. 80% amino acid identity in their ligand-binding domains.  This sequence divergence is reflected by marked pharmacol. differences in PXR activation profiles.  For example, the macrolide antibiotic rifampicin, the antidiabetic drug troglitazone, and the hypocholesterolemic drug SR12813 are efficacious activators of the human and rabbit PXR but have little activity on the rat and mouse PXR.  Conversely, pregnane 16α-carbonitrile is a more potent activator of the rat and mouse PXR than the human and rabbit receptor.  The activities of xenobiotics in PXR activation assays correlate well with their ability to induce CYP3A expression in primary hepatocytes.  Through the use of a novel scintillation proximity binding assay, the authors demonstrate that many of the compds. that induce CYP3A expression bind directly to human PXR.  These data establish PXR as a promiscuous xenobiotic receptor that has diverged during evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4cu4x3jOH8rVg90H21EOLACvtfcHk0ljq7w-Ed2qfuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislWjsg%253D%253D&md5=50bbd39e3285b9293b8a452798b5cffd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1210%2Fmend.14.1.0409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.14.1.0409%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DShenk%26aufirst%3DJ.%2BL.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26aulast%3DHamilton%26aufirst%3DG.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DTomkinson%26aufirst%3DN.%2BC.%2BO.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DLambert%26aufirst%3DM.%2BH.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Pregnane%2520X%2520Receptor%253A%2520A%2520Promiscuous%2520Xenobiotic%2520Receptor%2520That%2520Has%2520Diverged%2520during%2520Evolution%26jtitle%3DMol.%2520Endocrinol.%26date%3D2000%26volume%3D14%26spage%3D27%26epage%3D39%26doi%3D10.1210%2Fmend.14.1.0409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Burk, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raucy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hustert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockmöller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanger, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojnowski, L.</span><span> </span><span class="NLM_article-title">The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">38379</span><span class="NLM_x">–</span> <span class="NLM_lpage">38385</span><span class="refDoi"> DOI: 10.1074/jbc.M404949200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1074%2Fjbc.M404949200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=38379-38385&author=O.+Burkauthor=I.+Kochauthor=J.+Raucyauthor=E.+Hustertauthor=M.+Eichelbaumauthor=J.+Brockm%C3%B6llerauthor=U.+M.+Zangerauthor=L.+Wojnowski&title=The+Induction+of+Cytochrome+P450+3A5+%28CYP3A5%29+in+the+Human+Liver+and+Intestine+Is+Mediated+by+the+Xenobiotic+Sensors+Pregnane+X+Receptor+%28PXR%29+and+Constitutively+Activated+Receptor+%28CAR%29&doi=10.1074%2Fjbc.M404949200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M404949200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M404949200%26sid%3Dliteratum%253Aachs%26aulast%3DBurk%26aufirst%3DO.%26aulast%3DKoch%26aufirst%3DI.%26aulast%3DRaucy%26aufirst%3DJ.%26aulast%3DHustert%26aufirst%3DE.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DBrockm%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DZanger%26aufirst%3DU.%2BM.%26aulast%3DWojnowski%26aufirst%3DL.%26atitle%3DThe%2520Induction%2520of%2520Cytochrome%2520P450%25203A5%2520%2528CYP3A5%2529%2520in%2520the%2520Human%2520Liver%2520and%2520Intestine%2520Is%2520Mediated%2520by%2520the%2520Xenobiotic%2520Sensors%2520Pregnane%2520X%2520Receptor%2520%2528PXR%2529%2520and%2520Constitutively%2520Activated%2520Receptor%2520%2528CAR%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D38379%26epage%3D38385%26doi%3D10.1074%2Fjbc.M404949200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bertilsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Åsman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jendeberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sydow-Bäckman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postlind, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomquist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkenstam, A.</span><span> </span><span class="NLM_article-title">Identification of a human nuclear receptor defines a new signaling pathway for <i>CYP3A</i> induction</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12208</span><span class="NLM_x">–</span> <span class="NLM_lpage">12213</span><span class="refDoi"> DOI: 10.1073/pnas.95.21.12208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1073%2Fpnas.95.21.12208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12208-12213&author=G.+Bertilssonauthor=J.+Heidrichauthor=K.+Svenssonauthor=M.+%C3%85smanauthor=L.+Jendebergauthor=M.+Sydow-B%C3%A4ckmanauthor=R.+Ohlssonauthor=H.+Postlindauthor=P.+Blomquistauthor=A.+Berkenstam&title=Identification+of+a+human+nuclear+receptor+defines+a+new+signaling+pathway+for+CYP3A+induction&doi=10.1073%2Fpnas.95.21.12208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.21.12208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.21.12208%26sid%3Dliteratum%253Aachs%26aulast%3DBertilsson%26aufirst%3DG.%26aulast%3DHeidrich%26aufirst%3DJ.%26aulast%3DSvensson%26aufirst%3DK.%26aulast%3D%25C3%2585sman%26aufirst%3DM.%26aulast%3DJendeberg%26aufirst%3DL.%26aulast%3DSydow-B%25C3%25A4ckman%26aufirst%3DM.%26aulast%3DOhlsson%26aufirst%3DR.%26aulast%3DPostlind%26aufirst%3DH.%26aulast%3DBlomquist%26aufirst%3DP.%26aulast%3DBerkenstam%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520a%2520human%2520nuclear%2520receptor%2520defines%2520a%2520new%2520signaling%2520pathway%2520for%2520CYP3A%2520induction%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12208%26epage%3D12213%26doi%3D10.1073%2Fpnas.95.21.12208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Lehmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span> </span><span class="NLM_article-title">The Human Orphan Nuclear Receptor PXR Is Activated by Compounds That Regulate <i>CYP3A4</i> Gene Expression and Cause Drug Interactions</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1016</span><span class="NLM_x">–</span> <span class="NLM_lpage">1023</span><span class="refDoi"> DOI: 10.1172/JCI3703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1172%2FJCI3703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=9727070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1016-1023&author=J.+M.+Lehmannauthor=D.+D.+McKeeauthor=M.+A.+Watsonauthor=T.+M.+Willsonauthor=J.+T.+Mooreauthor=S.+A.+Kliewer&title=The+Human+Orphan+Nuclear+Receptor+PXR+Is+Activated+by+Compounds+That+Regulate+CYP3A4+Gene+Expression+and+Cause+Drug+Interactions&doi=10.1172%2FJCI3703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions</span></div><div class="casAuthors">Lehmann, Jurgen M.; McKee, David D.; Watson, Michael A.; Willson, Timothy M.; Moore, John T.; Kliewer, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1016-1023</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The cytochrome P 450 monooxygenase 3A4 (CYP3A4) is responsible for the oxidative metab. of a wide variety of xenobiotics including an estd. 60% of all clin. used drugs.  Although expression of the CYP3A4 gene is known to be induced in response to a variety of compds., the mechanism underlying this induction, which represents a basis for drug interactions in patients, has remained unclear.  The authors report the identification of a human (h) orphan nuclear receptor, termed the pregnane X receptor (PXR), that binds to a response element in the CYP3A4 promoter and is activated by a range of drugs known to induce CYP3A4 expression.  Comparison of hPXR with the recently cloned mouse PXR reveals marked differences in their activation by certain drugs, which may account in part for the species-specific effects of compds. on CYP3A gene expression.  These findings provide a mol. explanation for the ability of disparate chems. to induce CYP3A4 levels and, furthermore, provide a basis for developing in vitro assays to aid in predicting whether drugs will interact in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7B4VVObDCH7Vg90H21EOLACvtfcHk0lhsAkNSnqSoKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvVCqtLY%253D&md5=536bd0a0a80d2d6b36cdc7747a8e0fd0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1172%2FJCI3703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3703%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26atitle%3DThe%2520Human%2520Orphan%2520Nuclear%2520Receptor%2520PXR%2520Is%2520Activated%2520by%2520Compounds%2520That%2520Regulate%2520CYP3A4%2520Gene%2520Expression%2520and%2520Cause%2520Drug%2520Interactions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1016%26epage%3D1023%26doi%3D10.1172%2FJCI3703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kliewer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterström, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, J. M.</span><span> </span><span class="NLM_article-title">An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)80900-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2FS0092-8674%2800%2980900-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=9489701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=73-82&author=S.+A.+Kliewerauthor=J.+T.+Mooreauthor=L.+Wadeauthor=J.+L.+Staudingerauthor=M.+A.+Watsonauthor=S.+A.+Jonesauthor=D.+D.+McKeeauthor=B.+B.+Oliverauthor=T.+M.+Willsonauthor=R.+H.+Zetterstr%C3%B6mauthor=T.+Perlmannauthor=J.+M.+Lehmann&title=An+Orphan+Nuclear+Receptor+Activated+by+Pregnanes+Defines+a+Novel+Steroid+Signaling+Pathway&doi=10.1016%2FS0092-8674%2800%2980900-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway</span></div><div class="casAuthors">Kliewer, Steven A.; Moore, John T.; Wade, Laura; Staudinger, Jeff L.; Watson, Michael A.; Jones, Stacey A.; McKee, David D.; Oliver, Beverly B.; Willson, Timothy M.; Zetterstrom, Rolf H.; Perlmann, Thomas; Lehmann, Jurgen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-82</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Steroid hormones exert profound effects on differentiation, development, and homeostasis in higher eukaryotes through interactions with nuclear receptors.  We describe a novel orphan nuclear receptor, termed the pregnane X receptor (PXR), that is activated by naturally occurring steroids such as pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids.  PXR exists as two isoforms, PXR.1 and PXR.2, that are differentially activated by steroids.  Notably, PXR.1 is efficaciously activated by pregnenolone 16α-carbonitrile, a glucocorticoid receptor antagonist that induces the expression of the CYP3A family of steroid hydroxylases and modulates sterol and bile acid biosynthesis in vivo.  Our results provide evidence for the existence of a novel steroid hormone signaling pathway with potential implications in the regulation of steroid hormone and sterol homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcj-Q4c6TTLVg90H21EOLACvtfcHk0lhsAkNSnqSoKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlt1ensw%253D%253D&md5=1c24d97b161b497c4d2503e7b7adb778</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980900-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980900-9%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWade%26aufirst%3DL.%26aulast%3DStaudinger%26aufirst%3DJ.%2BL.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZetterstr%25C3%25B6m%26aufirst%3DR.%2BH.%26aulast%3DPerlmann%26aufirst%3DT.%26aulast%3DLehmann%26aufirst%3DJ.%2BM.%26atitle%3DAn%2520Orphan%2520Nuclear%2520Receptor%2520Activated%2520by%2520Pregnanes%2520Defines%2520a%2520Novel%2520Steroid%2520Signaling%2520Pathway%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D73%26epage%3D82%26doi%3D10.1016%2FS0092-8674%2800%2980900-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Baes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulick, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinoli, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, D. D.</span><span> </span><span class="NLM_article-title">A New Orphan Member of the Nuclear Hormone Receptor Superfamily That Interacts with a Subset of Retinoic Acid Response Elements</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1128%2FMCB.14.3.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=8114692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADyaK2cXis1ais7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1994&pages=1544-1552&author=M.+Baesauthor=T.+Gulickauthor=H.-S.+Choiauthor=M.+G.+Martinoliauthor=D.+Simhaauthor=D.+D.+Moore&title=A+New+Orphan+Member+of+the+Nuclear+Hormone+Receptor+Superfamily+That+Interacts+with+a+Subset+of+Retinoic+Acid+Response+Elements"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements</span></div><div class="casAuthors">Baes, Myriam; Gulick, Tod; Choi, Hueng Sik; Martinoli, Maria Grazia; Simha, Devendranath; Moore, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1544-52</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The authors have identified and characterized a new orphan member of the nuclear hormone receptor superfamily, called MB67, which is predominantly expressed in liver.  MB67 binds and trans-activates the retinoic acid response elements that control expression of the retinoic acid receptor β2 and alc. dehydrogenase 3 genes, both of which consist of direct repeat hexamers related to the consensus AGGTCA, sepd. by 5 bp.  MB67 binds these elements as a heterodimer with the 9-cis-retinoic acid receptor, RXR.  However, MB67 does not bind or activate other retinoic acid response elements with alternative hexamer arrangements or any of several other wild-type and synthetic hormone response elements examd.  The transactivation of retinoic acid response elements by MB67 is weaker than that conferred by the retinoic acid receptors but does not require the presence of all-trans retinoic acid, 9-cis-retinoic acid, or any exogenously added ligand.  The authors propose that MB67 plays an important role in the complex network of proteins that govern response to retinoic acid and its metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSjESKOun4vLVg90H21EOLACvtfcHk0lhsAkNSnqSoKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1ais7Y%253D&md5=7ff455f386465512605f9f0ad27abca8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FMCB.14.3.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.14.3.1544%26sid%3Dliteratum%253Aachs%26aulast%3DBaes%26aufirst%3DM.%26aulast%3DGulick%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DH.-S.%26aulast%3DMartinoli%26aufirst%3DM.%2BG.%26aulast%3DSimha%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DD.%2BD.%26atitle%3DA%2520New%2520Orphan%2520Member%2520of%2520the%2520Nuclear%2520Hormone%2520Receptor%2520Superfamily%2520That%2520Interacts%2520with%2520a%2520Subset%2520of%2520Retinoic%2520Acid%2520Response%2520Elements%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1994%26volume%3D14%26spage%3D1544%26epage%3D1552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Raucy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yueh, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, S. W.</span><span> </span><span class="NLM_article-title">A Cell-Based Reporter Gene Assay for Determining Induction of CYP3A4 in a High-Volume System</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span><span class="refDoi"> DOI: 10.1124/jpet.102.038653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fjpet.102.038653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=12235278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsV2qtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=412-423&author=J.+Raucyauthor=L.+Warfeauthor=M.-F.+Yuehauthor=S.+W.+Allen&title=A+Cell-Based+Reporter+Gene+Assay+for+Determining+Induction+of+CYP3A4+in+a+High-Volume+System&doi=10.1124%2Fjpet.102.038653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system</span></div><div class="casAuthors">Raucy, Judy; Warfe, Lyndon; Yueh, Mei-Fei; Allen, Scott W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">412-423</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Assessing the inducibility of CYP3A4 by various xenobiotics can predict potential drug interactions.  In the present investigation, human hepatoma cells were stably integrated with either the CYP3A4 enhancer region and a luciferase reporter gene or the CYP3A4-luciferase construct and the human pregnane X receptor (PXR).  Several colonies contg. one to three copies of luciferase per cell were identified by Southern blot anal.  Those transformants producing high luciferase activity in response to rifampicin were used to standardize a 96-well plate screening system with minimal inter- and intraplate variability.  Standardization also consisted of assessing viability of cells cultured in medium contg. various serum concns.  In cells maintained for 48 h in medium with less than 5% serum, a significant (p < 0.01) decline was obsd. in viability accompanied by altered induction.  A defined serum-free medium also produced less viable cells but did not alter the inductive response.  Treatment of transformants with various concns. of rifampicin produced a dose-response curve with maximal induction at 10 μM (5.6±0.18- and 2.1±0.3-fold above DMSO (DMSO)-treated cells in transformants with and without PXR, resp.).  Of addnl. agents examd. for their ability to induce CYP3A4, omeprazole (200 μM) was the most potent inducer (12.8±1.9- and 2.4±0.2-fold above DMSO-treated cells in transformants with and without PXR, resp.).  Mifepristone and mevastatin produced modest induction (∼3-fold) in the cell line contg. exogenous PXR, but produced less than 1.2-fold increases in cells lacking PXR.  Thus, only potent inducers can be identified in the cell line without PXR.  In contrast, cells contg. the receptor can be used to rank CYP3A4 induction.  Because a high vol. of chems. can be readily and accurately screened for their ability to induce CYP3A4 with this format, such a system could be valuable in the initial stages of preclin. drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZyXqBDWRWLVg90H21EOLACvtfcHk0liwQifjdxk7uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsV2qtrc%253D&md5=433cb89b72745771e8df9c07df65632f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.038653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.038653%26sid%3Dliteratum%253Aachs%26aulast%3DRaucy%26aufirst%3DJ.%26aulast%3DWarfe%26aufirst%3DL.%26aulast%3DYueh%26aufirst%3DM.-F.%26aulast%3DAllen%26aufirst%3DS.%2BW.%26atitle%3DA%2520Cell-Based%2520Reporter%2520Gene%2520Assay%2520for%2520Determining%2520Induction%2520of%2520CYP3A4%2520in%2520a%2520High-Volume%2520System%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D412%26epage%3D423%26doi%3D10.1124%2Fjpet.102.038653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Lemaire, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Sousa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahmani, R.</span><span> </span><span class="NLM_article-title">A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYB2B6 induction by pesticides</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2347</span><span class="NLM_x">–</span> <span class="NLM_lpage">2358</span><span class="refDoi"> DOI: 10.1016/j.bcp.2004.07.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.bcp.2004.07.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=2347-2358&author=G.+Lemaireauthor=G.+de+Sousaauthor=R.+Rahmani&title=A+PXR+reporter+gene+assay+in+a+stable+cell+culture+system%3A+CYP3A4+and+CYB2B6+induction+by+pesticides&doi=10.1016%2Fj.bcp.2004.07.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.07.041%26sid%3Dliteratum%253Aachs%26aulast%3DLemaire%26aufirst%3DG.%26aulast%3Dde%2BSousa%26aufirst%3DG.%26aulast%3DRahmani%26aufirst%3DR.%26atitle%3DA%2520PXR%2520reporter%2520gene%2520assay%2520in%2520a%2520stable%2520cell%2520culture%2520system%253A%2520CYP3A4%2520and%2520CYB2B6%2520induction%2520by%2520pesticides%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D2347%26epage%3D2358%26doi%3D10.1016%2Fj.bcp.2004.07.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Gao, Y.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkovec, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabut, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span> </span><span class="NLM_article-title">Attenuating pregnane X receptor (PXR) activation: A molecular modelling approach</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">124</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1080/00498250601050412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1080%2F00498250601050412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17484516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=124-138&author=Y.-D.+Gaoauthor=S.+H.+Olsonauthor=J.+M.+Balkovecauthor=Y.+Zhuauthor=I.+Royoauthor=J.+Yabutauthor=R.+Eversauthor=E.+Y.+Tanauthor=W.+Tangauthor=D.+P.+Hartleyauthor=R.+T.+Mosley&title=Attenuating+pregnane+X+receptor+%28PXR%29+activation%3A+A+molecular+modelling+approach&doi=10.1080%2F00498250601050412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach</span></div><div class="casAuthors">Gao, Y.-D.; Olson, S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. Y.; Tang, W.; Hartley, D. P.; Mosley, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-138</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that the pregnane X receptor (PXR) is a key regulator of cytochromes P 450 3A (e.g. CYP3A4 in human) gene expression.  As a result, activation of PXR may lead to CYP3A4 protein over-expression.  Because induction of CYP3A4 could result in clin. important drug-drug interactions, there has been a great interest in reducing the possibility of PXR activation by drug candidates in drug-discovery programs.  In order to provide structural insight for attenuating drug candidate-mediated PXR activation, we used a docking approach to study the structure-activity relationship for PXR activators.  Based on our docking models, it is proposed that introducing polar groups to the end of an activator should reduce its human PXR (hPXR) activity via destabilizing interactions in the hydrophobic areas of the PXR ligand-binding pocket.  A no. of analogs that incorporate these structural features then were designed and synthesized, and they exhibited significantly lower hPXR activation in a transactivation assay and decreased CYP3A4 induction in a human hepatocytes-based assay.  In addn., an example in which attenuating hPXR activation was achieved by sterically destabilizing the helixes 11 and 12 of the receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBZSC0secQoLVg90H21EOLACvtfcHk0liwQifjdxk7uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1ChsrY%253D&md5=400688510dd165a4a9632b6ba10bf267</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F00498250601050412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250601050412%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DOlson%26aufirst%3DS.%2BH.%26aulast%3DBalkovec%26aufirst%3DJ.%2BM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DRoyo%26aufirst%3DI.%26aulast%3DYabut%26aufirst%3DJ.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DE.%2BY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26atitle%3DAttenuating%2520pregnane%2520X%2520receptor%2520%2528PXR%2529%2520activation%253A%2520A%2520molecular%2520modelling%2520approach%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26spage%3D124%26epage%3D138%26doi%3D10.1080%2F00498250601050412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Salonen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellermann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span> </span><span class="NLM_article-title">Aromatic Rings in Chemical and Biological Recognition: Energetics and Structures</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4808</span><span class="NLM_x">–</span> <span class="NLM_lpage">4842</span><span class="refDoi"> DOI: 10.1002/anie.201007560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1002%2Fanie.201007560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVekt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=4808-4842&author=L.+M.+Salonenauthor=M.+Ellermannauthor=F.+Diederich&title=Aromatic+Rings+in+Chemical+and+Biological+Recognition%3A+Energetics+and+Structures&doi=10.1002%2Fanie.201007560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatic rings in chemical and biological recognition: energetics and structures</span></div><div class="casAuthors">Salonen, Laura M.; Ellermann, Manuel; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4808-4842</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes a multidimensional treatment of mol. recognition phenomena involving arom. rings in chem. and biol. systems.  It summarizes new results reported since the appearance of an earlier review in 2003 in host-guest chem., biol. affinity assays and biostructural anal., data base mining in the Cambridge Structural Database (CSD) and the Protein Data Bank (PDB), and advanced computational studies.  Topics addressed are arene-arene, perfluoroarene-arene, S···arom., cation-π, and anion-π interactions, as well as hydrogen bonding to π systems.  The generated knowledge benefits, in particular, structure-based hit-to-lead development and lead optimization both in the pharmaceutical and in the crop protection industry.  It equally facilitates the development of new advanced materials and supramol. systems, and should inspire further utilization of interactions with arom. rings to control the stereochem. outcome of synthetic transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8vdN7B4v_aLVg90H21EOLACvtfcHk0liwQifjdxk7uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVekt70%253D&md5=3684d00abc320d1ea0c71565495d5d5c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fanie.201007560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201007560%26sid%3Dliteratum%253Aachs%26aulast%3DSalonen%26aufirst%3DL.%2BM.%26aulast%3DEllermann%26aufirst%3DM.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DAromatic%2520Rings%2520in%2520Chemical%2520and%2520Biological%2520Recognition%253A%2520Energetics%2520and%2520Structures%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D4808%26epage%3D4842%26doi%3D10.1002%2Fanie.201007560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Bjornsson, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snikeris, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span> </span><span class="NLM_article-title">The Conduct of in vitro and in vivo Drug-Drug Interaction Studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) Perspective</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1124/dmd.31.7.815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fdmd.31.7.815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=12814957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=815-832&author=T.+D.+Bjornssonauthor=J.+T.+Callaghanauthor=H.+J.+Einolfauthor=V.+Fischerauthor=L.+Ganauthor=S.+Grimmauthor=J.+Kaoauthor=S.+P.+Kingauthor=G.+Miwaauthor=L.+Niauthor=G.+Kumarauthor=J.+McLeodauthor=R.+S.+Obachauthor=S.+Robertsauthor=A.+Roeauthor=A.+Shahauthor=F.+Snikerisauthor=J.+T.+Sullivanauthor=D.+Tweedieauthor=J.+M.+Vegaauthor=J.+Walshauthor=S.+A.+Wrighton&title=The+Conduct+of+in+vitro+and+in+vivo+Drug-Drug+Interaction+Studies%3A+A+Pharmaceutical+Research+and+Manufacturers+of+America+%28PhRMA%29+Perspective&doi=10.1124%2Fdmd.31.7.815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective</span></div><div class="casAuthors">Bjornsson, Thorir D.; Callaghan, John T.; Einolf, Heidi J.; Fischer, Volker; Gan, Lawrence; Grimm, Scott; Kao, John; King, S. Peter; Miwa, Gerald; Ni, Lan; Kumar, Gondi; McLeod, James; Obach, R. Scott; Roberts, Stanley; Roe, Amy; Shah, Anita; Snikeris, Fred; Sullivan, John T.; Tweedie, Donald; Vega, Jose M.; Walsh, John; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-832</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies.  There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs.  There is also a growing consensus for the standardization of cytochrome P 450 (P 450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients.  While existing guidances cover mainly P 450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed.  This article was prepd. by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metab. and Clin. Pharmacol. Tech. Working Groups and represents the current industry position.  The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compd. registration dossiers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogi0LDV4FgLVg90H21EOLACvtfcHk0liNoeQS7Vl5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D&md5=2a41b5f54f65504448656ac7f7409aea</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.7.815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.7.815%26sid%3Dliteratum%253Aachs%26aulast%3DBjornsson%26aufirst%3DT.%2BD.%26aulast%3DCallaghan%26aufirst%3DJ.%2BT.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DGrimm%26aufirst%3DS.%26aulast%3DKao%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DS.%2BP.%26aulast%3DMiwa%26aufirst%3DG.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMcLeod%26aufirst%3DJ.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DRoe%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DSnikeris%26aufirst%3DF.%26aulast%3DSullivan%26aufirst%3DJ.%2BT.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DThe%2520Conduct%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520Drug-Drug%2520Interaction%2520Studies%253A%2520A%2520Pharmaceutical%2520Research%2520and%2520Manufacturers%2520of%2520America%2520%2528PhRMA%2529%2520Perspective%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D815%26epage%3D832%26doi%3D10.1124%2Fdmd.31.7.815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selling, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecluyse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.-S.</span><span> </span><span class="NLM_article-title">CYP3A4 Induction by Drugs: Correlation Between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">804</span><span class="refDoi"> DOI: 10.1124/dmd.30.7.795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1124%2Fdmd.30.7.795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=12065438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=795-804&author=G.+Luoauthor=M.+Cunninghamauthor=S.+Kimauthor=T.+Burnauthor=J.+Linauthor=M.+Sinzauthor=G.+Hamiltonauthor=C.+Rizzoauthor=S.+Jolleyauthor=D.+Gilbertauthor=A.+Downeyauthor=D.+Mudraauthor=R.+Grahamauthor=K.+Carrollauthor=J.+Xieauthor=A.+Madanauthor=A.+Parkinsonauthor=D.+Christauthor=B.+Sellingauthor=E.+Lecluyseauthor=L.-S.+Gan&title=CYP3A4+Induction+by+Drugs%3A+Correlation+Between+a+Pregnane+X+Receptor+Reporter+Gene+Assay+and+CYP3A4+Expression+in+Human+Hepatocytes&doi=10.1124%2Fdmd.30.7.795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</span></div><div class="casAuthors">Luo, Gang; Cunningham, Mark; Kim, Sean; Burn, Tim; Lin, Jianrong; Sinz, Michael; Hamilton, Geraldine; Rizzo, Christopher; Jolley, Summer; Gilbert, Darryl; Downey, April; Mudra, Daniel; Graham, Richard; Carroll, Kathy; Xie, Jindong; Madan, Ajay; Parkinson, Andrew; Christ, Dave; Selling, Bernard; Lecluyse, Edward; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Induction of cytochrome P 450 3A4 (CYP3A4) is detd. typically by employing primary culture of human hepatocytes and measuring CYP3A4 mRNA, protein and microsomal activity.  Recently a pregnane X receptor (PXR) reporter gene assay was established to screen CYP3A4 inducers.  To evaluate results from the PXR reporter gene assay with those from the aforementioned conventional assays, 14 drugs were evaluated for their ability to induce CYP3A4 and activate PXR.  Sandwiched primary cultures of human hepatocytes from six donors were used and CYP3A4 activity was assessed by measuring microsomal testosterone 6β-hydroxylase activity.  Hepatic CYP3A4 mRNA and protein levels were also analyzed using branched DNA technol./Northern blotting and Western blotting, resp.  In general, PXR activation correlated with the induction potential obsd. in human hepatocyte cultures.  Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system.  Ritonavir and troleandomycin showed marked PXR activation but no increase (in the case of troleandomycin) or a significant decrease (in the case of ritonavir) in microsomal CYP3A4 activity.  It is concluded that the PXR reporter gene assay is a reliable and complementary method to assess the CYP3A4 induction potential of drugs and other xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoJw2uJawzuLVg90H21EOLACvtfcHk0liNoeQS7Vl5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVGru78%253D&md5=0de8fb68ebce41eed8d634cff33fad20</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.7.795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.7.795%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DCunningham%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DG.%26aulast%3DRizzo%26aufirst%3DC.%26aulast%3DJolley%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DDowney%26aufirst%3DA.%26aulast%3DMudra%26aufirst%3DD.%26aulast%3DGraham%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DParkinson%26aufirst%3DA.%26aulast%3DChrist%26aufirst%3DD.%26aulast%3DSelling%26aufirst%3DB.%26aulast%3DLecluyse%26aufirst%3DE.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DCYP3A4%2520Induction%2520by%2520Drugs%253A%2520Correlation%2520Between%2520a%2520Pregnane%2520X%2520Receptor%2520Reporter%2520Gene%2520Assay%2520and%2520CYP3A4%2520Expression%2520in%2520Human%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D795%26epage%3D804%26doi%3D10.1124%2Fdmd.30.7.795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Lee, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thangada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancellin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha’afi, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81661-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2FS0092-8674%2800%2981661-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=301-312&author=M.-J.+Leeauthor=S.+Thangadaauthor=K.+P.+Claffeyauthor=N.+Ancellinauthor=C.+H.+Liuauthor=M.+Klukauthor=M.+Volpiauthor=R.+I.+Sha%E2%80%99afiauthor=T.+Hla&title=Vascular+Endothelial+Cell+Adherens+Junction+Assembly+and+Morphogenesis+Induced+by+Sphingosine-1-Phosphate&doi=10.1016%2FS0092-8674%2800%2981661-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981661-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981661-X%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DThangada%26aufirst%3DS.%26aulast%3DClaffey%26aufirst%3DK.%2BP.%26aulast%3DAncellin%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DKluk%26aufirst%3DM.%26aulast%3DVolpi%26aufirst%3DM.%26aulast%3DSha%25E2%2580%2599afi%26aufirst%3DR.%2BI.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DVascular%2520Endothelial%2520Cell%2520Adherens%2520Junction%2520Assembly%2520and%2520Morphogenesis%2520Induced%2520by%2520Sphingosine-1-Phosphate%26jtitle%3DCell%26date%3D1999%26volume%3D99%26spage%3D301%26epage%3D312%26doi%3D10.1016%2FS0092-8674%2800%2981661-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Foss, F. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusa, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1016%2Fj.bmc.2006.10.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17113298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtleisL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=663-677&author=F.+W.+Fossauthor=A.+H.+Snyderauthor=M.+D.+Davisauthor=M.+Rouseauthor=M.+D.+Okusaauthor=K.+R.+Lynchauthor=T.+L.+Macdonald&title=Synthesis+and+biological+evaluation+of+%CE%B3-aminophosphonates+as+potent%2C+subtype-selective+sphingosine+1-phosphate+receptor+agonists+and+antagonists&doi=10.1016%2Fj.bmc.2006.10.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists</span></div><div class="casAuthors">Foss, Frank W.; Snyder, Ashley H.; Davis, Michael D.; Rouse, Michael; Okusa, Mark D.; Lynch, Kevin R.; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">663-677</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis of N-arylamide phosphonates and related aryl ether and arylamine analogs provided potent, subtype-selective agonists and antagonists of the five known sphingosine 1-phosphate (S1P) receptors (S1P1-5).  To this end, the syntheses of phosphoserine mimetics, i.e., selectively protected and optically active phosphonoserines, are described.  In vitro binding assays showed that the implementation of phosphonates as phosphate mimetics provided compds. with similar receptor binding affinities as compared to their phosphate precursors.  Meta-substituted arylamide phosphonates were discovered to be antagonists of the S1P1 and S1P3 receptors.  When administered to mice, an antagonist blocked the lymphopenia evoked by a S1P receptor agonist and caused capillary leakage in both lung and kidney.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqJ9NyWRyVe7Vg90H21EOLACvtfcHk0liV1sV6jp4VDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtleisL%252FP&md5=b50ee5f8179209124fae41960fc7b0b4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DSnyder%26aufirst%3DA.%2BH.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DRouse%26aufirst%3DM.%26aulast%3DOkusa%26aufirst%3DM.%2BD.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520%25CE%25B3-aminophosphonates%2520as%2520potent%252C%2520subtype-selective%2520sphingosine%25201-phosphate%2520receptor%2520agonists%2520and%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D663%26epage%3D677%26doi%3D10.1016%2Fj.bmc.2006.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boffey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilburn, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span> </span><span class="NLM_article-title">AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4400</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-4409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1158%2F0008-5472.CAN-04-4409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4389-4400&author=S.+R.+Wedgeauthor=J.+Kendrewauthor=L.+F.+Hennequinauthor=P.+J.+Valentineauthor=S.+T.+Barryauthor=S.+R.+Braveauthor=N.+R.+Smithauthor=N.+H.+Jamesauthor=M.+Dukesauthor=J.+O.+Curwenauthor=R.+Chesterauthor=J.+A.+Jacksonauthor=S.+J.+Boffeyauthor=L.+L.+Kilburnauthor=S.+Barnettauthor=G.+H.+P.+Richmondauthor=P.+F.+Wadsworthauthor=M.+Walkerauthor=A.+L.+Bigleyauthor=S.+T.+Taylorauthor=L.+Cooperauthor=S.+Beckauthor=J.+M.+J%C3%BCrgensmeierauthor=D.+J.+Ogilvie&title=AZD2171%3A+A+Highly+Potent%2C+Orally+Bioavailable%2C+Vascular+Endothelial+Growth+Factor+Receptor-2+Tyrosine+Kinase+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1158%2F0008-5472.CAN-04-4409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4409%26sid%3Dliteratum%253Aachs%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DValentine%26aufirst%3DP.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DChester%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DJ.%2BA.%26aulast%3DBoffey%26aufirst%3DS.%2BJ.%26aulast%3DKilburn%26aufirst%3DL.%2BL.%26aulast%3DBarnett%26aufirst%3DS.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DWadsworth%26aufirst%3DP.%2BF.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DBigley%26aufirst%3DA.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BT.%26aulast%3DCooper%26aufirst%3DL.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26atitle%3DAZD2171%253A%2520A%2520Highly%2520Potent%252C%2520Orally%2520Bioavailable%252C%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor-2%2520Tyrosine%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4389%26epage%3D4400%26doi%3D10.1158%2F0008-5472.CAN-04-4409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakley, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womersley, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2198</span><span class="NLM_x">–</span> <span class="NLM_lpage">2208</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=10.1158%2F1535-7163.MCT-07-0142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=17699717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2198-2208&author=N.+R.+Smithauthor=N.+H.+Jamesauthor=I.+Oakleyauthor=A.+Wainwrightauthor=C.+Copleyauthor=J.+Kendrewauthor=L.+M.+Womersleyauthor=J.+M.+J%C3%BCrgensmeierauthor=S.+R.+Wedgeauthor=S.+T.+Barry&title=Acute+pharmacodynamic+and+antivascular+effects+of+the+vascular+endothelial+growth+factor+signaling+inhibitor+AZD2171+in+Calu-6+human+lung+tumor+xenografts&doi=10.1158%2F1535-7163.MCT-07-0142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span></div><div class="casAuthors">Smith, Neil R.; James, Neil H.; Oakley, Ian; Wainwright, Anna; Copley, Clive; Kendrew, Jane; Womersley, Lynsey M.; Juergensmeier, Juliane M.; Wedge, Stephen R.; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2198-2208</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The vascular endothelial growth factor-A (VEGF-A) signaling pathway, a key stimulant of solid tumor vascularization, is primarily dependent on the activation of the endothelial cell surface receptor VEGF receptor-2 (VEGFR-2).  AZD2171 is an oral, highly potent small-mol. inhibitor of VEGFR tyrosine kinase activity that inhibits angiogenesis and the growth of human tumor xenografts in vivo.  Here, we show pharmacodynamic changes in VEGFR-2 phosphorylation induced by AZD2171.  In mouse lung tissue, a single dose of AZD2171 at 6 mg/kg inhibited VEGF-A-stimulated VEGFR-2 phosphorylation by 87% at 2 h with significant inhibition (≥60%) maintained to 24 h.  To examine inhibition of VEGFR-2 phosphorylation in tumor vasculature by immunohistochem., a comprehensive assessment of antibodies to various phosphorylation sites on the receptor was undertaken.  Antibodies to the phosphotyrosine epitopes pY1175/1173 and pY1214/1212 were found suitable for this application.  Calu-6 human lung tumor xenografts, from mice receiving AZD2171 or vehicle treatment (p.o., once daily), were examd. by immunohistochem.  A significant redn. in tumor vessel staining of phosphorylated VEGFR-2 (pVEGFR-2) was evident within 28 h of AZD2171 treatment (6 mg/kg).  This effect preceded a significant redn. in tumor microvessel d., which was detectable following 52 h of AZD2171 treatment.  These data show that AZD2171 is a potent inhibitor of VEGFR-2 activation in vivo and suggest that AZD2171 delivers therapeutic benefit in Calu-6 tumors by targeting vessels dependent on VEGFR-2 signaling for survival.  In addn., this work highlights the utility of measuring either pY1175/1173 or pY1214/1212 on VEGFR-2 as a pharmacodynamic marker of VEGFR-2 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVvyqU1WR9bVg90H21EOLACvtfcHk0liV1sV6jp4VDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D&md5=a6bef539c30c6cefc41a8d0eb433e418</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0142%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DOakley%26aufirst%3DI.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DCopley%26aufirst%3DC.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DWomersley%26aufirst%3DL.%2BM.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DAcute%2520pharmacodynamic%2520and%2520antivascular%2520effects%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520signaling%2520inhibitor%2520AZD2171%2520in%2520Calu-6%2520human%2520lung%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2198%26epage%3D2208%26doi%3D10.1158%2F1535-7163.MCT-07-0142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Makosza, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sienkiewicz, K.</span><span> </span><span class="NLM_article-title">Hydroxylation of Nitroarenes with Alkyl Hydroperoxide Anions via Vicarious Nucleophilic Substitution of Hydrogen</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">4199</span><span class="NLM_x">–</span> <span class="NLM_lpage">4208</span><span class="refDoi"> DOI: 10.1021/jo970726m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo970726m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=4199-4208&author=M.+Makoszaauthor=K.+Sienkiewicz&title=Hydroxylation+of+Nitroarenes+with+Alkyl+Hydroperoxide+Anions+via+Vicarious+Nucleophilic+Substitution+of+Hydrogen&doi=10.1021%2Fjo970726m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjo970726m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo970726m%26sid%3Dliteratum%253Aachs%26aulast%3DMakosza%26aufirst%3DM.%26aulast%3DSienkiewicz%26aufirst%3DK.%26atitle%3DHydroxylation%2520of%2520Nitroarenes%2520with%2520Alkyl%2520Hydroperoxide%2520Anions%2520via%2520Vicarious%2520Nucleophilic%2520Substitution%2520of%2520Hydrogen%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1998%26volume%3D63%26spage%3D4199%26epage%3D4208%26doi%3D10.1021%2Fjo970726m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86','PDB','5A86'); return false;">PDB: 5A86</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i81"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01078">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_75578"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01078">10.1021/acs.jmedchem.5b01078</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Protocols for physical property, ADMET, and pharmacokinetic assays described in this paper, characterization of mode of inhibition for compound <b>2</b>, protocol for S1P<sub>1</sub> receptor internalization assay, procedures for Matrigel plug angiogenesis and Evans blue dye pharmacodynamic experiments along with accompanying pharmacokinetic data and photographs, pharmacokinetic data from Calu6 tumor xenograft studies, and crystallographic collection and refinement data for PXR-compound <b>4</b> complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Spreadsheet of molecular formula strings for compounds in this article (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_001.pdf">jm5b01078_si_001.pdf (319.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01078/suppl_file/jm5b01078_si_002.csv">jm5b01078_si_002.csv (3.64 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates for the structure of compound <b>4</b> bound to human PXR have been deposited in the Protein Data Bank (PDB) under accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A86">5A86</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01078&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01078%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-17%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01078" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b2ae0ad03285","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
